UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 28, 2024
GlycoMimetics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware |
|
001-36177 |
|
06-1686563 |
(State or Other Jurisdiction of
Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
9708 Medical Center Drive
Rockville, MD 20850
(Address of Principal Executive Offices)
(240) 243-1201
(Registrant’s telephone number, including
area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| x | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, $0.001 par value |
GLYC |
The
Nasdaq Global Market |
Indícate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01
Entry into a Material Definitive Agreement.
Merger Agreement
On October 28, 2024, GlycoMimetics, Inc., a Delaware corporation (“GlycoMimetics”),
Gemini Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of GlycoMimetics (“First Merger Sub”),
Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of GlycoMimetics (“Second Merger
Sub” and, together with First Merger Sub, “Merger Sub”), and Crescent Biopharma, Inc., a Delaware corporation
(“Crescent”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”),
pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
(i) First Merger Sub will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the
surviving corporation of the merger (the “First Merger”) and (ii) immediately following the First Merger and as part
of the same overall transaction as the First Merger, Crescent will merge with and into Second Merger Sub (the “Second Merger”
and, together with the First Merger, the “Merger”). The Merger is intended to qualify for federal income tax purposes
as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.
Subject to the terms and conditions of the Merger Agreement, at the
closing of the Merger, (a) each then-outstanding share of Crescent common stock will be converted into the right to receive a number
of shares of GlycoMimetics common stock calculated in accordance with the Merger Agreement (the “Exchange Ratio”),
(b) each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of Series A
Preferred Stock (as defined below) of GlycoMimetics calculated in accordance with the Merger Agreement and (c) each then-outstanding option
to purchase Crescent common stock will be assumed by GlycoMimetics, subject to adjustment as set forth in the Merger Agreement. Under
the terms of the Merger Agreement, prior to the closing of the transaction, the board of directors of GlycoMimetics (the “Board”)
will accelerate the vesting of all equity awards of GlycoMimetics then outstanding but not then vested or exercisable. Each option to
acquire shares of GlycoMimetics’ common stock with an exercise price per share greater than the volume weighted average closing
trading price of a share of GlycoMimetics’ common stock on The Nasdaq Stock Market LLC (“Nasdaq”) for the five
(5) consecutive trading days ending three (3) days immediately prior to the closing date of the Merger (the “Parent Closing Price”)
will be cancelled in accordance with the terms of the Merger Agreement. At the closing of the Merger, each option to acquire shares of
GlycoMimetics’ common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted
into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares of GlycoMimetics common stock
underlying such option. At the closing of the Merger, each GlycoMimetics restricted stock unit will be cancelled and converted into the
right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock
underlying such GlycoMimetics restricted stock unit.]
Pursuant to the Exchange Ratio formula in the Merger Agreement, upon
the closing of the Merger (and prior to closing of the financing described below), on a pro forma basis and based upon the number of shares
of GlycoMimetics common stock expected to be issued in the Merger, pre-Merger Crescent stockholders will own approximately 86.21%
of the combined company and pre-Merger GlycoMimetics stockholders will own approximately 13.79% of the combined company. For purposes
of calculating the Exchange Ratio, (i) shares of GlycoMimetics common stock underlying warrants and other rights to receive shares
(other than Options to acquire shares of GlycoMimetics’ common stock, to the extent cancelled at or prior to closing of the Merger
in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the Merger will be deemed to be outstanding
(on a treasury share method basis), and (ii) all shares of Crescent common stock underlying outstanding Crescent stock options and
warrants will be deemed to be outstanding (on a treasury share method basis), except for certain stock option and other equity awards
made to directors, employees, consultants and other service providers of Crescent. The Exchange Ratio will be adjusted to the extent that
GlycoMimetics’ net cash at closing is less than $1.0 million and will be based on the amount of proceeds actually received
by GlycoMimetics in the financing transaction described below, as further described in the Merger Agreement.
In connection with the Merger, GlycoMimetics will seek the approval
of its stockholders to, among other things, (a) issue shares of GlycoMimetics common stock issuable in connection with the Merger (including
the shares of GlycoMimetics common stock issuable under the Series A Preferred Stock) and financing described below under the rules of
Nasdaq, and (b) amend its amended and restated certificate of incorporation, to (i) effect a reverse stock split of GlycoMimetics
common stock, (ii) increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to issue, (iii) change
the name of GlycoMimetics to Crescent Biopharma, Inc., (iv) redomicile GlycoMimetics from Delaware to such jurisdiction as may be determined
by Crescent (being either the Cayman Islands or Bermuda), and (v) such other changes as are mutually agreeable to GlycoMimetics and Crescent
(the “GlycoMimetics Voting Proposals”). In connection with these matters, GlycoMimetics intends to file with the Securities
and Exchange Commission (the “SEC”) a proxy statement and other relevant materials.
Each of GlycoMimetics and Crescent has agreed to customary representations,
warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1) using commercially reasonable
efforts to obtain the requisite approval of its stockholders, (2) non-solicitation of alternative acquisition proposals,
(3) the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing
of the Merger, (4) GlycoMimetics using commercially reasonable efforts to maintain the existing listing of the GlycoMimetics common stock
on Nasdaq and cause the shares of GlycoMimetics common stock to be issued in connection with the Merger to be approved for listing on
Nasdaq prior to the closing of the Merger, and (5) GlycoMimetics filing with the SEC and proxy statement regarding these matters (the
“Proxy Statement”).
Consummation of the Merger is subject to certain closing conditions,
including, among other things, (1) approval by GlycoMimetics stockholders of the GlycoMimetics Voting Proposals, (2) approval
by the requisite Crescent stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby,
(3) Nasdaq’s approval of the listing application to be submitted in connection with the Merger, (4) the SEC completing
its review of the Proxy Statement and the Proxy Statement having been mailed to the GlycoMimetics stockholders, (5) the expiration of
any applicable waiting periods (or extensions thereof) under the Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended, and
(6) the securities purchase agreement (described below) being in full force and effect providing for the receipt of not less than $100,000,000
(including in the proceeds any notes contributed as consideration in the financing transaction described below). Each party’s obligation
to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations
and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the
other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.
The Merger Agreement contains certain termination rights of each of
GlycoMimetics and Crescent. Upon termination of the Merger Agreement under specified circumstances, GlycoMimetics may be required to pay
Crescent a termination fee of $320,000 and Crescent may be required to pay GlycoMimetics a termination fee of $2,000,000. In addition,
Crescent may be required to pay GlycoMimetics an adjustable fee if Crescent terminates the merger agreement under specified circumstances,
which fee shall not exceed $2,000,000.
Pursuant to a Certificate of Designation of Preferences, Rights and
Limitations of the Series A Non-Voting Convertible Preferred Stock to be filed by GlycoMimetics with the Secretary of State of the State
of Delaware (the “Certificate of Designation”) in connection with the Merger Agreement and the transactions thereunder,
GlycoMimetics will establish the terms of a new series of preferred stock of GlycoMimetics designated as Series A Non-Voting Convertible
Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”). Holders of the Series A Preferred Stock
will be entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-GlycoMimetics common
stock basis, and in the same form as dividends actually paid on shares of the GlycoMimetics common stock. Except as otherwise required
by the Certificate of Designation or law, the Series A Preferred Stock will not have voting rights. However, as long as any shares of
Series A Preferred Stock are outstanding, GlycoMimetics will not, without the affirmative vote of the holders of a majority of the then
outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series
A Preferred Stock, (b) alter or amend the Certificate of Designation, (c) amend its certificate of incorporation, bylaws or other charter
documents (1) in any manner that adversely affects any rights of the holders of the Series A Preferred Stock, or (2) increase the authorized
number of directors constituting the Board of Directors or change the number of votes entitled to be cast by any director or directors
on any matter, (d) file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series
of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights,
privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, (e) issue further shares of the Series
A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series A Preferred Stock,
(f) at any time while at least 30% of the originally issued Series A Preferred Stock remains issued and outstanding, consummate either
(A) a Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation of GlycoMimetics or other
business combination in which the stockholders of GlycoMimetics immediately before such transaction do not hold at least a majority of
the capital stock of GlycoMimetics immediately after such transaction, or (g) enter into any agreement with respect to any of the foregoing.
The Certificate of Designation provides that for so long at least 30% of the Series A Preferred Stock remains issued and outstanding,
(i) the holders of record, exclusively and voting together as a separate class on an as-converted to common stock basis, shall be entitled
to elect two (2) directors of the GlycoMimetics (the “Preferred Directors”); and (iii) the holders of record of the
shares of common stock and of any other class or series of voting stock (including the Series A Preferred Stock), exclusively and voting
together as a single class on an as-converted to common stock basis, shall be entitled to elect the balance of the total number of directors
of GlycoMimetics (the “At-Large Directors”); provided, however, for administrative convenience, the initial Preferred
Directors may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Series A Preferred
Stock without a separate action by the holders. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution
or winding-up of GlycoMimetics.
The transaction has received approval by the Board of Directors of
both companies and is expected to close in the second quarter of 2025, subject to certain closing conditions, including, among other things,
approval by the stockholders of each company and the satisfaction of customary closing conditions.
Following the closing of the Merger, each share of Series A Preferred
Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series A Preferred
Stock, into a number of shares equal to 1,000 shares of GlycoMimetics common stock, subject to certain limitations, including that a holder
of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of GlycoMimetics common stock
if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage
(initially set at 9.99%) of the total number of shares of GlycoMimetics common stock issued and outstanding immediately after giving effect
to such conversion.
At the effective time of the Merger, the Board is expected to consist
of five (5) members, all of whom will be designated by Crescent. Upon the closing of the transaction, the combined company will be led
by Crescent’s chief executive officer.
Financing Transaction
Concurrently with the execution and delivery of the Merger Agreement,
certain institutional and accredited investors have entered into a securities purchase agreement (the “Purchase Agreement”)
with GlycoMimetics, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately
following to the consummation of the Merger, shares of GlycoMimetics common stock and pre-funded warrants (together, the “PIPE
Securities”) for an aggregate purchase price of approximately $200.0 million in a private placement (the “Private
Placement”). The closing of the Private Placement is conditioned on the satisfaction or waiver of the conditions set forth in
the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately following the closing of
the Merger.
The Purchase Agreement contains customary representations and warranties
of the Company, on the one hand, and the Purchasers, on the other hand, and customary indemnification provisions. The Private Placement
is also subject to stockholder approval which is expected to be received at the same time as the approval of the Merger.
The Company will enter into a Registration Rights Agreement (the “Registration
Rights Agreement”) with the Purchasers at closing, which will provide that the Company will register the resale of the Common
Shares and the shares of Common Stock issuable upon exercise of the pre-funded warrants. The Company will be required to prepare and file
a registration statement with the Securities and Exchange Commission no later than the 30th calendar date following the closing of the
Private Placement, and to use its commercially reasonable efforts to have the registration statement declared effective within 60 days
thereafter, subject to certain exceptions.
Support Agreements and Lock-Up Agreement
Concurrently with the execution of the Merger Agreement, (i) certain
stockholders of Crescent (solely in their respective capacities as Crescent stockholders) holding approximately 98% of the outstanding
shares of Crescent capital stock have entered into support agreements with GlycoMimetics and Crescent to vote all of their shares of Crescent
capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any
alternative acquisition proposals (the “Crescent Support Agreements”) and (ii) the directors and officers of GlycoMimetics
holding approximately 9% of the outstanding shares of GlycoMimetics common stock have entered into support agreements with GlycoMimetics
and Crescent to vote all of their shares of GlycoMimetics common stock in favor of the GlycoMimetics Voting Proposals and against any
alternative acquisition proposals (the “GlycoMimetics Support Agreements,” and, together with the Crescent Support
Agreements, the “Support Agreements”).
Concurrently with the execution of the Merger Agreement, certain executive
officers, directors and stockholders of Crescent have entered into lock-up agreements (the “Lock-Up Agreements”)
pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of GlycoMimetics common stock for the 180-day period
following the closing of the Merger.
The preceding
summaries of the Merger Agreement, the Certificate of Designation, the Support Agreements, the Purchase Agreement, the Registration Rights
Agreement and the Lock-Up Agreements do not purport to be complete and are qualified in their entirety by reference to the Merger
Agreement, the form Certificate of Designation, the form of Crescent Support Agreement, the form of GlycoMimetics Support Agreement, the
form of Purchase Agreement, the form of Registration Rights Agreement and the form of Lock-Up Agreement, which are filed as
Exhibits 2.1, 3.1, 10.1, 10.2, 10.3, 10.4 and 10.5, respectively, to this Current Report on Form 8-K and which are incorporated
herein by reference. The Merger Agreement has been attached as an exhibit to this Current Report on Form 8-K to provide
investors and securityholders with information regarding its terms. It is not intended to provide any other factual information about
Crescent or GlycoMimetics or to modify or supplement any factual disclosures about GlycoMimetics in its public reports filed with the
SEC. The Merger Agreement includes representations, warranties and covenants of Crescent, GlycoMimetics and Merger Sub made solely for
the purpose of the Merger Agreement and solely for the benefit of the parties thereto in connection with the negotiated terms of the Merger
Agreement. Investors should not rely on the representations, warranties and covenants in the Merger Agreement or any descriptions thereof
as characterizations of the actual state of facts or conditions of Crescent, GlycoMimetics or any of their respective affiliates. Moreover,
certain of those representations and warranties may not be accurate or complete as of any specified date, may be subject to a contractual
standard of materiality different from those generally applicable to SEC filings or may have been used for purposes of allocating risk
among the parties to the Merger Agreement, rather than establishing matters of fact.
Item 3.02 Unregistered Sales of Equity Securities.
To the extent required by this Item, the information included in Item
1.01 of this Current Report on Form 8-K is incorporated herein by reference. The PIPE Securities were offered and will be sold
in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof. Each of the investors represented
that it was an “accredited investor,” as defined in Regulation D, and is acquiring the Securities for investment only and
not with a view towards, or for resale in connection with, the public sale or distribution thereof. Neither this Current Report on Form
8-K nor any of the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy the PIPE Securities or any other
securities of Crescent or GlycoMimetics.
Item 5.01 Changes in Control
of Registrant.
To the extent required by this Item, the information included in Item
1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
To the extent required by this Item, the information included in Item
1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On October 29, 2024, GlycoMimetics issued a press
release announcing that the National Cancer Institute Phase 2/3 study of uproleselan did not meet its primary endpoint. The press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information
contained on the websites referenced in the press release is not incorporated herein by reference.
Also on October 29, 2024, GlycoMimetics and Crescent
issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.2 to this Current
Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in
the press release is not incorporated herein by reference.
Furnished as Exhibit 99.3 hereto and incorporated
herein by reference is the investor presentation that will be used by GlycoMimetics and Crescent in connection with the Merger, including
the webcast described below. GlycoMimetics plans to host a live webcast presentation to discuss the Merger as well as Crescent’s
platform and pipeline assets at 8:00 a.m. Eastern time on October 29, 2024. The live webcast presentation can be accessed at the Presentations
page of GlycoMimetics’ investor’s website or by using the participant webcast link (https://registrations.events/direct/NTM2740531).
A webcast of the presentation and associated slides will be available on the Presentations section of GlycoMimetics’ website at
https://ir.glycomimetics.com/ and a replay will be archived for 30 days following the presentation. Furnished as Exhibit 99.4 hereto and
incorporated herein by reference is the transcript that will be used by GlycoMimetics and Crescent in connection with the webcast.
The information in this Item 7.01, including Exhibits
99.1, 99.2, 99.3 and 99.4 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”),
or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
The National Cancer Institute (“NCI”)
informed the Company that the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the NCI and the Alliance
for Clinical Trials in Oncology (the “Alliance”) in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years
or older and fit for intensive chemotherapy did not show a statistically significant improvement in event free survival (EFS) for patients
receiving uproleselan in combination with 7+3 chemotherapy versus chemotherapy alone. The final pre-planned analysis of overall survival
was conducted on the full population of 267 patients in accordance with the revised statistical analysis plan and also did not show a
statistically significant difference between Uproleselan in combination with chemotherapy versus chemotherapy alone. Top line results
from NCI/Alliance trial A041701 are expected to be presented by the NCI at a future medical conference. The Company is coordinating with
the Alliance for transfer of full trial data for additional analysis, including subgroup analysis to evaluate if there are efficacy signals
in any patient population that may merit further study in future clinical trials.
Final Results of an investigator initiated Phase
2 Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML),
will be presented at future medical conference.
Forward-Looking Statements
This Current Report on Form 8-K and
the exhibits filed or furnished herewith contain forward-looking statements (including within the meaning of Section 21E of the Exchange
Act and Section 27A of the Securities Act) concerning GlycoMimetics, Crescent, the proposed transactions and other matters. These
forward-looking statements include express or implied statements relating to the structure, timing and completion of the proposed Merger;
the combined company’s listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of
the combined company; the expected executive officers and directors of the combined company; each company’s and the combined company’s
expected cash position at the closing of the proposed Merger (including completion of GlycoMimetics’s private placement) and cash
runway of the combined company; the expected contribution and payment of dividends in connection with the Merger, including the timing
thereof; the future operations of the combined company; the nature, strategy and focus of the combined company; the development and commercial
potential and potential benefits of any product candidates of the combined company; anticipated preclinical and clinical drug development
activities and related timelines, including the expected timing for data and other clinical results; the combined company having sufficient
resources to advance its pipeline candidates; and other statements that are not historical fact. The words “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “will,” “would” and similar expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting GlycoMimetics, Crescent or the proposed transaction will be those that have
been anticipated.
The forward-looking statements contained in this
communication are based on current expectations and beliefs concerning future developments and their potential effects and therefore subject
to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks associated with the possible failure
to satisfy the conditions to the closing or consummation of the Merger, including GlycoMimetics’ failure to obtain stockholder approval
for the Merger, risks associated with the potential failure to complete the financing transaction in a timely manner or at all, risks
associated with the uncertainty as to the timing of the consummation of the Merger and the ability of each of GlycoMimetics and Crescent
to consummate the transactions contemplated by the Merger, risks associated with GlycoMimetics’ continued listing on Nasdaq until
closing of the Merger, the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary
to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination
of the Merger prior to the closing or consummation of the Merger, risks associated with the possible failure to realize certain anticipated
benefits of the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on
the combined company’s business relationships, operating results and business generally; risks associated with the combined company’s
ability to manage expenses and unanticipated spending and costs that could reduce the combined company’s cash resources; risks related
to the combined company’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements;
risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates
or its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company or any of its directors
or officers related to the Merger Agreement or the transactions contemplated thereby; the ability of the combined company to obtain, maintain
and protect its intellectual property rights, in particular those related to its product candidates; the combined company’s ability
to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future
clinical trials; the combined company’s ability to replicate in later clinical trials positive results found in preclinical studies
and early-stage clinical trials of its product candidates; the combined company’s ability to realize the anticipated benefits of
its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or
developments and the combined company’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other
regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in
expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes
to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and
those risks and uncertainties and other factors more fully described in filings with the Securities and Exchange Commission, including
reports filed on Form 10-K, 10-Q and 8-K and in other filings made by GlycoMimetics with the SEC from time to
time and available at www.sec.gov. These forward-looking statements are based on current expectations, and with regard to the proposed
transaction, are based on GlycoMimetics’ current expectations, estimates and projections about the expected date of closing of the
proposed transaction and the potential benefits thereof, its business and industry, management’s beliefs and certain assumptions
made by GlycoMimetics, all of which are subject to change. Such forward-looking statements are made as of the date of this release, and
the parties undertake no obligation to update such statements to reflect subsequent events or circumstances, except as otherwise required
by securities and other applicable law.
No Offer or Solicitation
This Current Report on Form 8-K and
the exhibits filed or furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval
with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer
to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise,
nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities
shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain
exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or
indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the
mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate
or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED
HEREWITH ARE TRUTHFUL OR COMPLETE.
Important Additional Information
About the Proposed Transaction Will be Filed with the SEC
This Current Report on Form 8-K and
the exhibits filed or furnished herewith are not substitutes for the Proxy Statement or for any other document that GlycoMimetics may
file with the SEC in connection with the proposed transaction. In connection with the proposed transaction between GlycoMimetics and Crescent,
GlycoMimetics intends to file relevant materials with the SEC, including a proxy statement of GlycoMimetics. GlycoMimetics
URGES INVESTORS AND STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL
AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT GlycoMimetics, CRESCENT, THE PROPOSED TRANSACTION AND RELATED
MATTERS. Investors and stockholders will be able to obtain free copies of the Proxy Statement and other documents filed by GlycoMimetics
with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors
and stockholders should note that GlycoMimetics communicates with investors and the public using its website (www.glycomimetics.com)
and the investor relations website (www.glycomimetics.com/investor-relations) where anyone will be able to obtain free copies of
the Proxy Statement and other documents filed by GlycoMimetics with the SEC and stockholders are urged to read the Proxy Statement and
the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.
Participants in the Solicitation
GlycoMimetics,
Crescent and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders
in connection with the proposed transaction. Information about GlycoMimetics’s directors and executive officers including a description
of their interests in GlycoMimetics is included in GlycoMimetics’s most recent definitive proxy statement, as filed with the SEC
on April 1, 2024. Additional information regarding these persons and their interests in the proposed transaction will be included in the
Proxy Statement relating to the proposed transaction when it is filed with the SEC. These documents can be obtained free of charge from
the sources indicated above.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number |
|
Description |
| 2.1* |
Agreement and Plan of Merger and Reorganization, dated as of October 28, 2024, by and among GlycoMimetics Biopharma, Inc., Gemini Merger Sub Corp., Gemini Merger Sub II, LLC and Crescent Biopharma, Inc. |
| 3.1 |
Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock |
| 10.1 |
Form of Crescent Support Agreement |
| 10.2 |
Form of GlycoMimetics Support Agreement |
| 10.3 |
Form of GlycoMimetics Securities Purchase Agreement |
| 10.4 |
Form of Registration Rights Agreement |
| 10.5 |
Form of Lock-Up Agreement |
| 99.1 |
Press Release, issued on October 29, 2024 |
| 99.2 |
Joint Press Release, issued on October 29, 2024 |
| 99.3 |
Investor Presentation, dated October 2024 |
| 99.4 |
Conference Call Transcript dated October 29, 2024 |
| 104 |
Cover Page Interactive Data File (formatted as Inline XBRL) |
| * | Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes
to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however,
that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules
so furnished. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
GLYCOMIMETICS, INC. |
| |
|
(Registrant) |
| |
|
|
| |
By: |
/s/ Brian M. Hahn |
| Date: October 29, 2024 |
|
Name: Brian M. Hahn |
| |
|
Title: Senior Vice President and Chief Financial Officer |
Exhibit 2.1
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
among:
GlycoMimetics, Inc.
GEMINI
MERGER SUB CORP.;
GEMINI
Merger Sub II, LLC; and
Crescent
Biopharma, Inc.
Dated as of October 28, 2024
Table of Contents
| Section 1. Definitions and Interpretative
Provisions. |
3 |
| 1.1 |
Definitions |
3 |
| 1.2 |
Other Definitional and Interpretative Provisions |
20 |
| Section 2. Description of Transaction |
21 |
| 2.1 |
The Merger |
21 |
| 2.2 |
Effects of the Merger |
21 |
| 2.3 |
Closing; First Effective Time; Second Effective Time |
21 |
| 2.4 |
Organizational Documents; Directors and Officers |
22 |
| 2.5 |
Conversion of Company, First Merger Sub and Second
Merger Sub Equity Securities |
23 |
| 2.6 |
Closing of the Company’s Transfer Books |
25 |
| 2.7 |
Surrender of Company Capital Stock |
25 |
| 2.8 |
Calculation of Net Cash and Company Valuation. |
26 |
| 2.9 |
Further Action |
29 |
| 2.10 |
Intended Tax Treatment |
29 |
| 2.11 |
Withholding |
29 |
| 2.12 |
Appraisal Rights |
30 |
| Section 3. Representations and Warranties
of the Company |
30 |
| 3.1 |
Due Organization; Subsidiaries |
30 |
| 3.2 |
Organizational Documents |
31 |
| 3.3 |
Authority; Binding Nature of Agreement |
31 |
| 3.4 |
Vote Required |
31 |
| 3.5 |
Non-Contravention; Consents |
31 |
| 3.6 |
Capitalization. |
32 |
| 3.7 |
Financial Statements |
34 |
| 3.8 |
Absence of Changes |
35 |
| 3.9 |
Absence of Undisclosed Liabilities |
35 |
| 3.10 |
Title to Assets |
35 |
| 3.11 |
Real Property; Leasehold |
35 |
| 3.12 |
Intellectual Property |
35 |
| 3.13 |
Agreements, Contracts and Commitments |
38 |
| 3.14 |
Compliance; Permits; Restrictions |
40 |
| 3.15 |
Legal Proceedings; Orders |
43 |
| 3.16 |
Tax Matters |
43 |
| 3.17 |
Employee and Labor Matters; Benefit Plans. |
44 |
| 3.18 |
Environmental Matters |
47 |
| 3.19 |
Insurance |
48 |
| 3.20 |
No Financial Advisors |
48 |
| 3.21 |
Transactions with Affiliates |
48 |
| 3.22 |
Privacy and Data Security |
49 |
| 3.23 |
Ownership of Parent Capital Stock |
49 |
| 3.24 |
No Other Representations or Warranties |
49 |
| Section 4. Representations and Warranties
of Parent, First Merger and Second Merger Sub |
50 |
| 4.1 |
Due Organization; Subsidiaries |
50 |
| 4.2 |
Organizational Documents |
50 |
| 4.3 |
Authority; Binding Nature of Agreement |
51 |
| 4.4 |
Vote Required |
51 |
| 4.5 |
Non-Contravention; Consents |
51 |
| 4.6 |
Capitalization |
52 |
| 4.7 |
SEC Filings; Financial Statements |
54 |
| 4.8 |
Absence of Changes |
56 |
| 4.9 |
Absence of Undisclosed Liabilities |
56 |
| 4.10 |
Title to Assets |
56 |
| 4.11 |
Real Property; Leasehold |
57 |
| 4.12 |
Intellectual Property |
57 |
| 4.13 |
Agreements, Contracts and Commitments |
59 |
| 4.14 |
Compliance; Permits; Restrictions |
62 |
| 4.15 |
Legal Proceedings; Orders |
64 |
| 4.16 |
Tax Matters |
65 |
| 4.17 |
Employee and Labor Matters; Benefit Plans |
66 |
| 4.18 |
Environmental Matters |
69 |
| 4.19 |
Insurance |
69 |
| 4.20 |
Transactions with Affiliates |
69 |
| 4.21 |
No Financial Advisors |
69 |
| 4.22 |
Valid Issuance |
70 |
| 4.23 |
Privacy and Data Security |
70 |
| 4.24 |
No Other Representations or Warranties |
70 |
| Section 5. Certain Covenants of the
Parties |
71 |
| 5.1 |
Operation of Parent’s Business |
71 |
| 5.2 |
Operation of the Company’s Business |
73 |
| 5.3 |
Access and Investigation |
74 |
| 5.4 |
No Solicitation |
75 |
| 5.5 |
Notification of Certain Matters |
76 |
| Section 6. Additional Agreements of
the Parties |
77 |
| 6.1 |
Proxy Statement |
77 |
| 6.2 |
Company Stockholder Written Consent |
78 |
| 6.3 |
Parent Stockholder Meeting |
80 |
| 6.4 |
Efforts; Regulatory Approvals |
82 |
| 6.5 |
Company Options; Company Warrants |
83 |
| 6.6 |
Employee Benefits |
84 |
| 6.7 |
Indemnification of Officers and Directors |
86 |
| 6.8 |
Disclosure |
87 |
| 6.9 |
Listing |
88 |
| 6.10 |
Tax Matters |
88 |
| 6.11 |
Legends |
89 |
| 6.12 |
Officers and Directors |
89 |
| 6.13 |
Termination of Certain Agreements and Rights |
90 |
| 6.14 |
Section 16 Matters |
90 |
| 6.15 |
Allocation Information |
90 |
| 6.16 |
Parent SEC Documents |
90 |
| 6.17 |
Notice of Certain Transactions |
90 |
| 6.18 |
Obligations of Merger Subs |
91 |
| 6.19 |
Parent Financing |
91 |
| Section 7. Conditions Precedent to
Obligations of Each Party |
91 |
| 7.1 |
Regulatory Approvals |
91 |
| 7.2 |
No Restraints |
91 |
| 7.3 |
Stockholder Approval |
91 |
| 7.4 |
Listing |
91 |
| 7.5 |
Lock-Up Agreements |
91 |
| 7.6 |
Parent Charter Amendment |
91 |
| 7.7 |
Certificate of Designation |
91 |
| Section 8. Additional Conditions Precedent
to Obligations of Parent and Merger Subs |
92 |
| 8.1 |
Accuracy of Representations |
92 |
| 8.2 |
Performance of Covenants |
92 |
| 8.3 |
Documents |
92 |
| 8.4 |
No Company Material Adverse Effect |
93 |
| 8.5 |
Company Stockholder Written Consent |
93 |
| 8.6 |
Parent Financing |
93 |
| Section 9. Additional Conditions Precedent
to Obligation of the Company |
93 |
| 9.1 |
Accuracy of Representations |
93 |
| 9.2 |
Performance of Covenants |
94 |
| 9.3 |
Documents |
94 |
| 9.4 |
No Parent Material Adverse Effect |
94 |
| Section 10. Termination |
94 |
| 10.1 |
Termination |
94 |
| 10.2 |
Effect of Termination |
96 |
| 10.3 |
Expenses; Termination Fees |
96 |
| Section 11. Miscellaneous Provisions |
98 |
| 11.1 |
Non-Survival of Representations and Warranties |
98 |
| 11.2 |
Amendment |
98 |
| 11.3 |
Waiver |
98 |
| 11.4 |
Entire Agreement; Counterparts; Exchanges by Electronic
Transmission |
99 |
| 11.5 |
Applicable Law; Jurisdiction |
99 |
| 11.6 |
Assignability |
99 |
| 11.7 |
Notices |
100 |
| 11.8 |
Cooperation |
100 |
| 11.9 |
Severability |
100 |
| 11.10 |
Other Remedies; Specific Performance |
101 |
| 11.11 |
No Third-Party Beneficiaries |
101 |
Exhibits:
| Exhibit A-1 |
Form of
Parent Stockholder Support Agreement |
| Exhibit A-2 |
Form of
Company Stockholder Support Agreement |
| Exhibit B |
Form of
Lock-Up Agreement |
| Exhibit C |
Form of
Subscription Agreement |
| Exhibit D-1 |
First
Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit A
thereto, incorporated by reference into this Agreement |
| Exhibit D-2 |
Second
Certificate of Merger, incorporated by reference into this Agreement |
| Exhibit E |
Form of Certificate
of Designation |
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
This
Agreement and Plan of Merger and Reorganization (this “Agreement”) is made and entered into as of October 28,
2024, by and among GlycoMimetics, Inc., a Delaware corporation (“Parent”),
Gemini Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Parent
(“First Merger Sub”), Gemini Merger Sub II, LLC, a Delaware limited
liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub,
“Merger Subs”), and Crescent Biopharma, Inc., a Delaware
corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 1.
Recitals
A. Parent
and the Company intend to effect a merger of First Merger Sub with and into the Company (the “First Merger”) in accordance
with this Agreement and the DGCL. Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become
a wholly owned subsidiary of Parent.
B. Immediately
following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second
Merger Sub (the “Second Merger” and, together with the First Merger, the “Merger”), with Second
Merger Sub being the surviving entity of the Second Merger.
C. The
Parties intend that, (i) the First Merger and the Second Merger, taken together, will constitute an integrated transaction described
in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a “reorganization” within the meaning of Section 368(a) of
the Code, and (ii) this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury
Regulations Sections 1.368-2(g) and 1.368-3(a).
D. The
Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and
its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance
of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (iii) determined
to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve
this Agreement and thereby approve the Parent Stockholder Matters, including the Contemplated Transactions, and against any competing
proposals.
E. The
First Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of
First Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions
and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder
of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.
F. The
sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best
interests of Second Merger Sub and its sole member, (ii) approved and declared advisable this Agreement and the Contemplated Transactions
and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member
of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.
G. The
Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company
and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined
to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to
adopt this Agreement and thereby approve the Contemplated Transactions.
H. Concurrently
with the execution and delivery of this Agreement and as a condition and inducement to the Company’s willingness to enter into
this Agreement, each of the officers and directors set forth on Section A of the Parent Disclosure Letter (solely in
their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached
hereto as Exhibit A-1 (the “Parent Stockholder Support Agreement”), pursuant to which such Persons have,
subject to the terms and conditions set forth therein, agreed to vote all of their shares of Parent Capital Stock in favor of the approval
of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent’s
certificate of incorporation to effect the Nasdaq Reverse Split and any other matters, and against any competing proposals.
I. Concurrently
with the execution and delivery of this Agreement and as a condition and inducement to Parent’s willingness to enter into this
Agreement, each of the officers, directors and stockholders of the Company listed on Section A of the Company Disclosure
Letter (solely in their capacity as stockholders of the Company) are executing support agreements in favor of Parent in substantially
the form attached hereto as Exhibit A-2 (the “Company Stockholder Support Agreement”), pursuant to which
such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock
in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions and against any competing proposals.
J. Concurrently
with the execution and delivery of this Agreement and as a condition and inducement to Parent’s and the Company’s willingness
to enter into this Agreement, all of the stockholders of the Company or Parent listed on Section B of the Company Disclosure
Letter are executing lock-up agreements in substantially the form attached hereto as Exhibit B (the “Lock-Up Agreement,”
and collectively, the “Lock-Up Agreements”).
K. It
is expected that within two (2) Business Days after the date hereof, the holders of shares of Company Capital Stock sufficient to
adopt and approve this Agreement and the Merger as required under the DGCL and the Company’s certificate of incorporation and bylaws
will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent,
in order to obtain the Required Company Stockholder Vote.
L. Concurrently
with the execution and delivery of this Agreement, certain investors have executed a Securities Purchase Agreement in the form attached
hereto as Exhibit C among Parent and the Persons named therein (including as may be amended, restated and/or superseded from
time to time, the “Subscription Agreement”), pursuant to which such Persons will have agreed to purchase in the amounts
set forth therein shares of Parent Common Stock and pre-funded warrants to purchase Parent Common Stock following the Second Effective
Time (the “Parent Financing”).
Agreement
The Parties, intending to
be legally bound, agree as follows:
Section 1.
Definitions and Interpretative Provisions.
1.1 Definitions.
(a) For
purposes of this Agreement (including this Section 1):
“Acceptable Confidentiality
Agreement” means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty
thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation
or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent
relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with
respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality
agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.
“Acquisition Inquiry”
means, with respect to a Party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication
of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other
Party) that could reasonably be expected to lead to an Acquisition Proposal.
“Acquisition Proposal”
means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by
or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the
other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.
“Acquisition Transaction”
means any transaction or series of related transactions (other than any Interim Financing, any Company Acquisition, or the Parent Financing)
involving:
(a) any
merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization,
recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Person or “group” (as defined
in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership
of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries
or (ii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of
any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding
securities of any class of voting securities of such Party or any of its Subsidiaries; or
(b) any
sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account
for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.
“Affiliate”
shall have the meaning given to such term in Rule 145 under the Securities Act.
“Affordable Care
Act” means the Patient Protection and Affordable Care Act.
“Anticipated Closing
Date” means the anticipated Closing Date, as agreed upon by Parent and the Company.
“Business Day”
means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.
“Certificate of
Designation” means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock
in the form attached hereto as Exhibit E.
“COBRA”
means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section 4980B of the Code and Section 6 of
Title I of ERISA.
“Code”
means the Internal Revenue Code of 1986, as amended.
“Company Associate”
means any current employee, independent contractor, officer or director of the Company or any of its Subsidiaries.
“Company Board”
means the board of directors of the Company.
“Company Capital
Stock” means the Company Common Stock and the Company Preferred Stock.
“Company Capitalization
Representations” means the representations and warranties of the Company set forth in Sections 3.6(a) and
3.6(d).
“Company Common
Stock” means the common stock, $0.0001 par value per share, of the Company.
“Company Contract”
means any Contract: (a) to which the Company or any of its Subsidiaries is a Party, (b) by which the Company or any of its
Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation
or (c) under which the Company or any of its Subsidiaries has or may acquire any right or interest.
“Company Employee
Plan” means any Employee Plan that the Company or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes
to, (ii) may reasonably be expected to have any Liability, or (iii) utilizes to provide benefits to or otherwise cover any
current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses,
dependents, or beneficiaries), but excluding any Employee Plan in which the Company or any of its Subsidiaries participates that is sponsored
by any professional employer organization.
“Company Fundamental
Representations” means the representations and warranties of the Company set forth in Sections 3.1(a), 3.2,
3.3, 3.4, 3.5(a)(i) and 3.20.
“Company IP Rights”
means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled
by the Company or its Subsidiaries that are necessary for, or used or held for use in, the operation of the business of the Company and
its Subsidiaries as presently conducted.
“Company IP Rights
Agreement” means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information
provided under confidentiality agreements.
“Company Key Employee”
means any executive officer of the Company or any of its Subsidiaries.
“Company Material
Adverse Effect” means any Effect that, considered together with all other Effects that have occurred prior to the date of determination
of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the
business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; provided,
however, that Effects arising or resulting from the following shall not be taken into account in determining whether there has
been a Company Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions,
(b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this
Agreement, (c) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism
or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere
in the world or any governmental or other response or reaction to any of the foregoing, (d) any change in GAAP or applicable Law
or the interpretation thereof, (e) general economic or political conditions or conditions generally affecting the industries in
which the Company and its Subsidiaries operate or (f) any change in the cash position of the Company and its Subsidiaries which
results from operations in the Ordinary Course of Business; except in each case with respect to clauses (c), (d) and (e), to the
extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies
in the industries in which the Company and its Subsidiaries operate.
“Company Merger
Shares” means the product determined by multiplying (i) the Post-Closing Parent Shares by
(ii) the Company Allocation Percentage, in which:
| · | “Aggregate
Valuation” means the sum of (i) the Company Valuation, plus
(ii) the Parent Valuation. |
| · | “Company
Acquisition” means any acquisition or license of, by purchase or otherwise, a portion
of, or all or substantially all of, (i) the property or assets, (ii) the equity
securities or other evidence of beneficial ownership, or (iii) any division, line of
business or other business unit, in each case, of any Person other than Parent and its Subsidiaries. |
| · | “Company
Allocation Percentage” means the percentage (rounded to four decimal places) determined
by subtracting (i) the Parent Allocation Percentage from
(ii) 100 percent. |
| · | “Company
Outstanding Shares” means, without duplication, the total number of shares of Company
Capital Stock outstanding immediately prior to the First Effective Time (including any shares
of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the
exercise or conversion of securities issued in, any Interim Financing or Company Acquisition),
expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without
limitation or duplication, the exercise of all Company Options, Company Warrants or other
rights or commitments to receive shares of Company Common Stock or Company Preferred Stock
(or securities convertible or exercisable into shares of Company Common Stock or Company
Preferred Stock, including the Company Notes), whether conditional or unconditional or vested
or unvested, that are outstanding as of immediately prior to the First Effective Time; provided,
that Company Outstanding Shares shall exclude (i) any Company Options, Company Warrants
and any other equity awards issued under the Company Stock Plans (including any shares of
Company Common Stock issuable upon the exercise of such Company Options, Company Warrants
or other equity awards) issued to directors, employees, consultants or other service providers
following the date hereof but prior to the Closing (collectively, the “Service Provider
Grants”) and (ii) any shares of Company Common Stock underlying Company Notes
that are to be contributed as consideration in the Parent Financing pursuant to the Subscription
Agreement. |
| · | “Company
Valuation” means (i) $50,000,000, plus (ii) the Fair Market
Value of each Company Acquisition, plus (ii) the Fair Market Value of
any Interim Financing. |
| · | “Exchange
Ratio” means the ratio (rounded to four decimal places) equal to the quotient obtained
by dividing (i) the Company Merger Shares by (ii) the Company Outstanding Shares. |
| · | “Fair
Market Value” means (A) for a Company Acquisition, the sum of (i) in
the case any Company Capital Stock is issued as consideration for such Company Acquisition,
(a) $50,000,000, divided by the Company Outstanding Shares (calculated
as of the date hereof), multiplied by (b) the aggregate number of shares
of Company Capital Stock issued in such Company Acquisition, and (ii) in the case any
consideration other than cash or shares of Company Capital Stock is issued as consideration
for such Company Acquisition, the fair market value for such assets or securities as between
a willing buyer and a willing seller in an arm’s length, non-distressed transaction
occurring on the date of valuation, taking into account all relevant factors determinative
of value, as reasonably determined by the Company in good faith, and (B) for any Interim
Financing, (i) $50,000,000, divided by the Company Outstanding Shares
(calculated as of the date hereof), multiplied by (ii) the aggregate number
of shares of Company Capital Stock issued (or to be issued upon conversion or exercise of
any securities convertible into shares of Company Capital Stock) in such Interim Financing. |
| · | “Parent
Allocation Percentage” means the quotient (expressed as a percentage and rounded
to four decimal places) determined by dividing (i) the Parent Valuation
by (ii) the Aggregate Valuation. |
| · | “Parent
Net Cash Lower Amount” means, if Parent Net Cash is less than the Parent Net Cash
Lower Target, then the amount, if any, that the Parent Net Cash Target exceeds the Parent
Net Cash. |
| · | “Parent
Net Cash Lower Target” means $1,725,000. |
| · | “Parent
Net Cash Target” means $1,800,000. |
| · | “Parent
Net Cash Upper Amount” means, if Parent Net Cash is greater than Parent Net Cash
Upper Target, then the amount, if any, that the Parent Net Cash exceeds the Parent Net Cash
Target. |
| · | “Parent
Net Cash Upper Target” means $1,875,000. |
| · | “Parent
Outstanding Shares” means, without duplication, (including, without limitation,
the effects of the Nasdaq Reverse Split, if completed) the total number of shares of Parent
Common Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted
basis and as converted to Parent Common Stock basis and assuming, without limitation or duplication,
(i) the issuance of shares of Parent Common Stock in respect of all Parent Options,
warrants or other rights or commitments to receive shares of Parent Common Stock or Parent
Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock
or Parent Preferred Stock, but excluding any Parent Common Stock issuable in accordance with
the Parent Financing), whether conditional or unconditional, that are outstanding as of immediately
prior to the First Effective Time, and (ii) the settlement in shares of Parent Common
Stock of Parent Restricted Stock Units outstanding as of immediately prior to the Effective
Time on a net settlement basis as provided in Section 6.6(e). Notwithstanding
any of the foregoing, no Out of the Money Parent Options shall be included in the total number
of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding
Shares. |
| · | “Parent
Valuation” means the greater of (x)(i) $8,000,000, minus (ii) the
Parent Net Cash Lower Amount (if any) plus (iii) the Parent Net Cash Upper
Amount (if any), and (y)(i) the Parent Valuation Floor, minus (ii) the
Parent Net Cash Lower Amount (if any) plus (iii) the Parent Net Cash Upper
Amount (if any). |
| · | “Parent
Valuation Floor” means an amount equal to (i) 0.03, multiplied by (ii) the
sum of (A) the Company Valuation (as of immediately prior to the Closing), (B) the
aggregate Aggregate Purchase Amount (as defined in the Subscription Agreement) of the investors
thereunder, and (C) $8,000,000. |
| · | “Post-Closing
Parent Shares” mean the quotient determined by dividing (i) the
Parent Outstanding Shares by (ii) the Parent Allocation Percentage. |
“Company Notes”
means the convertible notes issued by the Company on or around October 24, 2024, including the second tranche contemplated thereunder.
“Company Options”
means options or other rights to purchase shares of Company Capital Stock issued by the Company.
“Company Preferred
Stock” means the shares of the Company’s capital stock designated as preferred stock, including the Company Series Seed
Preferred Stock.
“Company Registered
IP” means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued
under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks
and all applications and registrations for any of the foregoing.
“Company Series Seed
Preferred Stock” means a series of the Company’s preferred stock designated as Series Seed Preferred Stock, $0.0001
par value per share.
“Company Stock Plans”
means the Company’s 2024 Equity Incentive Plan.
“Company Triggering
Event” shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated
Transactions by the Required Company Stockholder Vote: (a) the Company Board shall have made a Company Board Adverse Recommendation
Change; (b) the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal;
or (c) the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition
Proposal.
“Company Warrants”
means warrants to purchase shares of Company Capital Stock issued by the Company.
“Confidentiality
Agreement” means the letter agreement dated as of September 17, 2024, between the Company and Parent.
“Consent”
means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).
“Contemplated Transactions”
means the Merger and the other transactions contemplated by this Agreement (other than the Parent Charter Amendment), the Parent Financing
and the Nasdaq Reverse Split (to the extent applicable and deemed necessary by Parent and the Company).
“Contract”
means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage,
license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or
any of its assets are bound or affected under applicable Law.
“DGCL”
means the General Corporation Law of the State of Delaware.
“DLLCA”
means the Delaware Limited Liability Company Act.
“Effect”
means any effect, change, event, circumstance, or development.
“Employee Plan”
means (A) an “employee benefit plan” within the meaning of Section 3(3) of ERISA whether or not subject to
ERISA; (B) other plan, program, policy or arrangement providing for stock options, stock purchases, equity-based compensation, bonuses
(including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation,
change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits),
pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits,
dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (A) above;
and (C) all other plans, programs, policies or arrangements providing compensation to employees, consultants and non-employee directors.
“Encumbrance”
means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation,
servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest
or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer
of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any
asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).
“Enforceability
Exceptions” means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and
(b) rules of law governing specific performance, injunctive relief and other equitable remedies.
“Entity”
means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited
liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or
joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.
“Environmental Law”
means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient
air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges,
releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials.
“ERISA Affiliate”
means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same “controlled
group” as such Entity under Sections 414(b), (c), (m) or (o) of the Code.
“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended.
“Exchange Act”
means the Securities Exchange Act of 1934, as amended.
“First Merger Sub
Board” means the board of directors of First Merger Sub.
“Governmental Authority”
means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature,
(b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or quasi-governmental authority
of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund,
foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority)
or (d) self-regulatory organization (including Nasdaq).
“Governmental Authorization”
means any: (a) permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration,
qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority
or pursuant to any Law or (b) right under any Contract with any Governmental Authority.
“Hazardous Materials”
means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical,
or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control
or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or
by-products.
“HSR Act”
means the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended.
“In the Money Parent
Option” shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price.
“Intellectual Property”
means: (a) United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions,
divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term
extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures
and inventions (collectively, “Patents”), (b) trademarks, service marks, trade names, domain names, corporate
names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration
thereof and goodwill associated therewith, (c) copyrights, including registrations and applications for registration thereof, (d) software,
including all source code, object code and related documentation, (e) formulae, customer lists, trade secrets, know-how, confidential
information and other proprietary rights and intellectual property, whether patentable or not, and (f) all United States and foreign
rights arising under or associated with any of the foregoing.
“Interim Financing”
means any sale (or series of related sales) by the Company of its Common Stock or Preferred Stock, as applicable, that is completed following
the date hereof; provided, however, that the issuance of Company Notes and the Parent Financing shall not be an Interim Financing.
“IRS”
means the United States Internal Revenue Service.
“Knowledge”
means, (i) with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably
be expected to know such fact in the ordinary course of the performance of such individual’s employment responsibilities, and (ii) with
respect to any Person that is an Entity the Knowledge of any executive officer of such Person as of the date such knowledge is imputed.
With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require
any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual
Property rights clearance searches.
“Law”
means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common
law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the
Financial Industry Regulatory Authority).
“Legal Proceeding”
means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate
proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other
Governmental Authority or any arbitrator or arbitration panel.
“Minimum Concurrent
Investment Amount” means (i) $100,000,000 minus (ii) the amount of proceeds actually received by the
Company in connection with any Interim Financing prior to the Closing.
“Multiemployer Plan”
means a “multiemployer plan,” as defined in Section 3(37) or 4001(a)(3) of ERISA.
“Multiple Employer
Plan” means a “multiple employer plan” within the meaning of Section 413(c) of the Code or Section 3(40)
of ERISA.
“Multiple Employer
Welfare Arrangement” means a “multiple employer welfare arrangement” within the meaning of Section 3(40) of
ERISA.
“Nasdaq Reverse
Split” means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining
compliance with Nasdaq listing standards.
“Nasdaq”
means The Nasdaq Stock Market.
“Order”
means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate
integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court
or Governmental Authority.
“Ordinary Course
of Business” means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business
and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar
stage of development.
“Organizational
Documents” means, with respect to any Person (other than an individual), (a) the certificate or articles of association
or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company,
operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization
of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of
such Person, in each case, as amended or supplemented.
“Out of the Money
Parent Options” shall mean Parent Options with an exercise price greater than the Parent Closing Price.
“Parent Associate”
means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries.
“Parent Balance
Sheet” means the audited balance sheet of Parent as of December 31, 2023, included in Parent’s Report on Form 10-K
for the year ended December 31, 2023, as filed with the SEC.
“Parent Board”
means the board of directors of Parent.
“Parent Capital
Stock” means the Parent Common Stock and the Parent Preferred Stock.
“Parent Capitalization
Representations” means the representations and warranties of Parent and Merger Subs set forth in Sections 4.6(a) and
4.6(d).
“Parent Closing
Price” means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5) consecutive
trading days ending three (3) trading days immediately prior to the Closing Date as reported by Bloomberg L.P.
“Parent Common Stock”
means the common stock, $0.001 par value per share, of Parent.
“Parent Contract”
means any Contract: (a) to which Parent is a party, (b) by which Parent or any Parent IP Rights or any other asset of Parent
is or may become bound or under which Parent has, or may become subject to, any obligation or (c) under which Parent has or may
acquire any right or interest.
“Parent Convertible
Preferred Stock” means Parent’s non-voting convertible preferred stock, par value $0.001 per share, with the rights,
preferences, powers and privileges specified in the Certificate of Designation.
“Parent Employee
Plan” means any Employee Plan that Parent or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes
to, (ii) may reasonably be expected to have any Liability, or (iii) utilizes to provide benefits to or otherwise cover any
current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents,
or beneficiaries), but excluding any Employee Plan in which the Parent or any of its Subsidiaries participates that is sponsored by any
professional employer organization.
“Parent
Fundamental Representations” means the representations and warranties of Parent and Merger Subs set forth in Sections 4.1(a),
4.2, 4.3, 4.4, 4.5(a)(i) and 4.21.
“Parent IP Rights
Agreement” means any Contract governing, related or pertaining to any Parent IP Rights.
“Parent IP Rights”
means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation
of the business of Parent.
“Parent Key Employee”
means (i) an executive officer of Parent; and (ii) any employee of Parent that reports directly to the Parent Board or to an
executive officer of Parent.
“Parent Material
Adverse Effect” means any Effect that, considered together with all other Effects that have occurred prior to the date of determination
of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the
business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; provided,
however, that Effects arising or resulting from the following shall not be taken into account in determining whether there has
been a Parent Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions,
(b) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing
or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether
a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking
of any action, or the failure to take any action, by Parent that is required to comply with the terms of this Agreement, (d) any
natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed
hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or
any governmental or other response or reaction to any of the foregoing, (e) any change in GAAP or applicable Law or the interpretation
thereof, (f) general economic or political conditions or conditions generally affecting the industries in which Parent or any of
its Subsidiaries operates, (g) failure to achieve or maintain any minimum level of Parent Net Cash, (h) any determination by
the SEC regarding Parent’s reporting status under the Exchange Act, or (i) any results, outcomes, data, indications, adverse
events, side effects or safety observations arising from preclinical trials, clinical trials and/or testing relating to Parent’s
Uproleselan (GMI-1271) program, including any requirement to conduct further clinical studies or tests or any increased incidence or
severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports of any new side
effects, adverse events or safety observations (or any public announcements relating to any of the foregoing); except, in each case with
respect to clauses (d), (e) and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries,
taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates.
Notwithstanding the above, a delisting of Parent Common Stock on Nasdaq shall constitute a Parent Material Adverse Effect, provided that
the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common
Stock on Nasdaq.
“Parent Net Cash”
means without duplication, (i) Parent’s unrestricted cash and cash equivalents and marketable securities determined, to the
extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance
with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the
Parent Balance Sheet, plus (ii) all prepaid expenses set forth on Section 1.1(a) of the Parent Disclosure
Letter, minus (iii) the sum of Parent’s consolidated short-term and long-term contractual obligations and liabilities
accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner
consistent with the manner in which such items were historically determined and in accordance with the financial statements (including
any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, minus
(iv) the aggregate amount (without duplication) of all fees and expenses incurred by Parent prior to the First Effective Time in
connection with the Contemplated Transactions, excluding any Parent Net Cash Excluded Expenses but including (to the extent not a Parent
Net Cash Excluded Expense): (a) any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers,
consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions; (b) 50% of
the fees paid to the SEC in connection with filing the Proxy Statement and any amendments and supplements thereto, with the SEC; (c) 50%
of the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements
thereto; (d) 50% of the Nasdaq Fees; (e) any bonus, retention payments, severance, change-in-control payments or similar payment
obligations (including payments with “single-trigger” provisions triggered at and as of the consummation of the transactions
contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation
of the Contemplated Transactions, together with any payroll Taxes associated therewith; (f) the costs associated with obtaining
the “D&O tail policy” pursuant to Section 6.7, in each case, to the extent unpaid as of the First Effective
Time; and (g) for the avoidance of doubt, the amount by which the actual amount of any Parent Net Cash Excluded Expense at Closing
exceeds the estimate set forth on Schedule 1.1(b) of the Parent Disclosure Letter, minus (v) all remaining rent
payments and any other Liabilities under Parent’s lease obligations, minus (vi) any unpaid Taxes of Parent and
its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date, and plus (vii) $300,000
for each month, or portion thereof, after June 30, 2025 by which Closing is delayed (except where such delay is caused primarily
by the actions of Parent), which amount shall begin accruing on July 1, 2025 (for example, if the Closing is delayed until (A) July 31,
2025 as a result of such failure then $300,000 will be added to Parent Net Cash or (B) August 30, 2025 as a result of such
failure then $600,000 will be added to Parent Net Cash); provided, however, that if any portion of the fees and expenses described
in subclauses (b), (c), and (d) of clause (iv) have been paid by Parent prior to the First Effective Time in an amount greater
than Parent’s share of such fee and expense described in subclauses (b), (c), and (d), then (x) such portion in excess of
Parent’s shares of such fee and expense described in subclauses (b), (c), and (d) shall not be deducted by reason of subclauses
(b), (c), and (d) of clause (v) and (y) such portion shall be added to the calculation of Parent Net Cash. For avoidance
of doubt, (i) the cash received in the Parent Financing will be excluded from the calculation of Parent Net Cash and (ii) the
calculation of Parent Net Cash may result in a number below $0.
“Parent Net Cash
Excluded Expenses” means those fees and expenses incurred by Parent prior to the First Effective Time in connection with the
Contemplated Transactions set forth on Section 1.1(b) of the Parent Disclosure Letter, which schedule shall include
a description and good faith estimate of such Parent Net Cash Excluded Expense as of immediately before the Closing.
“Parent Options”
means options or other rights to purchase shares of Parent Common Stock granted by Parent, including pursuant to any Parent Stock Plan.
“Parent Preferred
Stock” means the shares of Parent’s capital stock designated as preferred stock, par value $0.001 per share of Parent,
including the Parent Convertible Preferred Stock.
“Parent Registered
IP” means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under
the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all
applications for any of the foregoing.
“Parent Restricted
Stock Units” means any equity award with respect to Parent Common Stock that represents the right to receive in the future
shares of Parent Common Stock pursuant to any Parent Stock Plan.
“Parent Triggering
Event” shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent’s
stockholders and subject to Section 6.3(c): (a) Parent shall have failed to include in the Proxy Statement the
Parent Board Recommendation, (b) the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation
Change or subject to Section 6.3(e), publicly proposed, endorsed or recommended any Acquisition Proposal or (c) Parent
shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an
Acceptable Confidentiality Agreement permitted pursuant to Section 5.4).
“Party”
or “Parties” means the Company, Merger Subs and Parent.
“Permitted Alternative
Agreement” means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes
a Superior Offer.
“Permitted Encumbrance”
means (a) any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the
appropriate proceedings and for which adequate reserves will be or have been made on the Company Financial Statements or the Parent Balance
Sheet, as applicable, in accordance with GAAP, (b) minor non-monetary liens that have arisen in the Ordinary Course of Business
and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair
the operations of the Company or Parent, as applicable, (c) statutory liens to secure obligations to landlords, lessors or renters
under leases or rental agreements, (d) deposits or pledges made in connection with, or to secure payment of, workers’ compensation,
unemployment insurance or similar programs mandated by Law, (e) statutory liens in favor of carriers, warehousemen, mechanics and
materialmen, to secure claims for labor, materials or supplies for amounts that are not yet due and payable and (f) liens arising
under applicable securities Law.
“Person”
means any individual, Entity or Governmental Authority.
“Personal Information”
means any data or information that constitutes “personal information,” “personal data,” “personally identifiable
information,” “protected health information,” or any analogous term under applicable Law, including any such information
that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked,
directly or indirectly, with any identified or identifiable individual or household.
“Privacy Laws”
mean, collectively, (i) all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft,
breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking
technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information,
including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory
authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, or state data
protection authorities, including HIPAA, Section 5 of the Federal Trade Commission Act, the Controlling the Assault of Non-Solicited
Pornography And Marketing Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification
Laws, and (ii) any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data
security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic
mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer,
or other processing of Personal Information, including the Payment Card Industry Data Security Standard.
“Representatives”
means with respect to a Person, such Person’s directors, officers, employees, agents, attorneys, accountants, investment bankers,
advisors and other representatives.
“Sarbanes-Oxley
Act” means the Sarbanes-Oxley Act of 2002.
“SEC”
means the United States Securities and Exchange Commission.
“Securities Act”
means the Securities Act of 1933, as amended.
“Subsequent Transaction”
means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references
to 50% for these purposes).
“Subsidiary”
means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record,
(a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least
a majority of the members of such entity’s board of directors or other governing body or (b) at least 50% of the outstanding
equity, voting, beneficial or financial interests in such Entity.
“Superior Offer”
means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction
being treated as references to 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach
of this Agreement, (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good
faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof),
as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with
its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent’s stockholders
or the Company’s stockholders, as applicable, than the terms of the Contemplated Transactions, (c) is not subject to any financing
conditions (and if financing is required, such financing is then fully committed to the third party) and (d) is reasonably capable
of being completed on the terms proposed.
“Tax Return”
means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification,
form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required
to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or
payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to
any Tax.
“Tax”
means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts
tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise
tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll
tax, social security tax, customs duty, licenses tax, alternative or add-on minimum or other tax or similar charge, duty, levy, fee,
tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed),
and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto
(or attributable to the nonpayment thereof).
“Treasury Regulations”
means the United States Treasury regulations promulgated under the Code.
(b) Each of the following
terms is defined in the Section set forth opposite such term:
| Terms |
Section |
| AAA |
2.8(i) |
| Accounting Firm |
2.8(i) |
| Agreement |
Preamble |
| Allocation Certificate |
6.15 |
| Assumed Option |
6.5(a) |
| Assumed Warrant |
6.5(b) |
| Capitalization Date |
4.6(a) |
| Cash Determination Time |
2.8(a) |
| Certificate of Merger |
2.3 |
| Certifications |
4.7(a) |
| Closing Date |
2.3 |
| Closing |
2.3 |
| Company 409A Plan |
3.17(j) |
| Company Board Adverse Recommendation
Change |
6.2(d) |
| Company Board Recommendation |
6.2(c) |
| Company Disclosure Letter |
Section 3 |
| Company Financial Statements |
6.1(d) |
| Company Intervening Event |
6.2(d) |
| Company Material Contract |
3.13(a) |
| Company Material Contracts |
3.13(a) |
| Company Permits |
3.14(b) |
| Company Product Candidates |
3.14(d) |
| Company Real Estate Leases |
3.11 |
| Company Regulatory Permits |
3.14(d) |
| Company Required S-4 Information |
6.1(c) |
| Company Stockholder Support
Agreement |
Recital |
| Company Stockholder Written
Consents |
6.2(a) |
| Company Termination Fee |
10.3(b) |
| Company Valuation Calculation |
2.8(b) |
| Company Valuation Delivery
Date |
2.8(b) |
| Company Valuation Determination
Time |
2.8(b) |
| Company Valuation Dispute
Notice |
2.8(d) |
| Company Valuation Response
Date |
2.8(d) |
| Company Valuation Schedule |
2.8(b) |
| Company |
Preamble |
| Concurrent Investment |
Preamble |
| Costs |
6.7(a) |
| D&O Indemnified Parties |
6.7(a) |
| Dispute Notice |
2.8(c) |
| Dissenting Shares |
2.12(a) |
| Drug/Device Regulatory
Agency |
3.14(b) |
| Employment-Related Laws |
3.17(k) |
| End Date |
10.1(b) |
| Exchange Agent |
2.7(a) |
| FDA |
3.14(b) |
| FDCA |
3.14(c) |
| First Certificate of Merger |
2.3 |
| First Effective Time |
2.3 |
| First Merger |
Recital |
| First Step Surviving Corporation |
Section 2 |
| Form S-4 |
6.1(a) |
| GAAP |
Error!
Reference source not found. |
| Intended Tax Treatment |
2.10 |
| Liability |
3.9 |
| Lock-Up Agreement |
Recital |
| Lock-Up Agreements |
Recital |
| Merger Consideration |
2.5(a)(ii) |
| Merger Subs |
Preamble |
| Merger |
Recital |
| Nasdaq Fees |
6.9 |
| Nasdaq Listing Application |
6.9 |
| Notice Period |
6.2(d) |
| Ordinary Course Agreement |
3.16(g) |
| Parent 409A Plan |
4.17(j) |
| Parent Board Adverse Recommendation
Change |
6.3(c) |
| Parent Board Recommendation |
6.3(b) |
| Parent Charter Amendment |
2.4(b)(ii) |
| Parent Disclosure Letter |
Section 4 |
| Parent Intervening Event |
6.3(c) |
| Parent Material Contract |
4.13(a) |
| Parent Material Contracts |
4.13(a) |
| Parent Net Cash Calculation |
2.8(a) |
| Parent Net Cash Schedule |
2.8(a) |
| Parent Notice Period |
6.3(c) |
| Parent Permits |
4.14(b) |
| Parent Product Candidates |
4.14(d) |
| Parent Real Estate Leases |
4.11 |
| Parent Regulatory Permits |
4.14(d) |
| Parent SEC Documents |
4.7(a) |
| Parent Stock Plans |
4.6(c) |
| Parent Stockholder Matters |
6.3(a) |
| Parent
Stockholder Meeting |
6.3(a) |
| Parent Stockholder Support
Agreement |
Recital |
| Parent |
Preamble |
| PHSA |
3.14(c) |
| Post-Closing Welfare Plan |
6.6(b) |
| Pre-Closing Period |
5.1(a) |
| Privacy Policies |
3.22 |
| Proxy Statement |
6.1(a) |
| Registration Statement |
6.1(a) |
| Required Company Stockholder
Vote |
3.4 |
| Required Parent Stockholder
Vote |
4.4 |
| Response Date |
2.8(c) |
| SEC Documents |
6.16 |
| Second Certificate of Merger |
2.3 |
| Second Effective Time |
2.3 |
| Second Merger |
Recital |
| Stockholder Notice |
6.2(b) |
| Subscription Agreement |
Recital |
| Surviving Entity |
Section 2 |
| Tax Certificates |
6.10(c) |
| Transaction Litigation |
6.4(c) |
| WARN Act |
3.17(k) |
1.2 Other
Definitional and Interpretative Provisions. The words “hereof,” “herein” and “hereunder” and
words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement.
The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof.
References to Sections, Exhibits and Schedules are to Sections, Exhibits and Schedules of this Agreement unless otherwise specified.
Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this
Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter
gender shall include masculine and feminine gender. Whenever the words “include,” “includes” or “including”
are used in this Agreement, they shall be deemed to be followed by the words “without limitation,” whether or not they are
in fact followed by those words or words of like import. The word “or” is not exclusive. “Writing,” “written”
and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References
to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company
Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms
hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts
of the interpretation of this Agreement, but only Exhibit D-1 (including Exhibit A to such Exhibit) and Exhibit D-2 is
incorporated by reference and made a part hereof for purposes of Section 251 of the DGCL. References to any Person include the successors
and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated
thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to “$” and
“dollars” are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting
determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date
shall mean, unless otherwise specified, from and including or through and including, respectively. All references to “days”
shall be to calendar days unless otherwise indicated as a “Business Day.” Except as otherwise specifically indicated, for
purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of “Business Day”
and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in
the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to
be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree
that the Company Disclosure Letter or Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered
and lettered sections and subsections contained in Section 3 or Section 4, respectively. The disclosures in any
section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in
Section 3 or Section 4, respectively, to the extent it is readily apparent from a reading of the disclosure that
such disclosure is applicable to such other sections and subsections. The words “delivered” or “made available”
mean, with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date
of this Agreement, a copy of such material has been (a) posted to and continuously made available by a Party to the other Party
and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions
or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail
or in hard copy form prior to the execution of this Agreement.
Section 2.
Description of Transaction.
2.1 The
Merger. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger
Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue
as the surviving corporation in the First Merger (the “First Step Surviving Corporation”). Upon the terms and subject
to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and
into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger,
Second Merger Sub will continue as the surviving entity in the Second Merger (the “Surviving Entity”).
2.2 Effects
of the Merger. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL.
As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects
set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA.
2.3 Closing;
First Effective Time; Second Effective Time. Unless this Agreement is earlier terminated pursuant to the provisions of Section Section 10,
and subject to the satisfaction or waiver of the conditions set forth in Section 7, Section 8 and Section 9,
the consummation of the Merger (the “Closing”) shall take place remotely, as promptly as practicable (but in no event
later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth
in 6.19, Section 8 and Section 9, other than those conditions that by their nature are to be satisfied
at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent
and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the “Closing
Date.” Immediately prior to the Closing on the Closing Date, Parent shall file the Certificate of Designation with the office
of the Secretary of State of the State of Delaware. At the Closing, (i) the Parties shall cause the First Merger to be consummated
by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying
the applicable requirements of the DGCL and in form and substance attached hereto as Exhibit D-1 and incorporated herein
by reference (the “First Certificate of Merger”) and (ii) the Parties shall cause the Second Merger to be consummated
by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger,
satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as Exhibit D-2
and incorporated herein by reference (the “Second Certificate of Merger” and together with the First Certificate of
Merger, the “Certificate of Merger”). The First Merger shall become effective at the time of the filing of such Certificate
of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger
with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the “First
Effective Time”). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with
the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the
consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the “Second
Effective Time”).
2.4 Organizational
Documents; Directors and Officers.
(a) At
the First Effective Time:
(i) The
certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth
on Exhibit A to the First Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;
(ii) The
bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the
First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and
(iii) The
directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation
and bylaws of the First Step Surviving Corporation, shall be such persons as are designated by the Company prior to the First Effective
Time.
(b) At
the Second Effective Time:
(i) The
certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately
prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however,
that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A) change
the name of the Surviving Entity to “Crescent Biopharma Operating Company, LLC,” and (B) make such other changes as
are mutually agreed to by Parent and the Company;
(ii) The
limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the
limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter
amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective
Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving
Entity to “Crescent Biopharma Operating Company, LLC”;
(iii) The
certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Second
Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; provided, however,
that at the Second Effective Time, Parent shall file an amendment to its certificate of incorporation to (i) change the name of
Parent to “Crescent Biopharma, Inc.”, (ii) effect the Nasdaq Reverse Split (to the extent applicable and necessary),
(iii) increase the number of shares of Parent Capital Stock that Parent is authorized to issue to a number mutually agreed between
Parent and the Company, such amount to be sufficient to allow for consummation of the Contemplated Transactions, (iv) redomicile
Parent from Delaware to such jurisdiction as may be determined by the Company (being either the Cayman Islands or Bermuda), and (v) make
such other changes as are mutually agreeable to Parent and the Company (such amendment, the “Parent Charter Amendment”);
(iv) The
directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall
be as set forth in Section 6.12; and
(v) The
directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability
company agreement of Second Merger Sub, shall be as set forth in Section 6.12 after giving effect
to the provisions of Section 6.12, or such other persons as shall be mutually agreed upon by Parent
and the Company.
2.5 Conversion
of Company, First Merger Sub and Second Merger Sub Equity Securities.
(a) At
the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any
stockholder of the Company or Parent:
(i) any
shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and
shall cease to exist, and no consideration shall be delivered in exchange therefor; and
(ii) subject
to Section 2.5(c), (A) each share of Company Common Stock outstanding immediately prior to the First
Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to Section 2.5(a)(i) and
excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the
Exchange Ratio, and (B) each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (excluding
shares of Company Capital Stock to be canceled pursuant to Section 2.5(a)(i) and excluding Dissenting
Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x) the
Exchange Ratio divided by (y) 1,000 (collectively, the “Merger Consideration”).
(b) If
any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase
option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company,
then the shares of Parent Capital Stock issued in exchange for such shares of Company Capital Stock will to the same extent be unvested
and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked
with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective
Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement
or other agreement.
(c) No
fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional
shares shall be issued. Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent
Common Stock (on a per certificate basis) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder
of a letter of transmittal in accordance with Section 2.7 and any accompanying documents as required therein:
(i) one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company
Common Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Parent Common Stock if the aggregate
amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is less than 0.50,
with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a
holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred
Stock issuable to such and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder
of a letter of transmittal in accordance with Section 2.7 and any accompanying documents as required therein,
rounded up to the nearest whole share of Parent Preferred Stock.
(d) All
Company Options (including any Service Provider Grants) outstanding immediately prior to the First Effective Time shall be treated in
accordance with Section 6.5(a). All Company Warrants outstanding immediately prior to the First Effective Time
shall be treated in accordance with Section 6.5(b).
(e) Each
share of common stock, $0.001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective
Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value
per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares
shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.
(f) If,
between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall
have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision,
reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken
into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to
the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital
Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior
to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change;
provided, however, that nothing herein will be construed to permit the Company or Parent to take any action with respect
to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.
(g) At
the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation,
Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately
prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall
be made with respect thereto.
2.6 Closing
of the Company’s Transfer Books. At the First Effective Time: (a) all Company Capital Stock outstanding immediately prior
to the First Effective Time shall be treated in accordance with Section 2.5(a), and all holders of certificates representing
Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders
of the Company and (b) the stock transfer books of the Company shall be closed with respect to all Company Capital Stock outstanding
immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer
books after the First Effective Time.
2.7 Surrender
of Company Capital Stock.
(a) On
or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as
exchange agent in the Merger (the “Exchange Agent”). At the First Effective Time, Parent shall deposit with the Exchange
Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to Section 2.5(a) in
exchange for Company Capital Stock.
(b) Promptly
after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of
Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary
form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of physical stock
certificates representing shares of Company Capital Stock, (the “Company Stock Certificates”) shall be effected, and
risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent) and (ii) instructions
for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry
shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated
Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents
as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate or uncertificated
shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration
(in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of Section 2.5(a) and
Section 2.5(c) and (B) the Company Stock Certificate or uncertificated shares of Company Capital Stock
so surrendered shall be canceled. Until surrendered as contemplated by this Section 2.7(b), each Company Stock
Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent
only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate
shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of
Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit
with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the
lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably
request.
(c) No
dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time
shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such
holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of
Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this Section 2.7
(at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to
receive all such dividends and distributions, without interest).
(d) Any
shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates as
of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates
who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance
with this Section 2.7 shall thereafter look only to Parent for satisfaction of their claims for Parent Capital
Stock and any dividends or distributions with respect to shares of Parent Capital Stock.
(e) No
Person shall be liable to any holder of any Company Stock Certificate or uncertificated shares of Company Capital Stock or to any other
Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts
delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.
2.8 Calculation
of Net Cash and Company Valuation.
(a) No
later than five (5) Business Days before the Closing, Parent will deliver to the Company a schedule (the “Parent Net Cash
Schedule”) setting forth, in reasonable detail, Parent’s good faith, estimated calculation of the components of Parent
Net Cash, including any Parent Net Cash Lower Amount or Parent Net Cash Upper Amount (the “Parent Net Cash Calculation”)
as of 11:59 p.m. on the Business Day prior to the Anticipated Closing Date (the “Cash Determination Time”) prepared
and certified by Parent’s chief financial officer (or if there is no chief financial officer at such time, the principal financial
and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably
requested by the Company, the work papers and back-up materials used or useful in preparing the Parent Net Cash Schedule and, if reasonably
requested by the Company, Parent’s internal finance personnel and its accountants and counsel at reasonable times and upon reasonable
notice. The Parent Net Cash Calculation shall include Parent’s determination, as of the Cash Determination Time, of the defined
terms in Section 1.1(a) necessary to calculate the Exchange Ratio. During the period after the delivery
of the Parent Net Cash Schedule and prior to the Closing, the Company shall have an opportunity to review the Parent Net Cash Schedule
and Parent shall reasonably cooperate with the Company in good faith to respond to any questions regarding the Parent Net Cash Schedule
raised by the Company; provided, that this shall in no way limit or otherwise affect the Company’s remedies under this Agreement
or otherwise, or constitute an acknowledgement by the Company of the accuracy of the amounts reflected therein.
(b) No
later than five (5) Business Days before the Closing, the Company will deliver to Parent a schedule (the “Company Valuation
Schedule”) setting forth, in reasonable detail, the Company’s good faith, estimated calculations of the components of
the Company Valuation (the “Company Valuation Calculation”) and the date of delivery of such schedule being (the “Company
Valuation Delivery Date”) as of 11:59 p.m. on the last Business Day prior to the Anticipated Closing Date (the “Company
Valuation Determination Time”) prepared and certified by the Company’s chief financial officer (or if there is no chief
financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to
Parent, as reasonably requested by Parent, the work papers and back-up materials used or useful in preparing the Company Valuation Schedule
and, if reasonably requested by Parent, the Company’s accountants and counsel at reasonable times and upon reasonable notice. During
the period after the delivery of the Company Valuation Schedule and prior to the Closing, Parent shall have an opportunity to review
the Company Valuation Schedule and the Company shall reasonably cooperate with Parent in good faith to respond to any questions regarding
the Company Valuation Schedule raised by Parent; provided, that this shall in no way limit or otherwise affect the Parent’s remedies
under this Agreement or otherwise, or constitute an acknowledgement by Parent of the accuracy of the amounts reflected therein.
(c) No
later than three (3) Business Days after the Cash Determination Time (the last day of such period, the “Response Date”),
the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect
to Parent (a “Dispute Notice”). Any Dispute Notice shall identify in reasonable detail and to the extent known the
nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials
supporting the basis for such revisions.
(d) No
later than three (3) Business Days after the Company Valuation Delivery Date (the last day of such period, the “Company
Valuation Response Date”), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering
a written notice to that effect to the Company (a “Company Valuation Dispute Notice”). Any Company Valuation Dispute
Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation
Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.
(e) If,
on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation
or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in Section 2.8(c), then
the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined for purposes
of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.
(f) If,
on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation
Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in
Section 2.8(d), then the Company Valuation Calculation as set forth in the Company Valuation Schedule shall be
deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation
Determination Time for purposes of this Agreement.
(g) If
the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly
meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which
agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent
the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.
(h) If
Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent
and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination
of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined
for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this
Agreement.
(i) If
Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination
Time pursuant to Section 2.8(g) or the components of Company Valuation as of the Company Valuation Determination
Time pursuant to Section 2.8(h) within three days after delivery of the Dispute Notice or the Company Valuation
Dispute Notice, as applicable, (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements
as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing
jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5) days, then
either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (“AAA”)
make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA,
the “Accounting Firm”). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and back-up
materials used in preparing the Parent Net Cash Schedule and the Dispute Notice and the Company Valuation Schedule and the Company Valuation
Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination
within five (5) Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present
to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; provided,
however, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the
Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination
of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered
to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to
have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the
components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay
the Closing until the resolution of the matters described in this Section 2.8(i). The fees and expenses of the
Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash
or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total
disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this Section 2.8(i) applies
as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company
Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this Section 2.8(i),
the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later
than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the
Company Valuation if the Closing Date is more than thirty (30) days after the Anticipated Closing Date.
2.9 Further
Action. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary
or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and
to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall
use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second
Merger Sub, in the name of the Surviving Entity and otherwise) to take such action.
2.10 Intended
Tax Treatment. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the
Merger is intended to qualify as a reorganization within the meaning of Section 368(a) of the Code (the “Intended
Tax Treatment”). The Parties adopt this Agreement as a “plan of reorganization” within the meaning of Treasury
Regulations Sections 1.368-2(g) and 1.368-3.
2.11 Withholding.
Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable
pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable
Law; provided that the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify
such Persons of any intention to withhold any portion of such consideration and cooperate with such Persons to reduce or eliminate any
such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the
appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person
to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees
for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable.
2.12 Appraisal
Rights.
(a) Notwithstanding
any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First
Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for
such shares of Company Capital Stock in accordance with the DGCL (collectively, the “Dissenting Shares”) shall not
be converted into or represent the right to receive the Merger Consideration described in Section 2.5 attributable
to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares
of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect
or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned
by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares
of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to
be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration,
without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in Sections 2.5
and 2.7.
(b) The
Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company,
withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in
connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such
demands. The Company shall not, except with Parent’s prior written consent, not to be unreasonably withheld, delayed or conditioned,
make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree
to do any of the foregoing.
Section 3.
Representations and Warranties of the Company.
Except as set forth in the
written disclosure document delivered by the Company to Parent (the “Company Disclosure Letter”) concurrently with
the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows:
3.1 Due
Organization; Subsidiaries.
(a) The
Company is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under
the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its
business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets
in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under
all Contracts by which it is bound.
(b) The
Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under
the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires
such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would
not be reasonably expected to have a Company Material Adverse Effect.
(c) The
Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit
sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been,
directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company
has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment
in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable
for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.
3.2 Organizational
Documents. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company
is not in breach or violation of its Organizational Documents in any material respect.
3.3 Authority;
Binding Nature of Agreement. The Company has all necessary corporate power and authority to enter into and to perform its
obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board has (i) determined that the
Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and
declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject
to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve
the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization,
execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.
3.4 Vote
Required. The affirmative vote (or written consent) of (i) the holders of a majority of the shares of Company Capital Stock
outstanding on the record date, voting as a single class on an as-converted basis, and (ii) the holders of a majority
of the shares of Company Series Seed Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate
class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement
and approve the Contemplated Transactions (collectively, the “Required Company Stockholder Vote”).
3.5 Non-Contravention;
Consents.
(a) Subject
to obtaining the Required Company Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the
filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, neither (x) the execution, delivery
or performance of this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly
(with or without notice or lapse of time):
(i) contravene,
conflict with or result in a violation of any of the provisions of the Company’s Organizational Documents;
(ii) contravene,
conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated
Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned
or used by the Company, is subject;
(iii) contravene,
conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right
to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise
relates to the business of the Company, or any of the assets owned, leased or used by the Company;
(iv) contravene,
conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or
give any Person the right to: (A) declare a default or exercise any remedy under any Company Material Contract, (B) any material
payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C) accelerate the maturity
or performance of any Company Material Contract or (D) cancel, terminate or modify any term of any Company Material Contract, except
in the case of any nonmaterial breach, default, penalty or modification; or
(v) result
in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted
Encumbrances).
(b) Except
for (i) the Required Company Stockholder Vote, (ii) the filing of the Certificate of Merger and Certificate of Designation
with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iii) compliance with any applicable requirements
of the HSR Act (if applicable) and (iv) such consents, waivers, approvals, orders, authorizations, registrations, declarations and
filings as may be required under applicable federal and state securities laws, the Company was not, is not, nor will be required to make
any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery
or performance of this Agreement or (y) the consummation of the Contemplated Transactions.
(c) No
state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements
or any of the Contemplated Transactions.
3.6 Capitalization.
(a) The
authorized capital stock of the Company consists of (i) 40,000,000 shares of Company Common Stock of which 27,049,180 shares have
been issued and are outstanding as of the date hereof and (ii) 20,000,000 shares of Company Preferred Stock, of which 20,000,000
shares have been designated Series Seed Preferred Stock and 20,000,000 have been issued and are outstanding as of the date hereof.
The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company’s capital
stock is held by the Persons and in the amounts set forth in Section 3.6(a) of the Company Disclosure Letter,
which further sets forth for each such Person (i) the name of such Person and the number of shares held, (ii) the class
and series of such shares, (iii) the number of the applicable book-entry positions representing such shares or the number of the
certificate representing such shares, (iv) whether such Person is or has ever been an employee, and (v) the state of residence
of such Person. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or
accrued but unpaid dividends with respect to any shares of the Company’s capital stock and the Company has never declared or paid
any dividend or other distribution.
(b) All
of the outstanding Company Capital Stock as set out in Section 3.6(a) of the Company Disclosure Letter have
been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances
set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding Company Capital Stock is entitled
or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company
Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract
relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or
granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it
bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital
Stock or other securities. Section 3.6(b) of the Company Disclosure Letter accurately and completely describes
all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of
stock options) and specifies which of those repurchase rights are currently exercisable.
(c) Except
for the Company Stock Plans and except as set forth on Section 3.6(c) of the Company Disclosure Letter,
the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation
for any Person. Section 3.6(c) of the Company Disclosure Letter sets forth the following information with
respect to each Company Option outstanding as of the date hereof: (i) the name of the holder, (ii) the number of shares of
Company Common Stock subject to such Company Option as of the date hereof, (iii) the exercise price of such Company Option, (iv) the
date on which such Company Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi) the
date on which such Company Option expires, (vii) whether such Company Option is intended to be an “incentive stock option”
(as defined in the Code) or a nonqualified stock option and (viii) in the case of a Company Option, the plan pursuant to which such
Company Option was granted. The Company has made available to Parent accurate and complete copies of equity incentive plans pursuant
to which the Company has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board
and stockholder approval of the Company Stock Plans and any amendments thereto.
(d) Except
for the outstanding Company Options or as set forth on Section 3.6(d) of the Company Disclosure Letter,
there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any
Company Capital Stock or other securities of the Company, (ii) outstanding security, instrument or obligation that is or may become
convertible into or exchangeable for any shares of the capital stock or other securities of the Company, (iii) stockholder rights
plan (or similar plan commonly referred to as a “poison pill”) or Contract under which the Company is or may become obligated
to sell or otherwise issue any Company Capital Stock or any other securities or (iv) condition or circumstance that may give rise
to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any
shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock,
profit participation or other similar rights with respect to the Company.
(e) All
outstanding Company Capital Stock, Company Options and other securities of the Company have been issued and granted in compliance in
all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth
in applicable Contracts.
(f) The
Company Capital Stock are uncertificated.
3.7 Financial
Statements.
(a) The
Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed
in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit
preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company’s
assets, (iii) access to the Company’s assets is permitted only in accordance with management’s general or specific authorization
and (iv) the recorded accountability for the Company’s assets is compared with the existing assets at regular intervals and
appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of
similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes.
(b) Section 3.7(c) of
the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating
or governing, all securitization transactions and “off-balance sheet arrangements” (as defined in Item 303(c) of Regulation
S-K under the Exchange Act) effected by the Company.
(c) There
have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed
by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company
Board or any committee thereof. Neither the Company nor its independent auditors have identified (i) any significant deficiency
or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii) any
fraud, whether or not material, that involves the Company, the Company’s management or other employees who have a role in the preparation
of financial statements or the internal accounting controls utilized by the Company or (iii) any claim or allegation regarding any
of the foregoing.
3.8 Absence
of Changes. Except as set forth on Section 3.8 of the Company Disclosure Letter, between the date of its incorporation
and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution
and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Company
Material Adverse Effect or (b) action, event or occurrence that would have required consent of Parent pursuant to Section 5.2(b) of
this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.
3.9 Absence
of Undisclosed Liabilities. Since the date of its incorporation, the Company does not have any liability, indebtedness, obligation,
expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise
(each a “Liability”), except for: (a) Liabilities disclosed, reflected or reserved against (or to be disclosed,
reflected or reserved against) in Company Financial Statements, (b) normal and recurring current Liabilities that have been incurred
by the Company since the date hereof in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty,
tort, infringement or violation of Law), (c) Liabilities for performance of obligations of the Company under Company Contracts,
(d) Liabilities incurred in connection with the Contemplated Transactions, and (e) Liabilities described in Section 3.9
of the Company Disclosure Letter.
3.10 Title
to Assets. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests
in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned
by it, including all tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets
are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances.
3.11 Real
Property; Leasehold. The Company does not own and has never owned any real property, nor is the Company party to any agreement to
purchase or sell any real property. The Company has made available to Parent (a) an accurate and complete list of all real
properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate
that is in the possession of or leased by the Company and (b) copies of all leases under which any such real property is possessed
(the “Company Real Estate Leases”), each of which is in full force and effect, with no existing material default thereunder
by the Company or to the Company’s Knowledge, the other party thereto.
3.12 Intellectual
Property.
(a) Section 3.12(a) of
the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP.
(b) Section 3.12(b) of
the Company Disclosure Letter accurately identifies (i) all Company Contracts pursuant to which any Company IP Rights are licensed
to the Company (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form
pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is
not incorporated into, or material to the development, manufacturing or distribution of, any of the Company’s products or services,
(B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents
or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Company
and its employees in Company’s standard form thereof) and (ii) whether the license or licenses granted to the Company are
exclusive or nonexclusive.
(c) Section 3.12(c) of
the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or
covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any
Company IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Company
IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic
collaborator, supplier or service providers to provide services for the Company’s benefit).
(d) The
Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any
way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world.
(e) The
Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i) Company IP Rights licensed to
the Company, or co-owned rights each as identified in Section 3.12(e) of the Company Disclosure Letter,
(ii) any non-customized software that (A) is licensed to the Company solely in executable or object code form pursuant to a
nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated
into, or material to the development, manufacturing or distribution of, any of the Company’s products or services and (iii) any
Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in
each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:
(i) All
documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed,
delivered and filed in a timely manner with the appropriate Governmental Authority.
(ii) Each
Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual
Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the
Company and confidentiality provisions protecting trade secrets and confidential information of the Company.
(iii) To
the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether
currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company.
To the Knowledge of the Company, no employee of the Company is (a) bound by or otherwise subject to any Contract restricting him
or her from performing his or her duties for the Company or (b) in breach of any Contract with any former employer or other Person
concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential
information comprising Company IP Rights purported to be owned by the Company.
(iv) No
funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution
were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership
interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution
owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of
the date of this Agreement.
(v) The
Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary
information that the Company holds, or purports to hold, as confidential or a trade secret.
(vi) The
Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP
Rights to any other Person.
(f) The
Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to
each of the Company IP Rights Agreements: (i) each such agreement is valid and binding on the Company and in full force and effect,
(ii) the Company has not received any written notice of termination or cancellation under such agreement, or received any written
notice of breach or default under such agreement, which breach has not been cured or waived and (iii) the Company, and to the Knowledge
of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect.
(g) The
manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold
or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to
the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of
any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the
Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating
any Company IP Rights Agreement.
(h) As
of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference
or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership
or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting
that any Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed
or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed,
misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding
order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company
IP Rights.
(i) Each
item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable
Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force
and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted
is valid and enforceable.
(j) To
the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company
conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other
Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has
or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP.
(k) Except
as set forth in Sections 3.12(b), 3.12(c) or 3.12(k) of the Company
Disclosure Letter or as contained in “off-the-shelf” license agreements entered into in the Ordinary Course of Business by
the Company, (i) the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with
respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole
and (ii) the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability
of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or
responsibility remains in force as of the date of this Agreement.
(l) The
Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the
grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with
respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license
or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually
or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.
3.13 Agreements,
Contracts and Commitments.
(a) Section 3.13(a) of
the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement (each, a “Company
Material Contract” and collectively, the “Company Material Contracts”):
(i) each
Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;
(ii) each
Company Contract containing (A) any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of
business or compete with any Person, or limiting the development, manufacture or distribution of the Company’s products or services
(B) any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;
(iii) each
Company Contract (A) pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B) pursuant
to which the Company granted any Person an exclusive license under any Company IP Rights;
(iv) each
Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant
to its express terms and not cancelable without penalty;
(v) each
Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its
Subsidiaries, or of a product;
(vi) each
Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case,
involving payments in excess of $100,000 after the date of this Agreement;
(vii) each
Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or
instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with
respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;
(viii) each
Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express
terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement
involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any
dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which
the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the
Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or
(D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration
to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute
or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course
of Business;
(ix) each
Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory
services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement
in excess of $100,000 pursuant to its express terms;
(x) each
Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual
obligations of payment by, or annual payments to, the Company in excess of $100,000;
(xi) each
Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company or any of its Subsidiaries
has outstanding obligations to pay consideration in excess of $100,000;
(xii) any
other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment
or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in
the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to
the business or operations of the Company taken as a whole; or
(xiii) Company
Real Estate Leases.
(b) The
Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments
thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company’s Knowledge,
as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received
notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner,
and, if such Company Material Contract provides for a cure period, the Company or such other party fails to have cured such breach, violation
or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company
Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse
Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full
force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company
Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material
term or provision of any Company Material Contract.
3.14 Compliance;
Permits; Restrictions.
(a) The
Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or
other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the
Company. There is no agreement or Order binding upon the Company which (i) has or would reasonably be expected to have the effect
of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the
conduct of business by the Company as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company’s
ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect
of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.
(b) Except
for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (“FDA”) or other comparable
Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing,
advertising, distribution and importation or exportation of drug or medical device products (“Drug/Device Regulatory Agency”),
the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the
“Company Permits”). Section 3.14(b) of the Company Disclosure Letter identifies each
Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the
Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The
rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately
after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and
immediately prior to the First Effective Time.
(c) There
are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company
of the Federal Food, Drug, and Cosmetic Act (“FDCA”), the Public Health Service Act (“PHSA”), FDA
regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.
(d) The
Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the
business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing,
advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the “Company
Product Candidates”) (collectively, the “Company Regulatory Permits”) and no such Company Regulatory Permit
has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner, other than immaterial
adverse modifications. Section 3.14(d) of the Company Disclosure Letter identifies each Company Regulatory
Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not
received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory
Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Company Regulatory
Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory
Permit. The Company has made available to Parent all information requested by Parent in the Company’s possession or control relating
to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising,
distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following
(to the extent there are any): (x) adverse event reports; preclinical, clinical and other study reports and material study data;
inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence
to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports,
material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information
is accurate and complete in all material respects.
(e) All
clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company
or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending,
are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in
all material respects with the applicable protocols and in compliance in all material respects with the applicable regulations of the
Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has
not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority,
institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening
to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by
or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company
Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical
study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies
involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical
investigators, researchers or clinical staff has been threatened or is pending.
(f) The
Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject
of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company
Product Candidates, by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”
Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory
Agency under a comparable policy. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective
officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to
make any statement, in each case in respect of its business or products that would violate the FDA’s “Fraud, Untrue Statements
of Material Facts, Bribery, and Illegal Gratuities” Final Policy, and any amendments thereto or a comparable policy of any other
Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any
Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any
crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section 335a
or (ii) any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or
investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company,
any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents.
(g) All
manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company
Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA’s
standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and 600-610
and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.
(h) Neither
the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any
Company Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has
received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA
or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been
complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither
the FDA nor any other Drug/Device Regulatory Agency is considering such action.
3.15 Legal
Proceedings; Orders.
(a) There
is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding:
(i) that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the
material assets owned or used by the Company or any of its Subsidiaries or (ii) that challenges, or that may have the effect of
preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.
(b) There
is no Order to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its
Subsidiaries, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits
such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any
of its Subsidiaries or any material assets owned or used by the Company or any of its Subsidiaries.
3.16 Tax
Matters.
(a) The
Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed
by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete
in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction
where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction.
(b) All
material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account
any applicable extensions).
(c) The
Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in
connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.
(d) There
are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a) of the definition of “Permitted
Encumbrances”) upon any of the assets of the Company.
(e) No
deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority
in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments,
examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver
of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment
or deficiency that, in each case, is currently in effect.
(f) The
Company has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code
in the last five (5) years.
(g) The
Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary
commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an “Ordinary
Course Agreement”).
(h) The
Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common
parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations Section 1.1502-6
(or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course
Agreement).
(i) The
Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported
or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code.
(j) The
Company has not entered into any transaction identified as a “listed transaction” for purposes of Treasury Regulations Sections 1.6011-4(b)(2) or
301.6111-2(b)(2).
(k) The
Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably
be expected to prevent or impede the Intended Tax Treatment.
3.17 Employee
and Labor Matters; Benefit Plans.
(a) The
Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of
the Company or any of its Subsidiaries, whether full- or part-time, such employee’s annual salary (or if hourly, hourly rate),
most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company, or any
of its Subsidiaries, that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise.
The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual
independent contractor engaged by the Company, such contractor’s rate of compensation.
(b) The
employment of the Company’s and each of its Subsidiaries’ employees is terminable by the Company and/or its applicable Subsidiary
at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently
effective and material.
(c) Neither
the Company nor any of its Subsidiaries is a party to, bound by the terms of, and does not have a duty to bargain under, any collective
bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing
or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company.
(d) Section 3.17(d) of
the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable “at will”
without any contractual obligation on the part of the Company or any of its Subsidiaries to make any severance, termination, change in
control or similar payment and that are substantively identical to the employment arrangements made available to Parent).
(e) Each
Company Employee Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination
or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would
reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related
trust.
(f) Each
Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable
Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine
claims for benefits) is pending or, to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments
and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued
in accordance with the terms of the applicable Company Employee Plan and applicable Law.
(g) Neither
the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years,
maintained, contributed to or been required to contribute to (i) any “employee benefit plan” that is or was subject
to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare
benefit plan within the meaning of Section 419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer
Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.
(h) No
Company Employee Plan provides for, and neither the Company nor any of its Subsidiaries has promised to provide any, medical or other
welfare benefits to any service provider beyond termination of service or retirement, other than (i) pursuant to COBRA or an analogous
state law requirement or (ii) continuation coverage through the end of the month in which such termination or retirement occurs.
The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan.
(i) No
Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.
(j) Each
Company Employee Plan that constitutes in any part a “nonqualified deferred compensation plan” (as such term is defined under
Section 409A(d)(1) of the Code and the guidance thereunder) (each, a “Company 409A Plan”) has been operated
and maintained in all material respects in operational and documentary compliance with the requirements of Section 409A of the Code
and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms
of the Company 409A Plan, will be subject to the penalties of Section 409A(a)(1) of the Code.
(k) The
Company and each of its Subsidiaries is, and has been, in material compliance with all applicable federal, state and local laws, rules and
regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding,
prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration
status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, “plant closings”
and “mass layoffs” within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the
“WARN Act”), labor practices or disputes, restrictive covenants, employment agreements, workers’ compensation
and long-term disability policies, leaves of absence and worker privacy (collectively, “Employment-Related Laws”),
and in each case, with respect to employees of the Company and any of its Subsidiaries: (i) has withheld and reported all material
amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees,
(ii) is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply
with any of the foregoing and (iii) is not liable for any material payment to any trust or other fund governed by or maintained
by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits
or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal
Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or
reasonably anticipated against or involving the Company or any of its Subsidiaries or any trustee of the Company or any of its Subsidiaries
relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits)
or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims
or actions against the Company, any trustee or any trustee of any Subsidiary of the Company under any workers’ compensation policy
or long-term disability policy. The Company is not a party to a conciliation agreement, consent decree or other agreement or Order with
any federal, state or local agency or Governmental Authority with respect to employment practices.
(l) The
Company has no material liability with respect to any misclassification, since its incorporation, of: (i) any Person as an independent
contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly
classified as exempt from overtime wages. Neither the Company nor any of its Subsidiaries has taken any action which would constitute
a “plant closing” or “mass layoff” within the meaning of the WARN Act, issued any notification of a plant closing
or mass layoff required by the WARN Act (nor has the Company or any of its Subsidiaries been under any requirement or obligation to issue
any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.
(m) To
the Company’s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout,
job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to
any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company’s
Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown,
work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.
(n) Neither
the Company nor any of its Subsidiaries is, nor has the Company nor any of its Subsidiaries been, engaged in any material unfair labor
practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance
pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right,
labor dispute, wages and hours, leave of absence, plant closing notification, workers’ compensation policy, long-term disability
policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current
or former employee of the Company or any of its Subsidiaries including charges of unfair labor practices or discrimination complaints.
(o) There
is no contract, agreement, plan or arrangement to which the Company or any of its Subsidiaries is a party or by which it is bound to
compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not
limited to, Section 4999 or Section 409A of the Code.
(p) Neither
the Company nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement,
the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction
with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of,
any payment or benefit to any employee, officer, director or other service provider of the Company or any of its Subsidiaries.
3.18 Environmental
Matters. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company
of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse
Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental
Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and,
to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company’s compliance with any
Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse
Effect. To the Knowledge of the Company: (i) no current or prior owner of any property leased or controlled by the Company has received
any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental
Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with
or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental
Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents
in the Company’s possession or control relating to the Company, including the Company’s business and current or former facilities.
3.19 Insurance.
The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs
and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full
force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy
notifications from insurance carriers, the Company has not received any notice or other communication regarding any actual or possible:
(i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or
rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance
carrier(s) of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation
of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so.
3.20 No
Financial Advisors. Except as set forth on Section 3.20 of the Company Disclosure Letter, no broker, finder or investment
banker is entitled to any brokerage fee, finder’s fee, opinion fee, success fee, transaction fee or other fee or commission in
connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.
3.21 Transactions
with Affiliates. Section 3.21 of the Company Disclosure Letter describes any material transactions or relationships
between, on one hand, the Company and, on the other hand, any (a) executive officer or director of the Company or any of such executive
officer’s or director’s immediate family members, (b) owner of more than 5% of the voting power of the outstanding Company
Capital Stock or (c) to the Knowledge of the Company, any “related person” (within the meaning of Item 404 of Regulation
S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b) or
(c) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.
3.22 Privacy
and Data Security. The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms
of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach
notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology,
or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including
any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians
and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection
with the operation of the Company’s business), except, in each case, for such noncompliance as has not had, and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company
(i) has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws
and are designed to protect the privacy and security of Personal Information (the “Privacy Policies”) and (ii) has
complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened
against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts
governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization,
sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling,
use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there
have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access,
use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any
service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation
to any Person under applicable Law or pursuant to the terms of any Company Contract.
3.23 Ownership
of Parent Capital Stock. None of the Company, their directors or, to the knowledge of the Company, any of its officers, Affiliates,
or employees of the Company or any of its controlled Affiliates (a) has owned any shares of Parent’s capital stock; or (b) has
been an “interested stockholder” (as defined in Section 203 of the DGCL) of Parent, in each case during the three years
prior to the date hereof.
3.24 No
Other Representations or Warranties. The Company hereby acknowledges and agrees that, except for the representations and warranties
contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty
with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective
Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set
forth in Section 4 (in each case as qualified and limited by the Parent Disclosure Letter))
none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness
thereof).
Section 4.
Representations and Warranties of Parent, First Merger and Second Merger Sub.
Except (i) as set forth
in the written disclosure document delivered by Parent to the Company (the “Parent Disclosure Letter”) concurrently
with the execution of this Agreement or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof
and publicly available on the SEC’s Electronic Data Gathering Analysis and Retrieval system (but (A) without giving effect
to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B) excluding any disclosures contained
under the heading “Risk Factors” and any disclosure of risks included in any “forward-looking statements” disclaimer
or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it
being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure
Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or
subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows:
4.1 Due
Organization; Subsidiaries.
(a) Each
of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated or formed, as applicable, validly existing and in
good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has all necessary corporate power
and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or
lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to
perform its obligations under all Contracts by which it is bound. Since the date of its incorporation, Merger Subs have not engaged in
any activities other than in connection with or as contemplated by this Agreement.
(b) Each
of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction),
under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted
requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate
would not be reasonably expected to have a Parent Material Adverse Effect.
(c) Parent
has no Subsidiaries other than Merger Subs and except as set forth on Section 4.1(c) of the Parent Disclosure Letter,
Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or
indirectly, any other Entity other than Merger Subs. Except as set forth on Section 4.1(c) of the Parent Disclosure
Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint
venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which
it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been
a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited
partnership or other Entity.
4.2 Organizational
Documents. Parent has delivered to the Company accurate and complete copies of Parent’s Organizational Documents. Parent is
not in breach or violation of its Organizational Documents in any material respect.
4.3 Authority;
Binding Nature of Agreement. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform
its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board has: (a) determined that
the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b) approved and
declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the
stockholders of the Company pursuant to the terms of this Agreement and (c) determined to recommend, upon the terms and subject
to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Contemplated Transactions, and, if
deemed necessary by Parent and the Company, the amendment to the certificate of incorporation of the Parent to (i) change the name
of Parent to “Crescent Biopharma, Inc.”, (ii) effect the Nasdaq Reverse Split and (iii) make such other changes
as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous
written consent) has: (x) determined that the Contemplated Transactions are fair to, advisable and in the best interests of First
Merger Sub and its sole stockholder, (y) deemed advisable and approved this Agreement and the Contemplated Transactions and (z) determined
to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote
to adopt this Agreement and thereby approve the Contemplated Transactions. The sole member of Second Merger Sub (by unanimous written
consent) has: (A) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger
Sub and the sole member; and (B) deemed advisable and approved this Agreement and the Contemplated Transactions. This Agreement
has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company
and the accuracy of the representation in Section 3.23, constitutes the legal, valid and binding obligation of Parent
and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.
4.4 Vote
Required. Assuming the accuracy of the representation in Section 3.23, the affirmative vote of a majority of the
shares of Parent Common Stock properly cast at the Parent Stockholder Meeting is the only vote of the holders of any class or series
of Parent’s capital stock necessary to approve this Agreement and thereby approve the Contemplated Transactions and clauses (i),
(ii) and (iii) of the definition of “Parent Charter Amendment” (collectively, the “Required Parent Stockholder
Vote”).
4.5 Non-Contravention;
Consents.
(a) Subject
to obtaining the Required Parent Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the
filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, and assuming the accuracy of the representation
in Section 3.23, neither (x) the execution, delivery or performance of this Agreement by Parent or Merger
Subs, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of
time):
(i) contravene,
conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries;
(ii) contravene,
conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated
Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of
the assets owned or used by Parent or its Subsidiaries, is subject;
(iii) contravene,
conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right
to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries
or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent;
(iv) contravene,
conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or
give any Person the right to: (A) declare a default or exercise any remedy under any Parent Material Contract, (B) any material
payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C) accelerate the
maturity or performance of any Parent Material Contract or (D) cancel, terminate or modify any term of any Parent Material Contract,
except in the case of any nonmaterial breach, default, penalty or modification; or
(v) result
in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except
for Permitted Encumbrances).
(b) Except
for (i) any Consent set forth on Section 4.5(a) of the Parent Disclosure Letter under any Parent Contract,
(ii) the Required Parent Stockholder Vote, (iii) the filing of the Certificate of Merger and Certificate of Designation with
the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iv) compliance with any applicable requirements
of the HSR Act (if applicable) and (v) such consents, waivers, approvals, orders, authorizations, registrations, declarations and
filings as may be required under applicable federal and state securities laws, and assuming the accuracy of the representation in Section 3.23,
neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any
Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation
of the Contemplated Transactions.
(c) Assuming
the accuracy of the representation in Section 3.23, the Parent Board and the First Merger Sub Board have taken
and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section 203
of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the
Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement
or any of the other Contemplated Transactions.
4.6 Capitalization.
(a) The
authorized capital stock of Parent consists of (i) 150,000,000 shares of Parent Common Stock of which 64,483,958 shares have been
issued and are outstanding as of September 30, 2024 (the “Capitalization Date”) and (ii) 5,000,000 shares
of Parent Preferred Stock, par value $0.001 per share, of which none have been designated. No shares of Parent Preferred Stock have been
issued and are outstanding as of the Capitalization Date. Parent does not hold any shares of its capital stock in its treasury.
(b) All
of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and
are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None
of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance
or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent.
Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from
purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent
Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase,
redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. Section 4.6(b) of
the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent
Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently
exercisable.
(c) Except
for the Parent 2003 Stock Incentive Plan, the Parent 2013 Equity Incentive Plan and the Parent 2020 Inducement Plan (each as may be amended
from time to time, collectively, the “Parent Stock Plans”) and except as set forth on Section 4.6(c) of
the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing
for any equity-based compensation for any Person. As of the Capitalization Date, Parent has reserved 14,257,627 shares of Parent Common
Stock for issuance under the Parent Stock Plans, of which 13,163,469 shares have been issued and are currently outstanding, 117,157 shares
have been reserved for issuance upon exercise or settlement of Parent Options and Parent Restricted Stock Units, as applicable, granted
under the Parent Stock Plans, and 977,001 shares remain available for future issuance pursuant to the Parent Stock Plans. As of the Capitalization
Date, Parent has reserved 3,554,364 shares of Parent Common Stock for future issuance pursuant to the Parent ESPP (of which 0 shares
have been issued and are currently outstanding). Section 4.6(c) of the Parent Disclosure Letter sets forth
the following information with respect to each Parent Option outstanding as of the Capitalization Date, as applicable: (i) the name
of the holder, (ii) the number of shares of Parent Common Stock subject to such Parent Option and Parent Restricted Stock Units
as of the Capitalization Date, (iii) the exercise price of such Parent Option, (iv) the date on which such Parent Option or
Parent Restricted Stock Unit was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi) the
date on which such Parent Option expires, (vii) whether such Parent Option is intended to be an “incentive stock option”
(as defined in the Code) or a nonqualified stock option and (viii) in the case of a Parent Option, the plan pursuant to which such
Parent Option was granted. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to
which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and
stockholder approval of the Parent Stock Plans and any amendments thereto.
(d) Except
for the outstanding Parent Options and Parent Restricted Stock Units, or as set forth on Section 4.6(d) of
the Parent Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently
exercisable) to acquire any shares of the capital stock or other securities of Parent, (ii) outstanding security, instrument or
obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent,
(iii) stockholder rights plan (or similar plan commonly referred to as a “poison pill”) or Contract under which Parent
is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv) condition
or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is
entitled to acquire or receive any shares of capital stock or other securities of Parent. There are no outstanding or authorized stock
appreciation, phantom stock, profit participation or other similar rights with respect to Parent.
(e) All
outstanding shares of Parent Common Stock, Parent Options and Parent Restricted Stock Units, and other securities of Parent have been
issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all
requirements set forth in applicable Contracts.
(f) With
respect to Parent Options and Parent Restricted Stock Units granted pursuant to the Parent Stock Plans, (i) each grant of a Parent
Option or Parent Restricted Stock Unit was duly authorized no later than the date on which the grant of such Parent Option and Parent
Restricted Stock Unit was by its terms to be effective (the “Parent Grant Date”) by all necessary corporate action,
including, as applicable, approval by the Parent Board (or a duly constituted and authorized committee thereof) or duly authorized officer
and any required stockholder approval by the necessary number of votes or written consents, (ii) each Parent Option and Parent Restricted
Stock Unit grant was made in accordance with the terms of the Parent Stock Plan pursuant to which it was granted and all other applicable
Law and regulatory rules or requirements, and (iii) the per share exercise price of each Parent Option was not less than the
fair market value of a share of Parent Common Stock on the applicable Parent Grant Date.
4.7 SEC
Filings; Financial Statements.
(a) Parent
has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be
filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the “Parent SEC Documents”). As
of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date
of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities
Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule 13a-14
under the Exchange Act and (ii) 18 U.S.C. §1350 (Section 906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents
(collectively, the “Certifications”) are accurate and complete and comply as to form and content with all applicable
Laws. As used in this Section 4.7, the term “file” and variations thereof shall be broadly construed
to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.
(b) The
financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied
as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations
of the SEC applicable thereto, (ii) were prepared in accordance with GAAP (except as may be indicated in the notes to such financial
statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited
financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected
to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly
present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations
and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to
the date hereof, there has been no material change in Parent’s accounting methods or principles that would be required to be disclosed
in Parent’s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of
its Subsidiaries are true and complete in all material respects.
(c) Parent’s
auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as
defined in Section 2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, “independent” with respect
to Parent within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of Parent, in compliance with subsections
(g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public
Company Accounting Oversight Board thereunder.
(d) Except
as set forth on Section 4.7(d) of the Parent Disclosure Letter, Parent has not received any comment letter
from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of
listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.
(e) There
have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed
by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board
or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required
by the Sarbanes-Oxley Act.
(f) Parent
is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable
listing and governance rules and regulations of Nasdaq.
(g) Parent
maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance
(i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent’s transactions and dispositions
of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP,
(iii) that receipts and expenditures are made only in accordance with the authorization policy and (iv) regarding prevention
or timely detection of the unauthorized acquisition, use or disposition of Parent’s assets that could have a material effect on
Parent’s financial statements. Parent has evaluated the effectiveness of Parent’s internal control over financial reporting
and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or
Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as
of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent’s auditors
and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure)
(A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
that are reasonably likely to adversely affect Parent’s ability to record, process, summarize and report financial information
and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Parent’s
or its Subsidiaries’ internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to
the date hereof, Parent’s internal control over financial reporting is effective at the reasonable assurance level and Parent has
not identified any material weaknesses in the design or operation of Parent’s internal control over financial reporting.
(h) Parent’s
“disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are
designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and
forms of the SEC, and that all such information is accumulated and communicated to Parent’s principal executive officer and principal
financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure
controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures
as required by Rule 13a-15 of the Exchange Act.
4.8 Absence
of Changes. Except as set forth on Section 4.8 of the Parent Disclosure Letter, between December 31, 2023 and
the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance
of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material
Adverse Effect or (b) action, event or occurrence that would have required consent of the Company pursuant to Section Section 5(b) of
this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.
4.9 Absence
of Undisclosed Liabilities. Since December 31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for:
(a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b) normal and recurring current Liabilities
that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none
of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance
of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d) Liabilities incurred in connection with the Contemplated
Transactions or the Subscription Agreement, and (e) Liabilities described in Section 4.9 of the Parent Disclosure
Letter.
4.10 Title
to Assets. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets,
valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations
or purported to be owned by it, including: (a) all tangible assets reflected on the Parent Balance Sheet and (b) all other
tangible assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of
leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.
4.11 Real
Property; Leasehold. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to
any agreement to purchase or sell any real property. Parent has made available to the Company (a) an accurate and complete list
of all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other
real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b) copies of all leases under which
any such real property is possessed (the “Parent Real Estate Leases”), each of which is in full force and effect,
with no existing material default thereunder by Parent or its Subsidiaries or, to Parent’s Knowledge, the other party thereto.
4.12 Intellectual
Property.
(a) Section 4.12(a) of
the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.
(b) Section 4.12(b) of
the Parent Disclosure Letter accurately identifies (i) all Parent Contracts pursuant to which any Parent IP Rights are licensed
to Parent (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant
to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated
into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B) any Intellectual
Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any
confidential information provided under confidentiality agreements and (D) agreements between Parent and its employees in Parent’s
standard form thereof) and (ii) whether the license or licenses granted to Parent are exclusive or nonexclusive.
(c) Section 4.12(c) of
the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or
covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any
Parent IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Parent
IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic
collaborator, supplier or service providers to provide services for Parent’s benefit).
(d) Neither
Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other
provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any
Parent IP Rights anywhere in the world.
(e) Parent
or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i) Parent
IP Rights licensed to Parent, or co-owned rights each as identified in Section 4.12(e) of the Parent Disclosure
Letter, (ii) any non-customized software that (A) is licensed to Parent solely in executable or object code form pursuant to
a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated
into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries’ products or services
and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or
other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality
of the foregoing:
(i) All
documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed,
delivered, and filed in a timely manner with the appropriate Governmental Authority.
(ii) Each
Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development
of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment
of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information
of Parent and its Subsidiaries.
(iii) To
the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any
claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be
owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a) bound by or otherwise subject
to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b) in breach of any Contract
with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality
provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such
Subsidiary.
(iv) No
funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in
part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.
(v) Parent
and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights
in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.
(vi) Parent
or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership
of, any Parent IP Rights to any other Person.
(f) Parent
has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.
(g) The
manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold
or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any
material respect, and, to the Knowledge of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual
Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect.
To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any
Parent IP Rights Agreement.
(h) As
of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference
or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale,
license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the
proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes
or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated
or otherwise violated any Intellectual Property of any Person.
(i) To
the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts
or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except
as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered
or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance
with GAAP.
(j) Except
as may be set forth in the Contracts listed on Section 4.12(b), 4.12(c) or 4.12(k) of
the Parent Disclosure Letter or as contained in “off-the-shelf” license agreements entered into in the Ordinary Course of
Business by Parent, (i) Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with
respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and
(ii) Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability
of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or
responsibility remains in force as of the date of this Agreement.
(k) Neither
Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement,
will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such
Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell
or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not
individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.
4.13 Agreements,
Contracts and Commitments.
(a) Section 4.13
of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement other than the
Subscription Agreement (each, an “Parent Material Contract” and collectively, the “Parent Material Contracts”):
(i) each
Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or
retirement plans, or any other employee benefit plans or arrangements;
(ii) each
Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating
to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting
or independent contractor services, not terminable by Parent on thirty (30) calendar days’ or less notice without liability;
(iii) each
Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any
of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated
Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits
of which will be calculated on the basis of any of the Contemplated Transactions;
(iv) each
Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;
(v) each
Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business
or compete with any Person, or limiting the development, manufacture or distribution of the Parent’s products or services (B) any
most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;
(vi) each
Parent Contract (A) pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B) pursuant
to which Parent granted any Person an exclusive license under any Parent IP Rights;
(vii) each
Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries,
or of a product;
(viii) each
Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant
to its express terms and not cancelable without penalty;
(ix) each
Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case,
involving payments in excess of $100,000 after the date of this Agreement;
(x) each
Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries
has outstanding obligations to pay consideration in excess of $100,000;
(xi) each
Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or
instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with
respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;
(xii) each
Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms
relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving
provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C) any dealer,
distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent
or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant
to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in
whole or in part, by Parent or such Subsidiary or (D) any Contract to license any patent, trademark registration, service mark registration,
trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent
or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries,
in each case, except for Parent Contracts entered into in the Ordinary Course of Business;
(xiii) each
Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory
services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement
in excess of $100,000 pursuant to its express terms;
(xiv) each
Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound
(other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary
in excess of $100,000;
(xv) any
Parent Real Estate Lease;
(xvi) a
Contract disclosed in or required to be disclosed in Section 4.12(b) or Section 4.12(c) of
the Parent Disclosure Letter; or
(xvii) any
other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or
any of its Subsidiaries, and (A) which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement
under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement
in excess of $100,000 in the aggregate or (B) that is material to the business or operations of Parent and its Subsidiaries taken
as a whole.
(b) Parent
has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments
thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent’s Knowledge as of the
date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice
that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and,
if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or
default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material
Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect.
As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and
in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms
of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other
material term or provision of any Parent Material Contract.
4.14 Compliance;
Permits; Restrictions.
(a) Parent
and each of its Subsidiaries is, and since January 1, 2023, has been in material compliance with all applicable Laws. No investigation,
claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened
against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i) has
or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its
Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of
its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent’s ability to comply
with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing,
delaying, making illegal or otherwise interfering with the Contemplated Transactions.
(b) Except
for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental
Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the
“Parent Permits”). Section 4.14(b) of the Parent Disclosure Letter identifies each Parent
Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending
or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit.
The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second
Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and
immediately prior to the First Effective Time.
(c) There
are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of
its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated
by a Drug/Device Regulatory Agency.
(d) Each
of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary
for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing,
processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of
any of its product candidates (the “Parent Product Candidates”) (the “Parent Regulatory Permits”)
and no such Parent Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in
any adverse manner other than immaterial adverse modifications. Section 4.14(d) of the Parent Disclosure
Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the
Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January 1, 2023, received any written notice
or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A) any material
violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B) any revocation,
withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available
to the Company all information requested by the Company in Parent’s or its Subsidiaries’ possession or control relating to
material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising,
distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following
(to the extent there are any): (x) adverse event reports; pre-clinical, clinical and other study reports and material study data;
inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence
to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports,
material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information
are accurate and complete in all material respects.
(e) All
clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which
Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since
January 1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific
research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies
and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January 1, 2023, neither Parent nor any
of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency
requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any
clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries
or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher
or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its
Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent,
no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.
(f) Neither
Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate
is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the
FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth
in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable
policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers,
employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement,
in each case in respect of its business or products that would violate FDA’s “Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities” Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the
Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees
or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in
a material debarment or exclusion under (i) 21 U.S.C. Section 335a or (ii) any similar applicable Law. To the Knowledge
of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products
are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with
respect to any Parent Product Candidate, or any of its officers, employees or agents.
(g) All
manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with
any Parent Product Candidate, since January 1, 2023, have been and are being conducted in compliance in all material respects with
applicable Laws, including the FDA’s standards for current good manufacturing practices, including applicable requirements contained
in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside
the United States.
(h) None
of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory,
with respect to any Parent Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition
or (ii) has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice
from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have
not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent,
neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.
4.15 Legal
Proceedings; Orders.
(a) There
is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding:
(i) that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material
assets owned or used by Parent or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying,
making illegal or otherwise interfering with, the Contemplated Transactions.
(b) There
is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries
is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that
prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent
or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.
4.16 Tax
Matters.
(a) Each
of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material
Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were
true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental
Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries
is subject to taxation by that jurisdiction.
(b) All
material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely
paid (taking into account any applicable extensions).
(c) Each
of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to
have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder
or other third party.
(d) There
are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a) of the definition of “Permitted
Encumbrances”) upon any of the assets of Parent or any of its Subsidiaries.
(e) No
deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed
by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened)
material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of
its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material
amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.
(f) Neither
Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements),
other than Ordinary Course Agreements.
(g) Neither
Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other
than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes
of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar provision of state,
local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).
(h) Neither
Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a
transaction that was purported or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of
the Code.
(i) Neither
Parent nor any of its Subsidiaries has entered into any transaction identified as a “listed transaction” for purposes of
Treasury Regulations Sections 1.6011-4(b)(2) or 301.6111-2(b)(2).
(j) Neither
Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that
would reasonably be expected to prevent or impede the Intended Tax Treatment.
4.17 Employee
and Labor Matters; Benefit Plans.
(a) The
Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries,
such employee’s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on
leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly,
hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list
setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such
contractor’s name, duties and rate of compensation.
(b) The
employment of Parent’s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete
copies of all employee manuals and handbooks, to the extent currently effective and material.
(c) Parent
is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract
with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of
Parent, purporting to represent or seeking to represent any employees of Parent.
(d) Section 4.17(d) of
the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable “at will”
without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control
or similar payment and that are substantively identical to the employment arrangements made available to the Company).
(e) Each
Parent Employee Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination
or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably
be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.
(f) Each
Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable
Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine
claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or
contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance
with the terms of the applicable Parent Employee Plan and applicable Law.
(g) Neither
Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years,
maintained, contributed to or been required to contribute to (i) any “employee benefit plan” that is or was subject
to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare
benefit plan within the meaning of Section 419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer
Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.
(h) No
Parent Employee Plan provides for, and neither Parent nor any of its Subsidiaries has promised to provide any, medical or other welfare
benefits to any service provider beyond termination of service or retirement, other than (i) pursuant to COBRA or an analogous state
law requirement or (ii) continuation coverage through the end of the month in which such termination or retirement occurs. Parent
does not sponsor or maintain any self-funded medical or long-term disability benefit plan.
(i) No
Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.
(j) Each
Parent Employee Plan that constitutes in any part a “nonqualified deferred compensation plan” (as such term is defined under
Section 409A(d)(1) of the Code and the guidance thereunder) (each, a “Parent 409A Plan”) has been operated
and maintained in all material respects in operational and documentary compliance with the requirements of Section 409A of the Code
and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms
of the Parent 409A Plan, will be subject to the penalties of Section 409A(a)(1) of the Code.
(k) Parent
is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i) has withheld
and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other
payments to employees, (ii) is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty
for failure to comply with any of the foregoing and (iii) is not liable for any material payment to any trust or other fund governed
by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or
other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no
material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened
or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director,
employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of
Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or
any trustee of any Subsidiary of Parent under any workers’ compensation policy or long-term disability policy. Parent is not a
party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental
Authority with respect to employment practices.
(l) Parent
has no material liability with respect to any misclassification within the past three (3) years of: (i) any Person as an independent
contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly
classified as exempt from overtime wages. Parent has not taken any action which would constitute a “plant closing” or “mass
layoff” within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act
(nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under
the WARN Act that remains unsatisfied.
(m) To
the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action,
union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate.
No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly
or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout,
job action, union organizing activity, question concerning representation or any similar activity or dispute.
(n) Parent
is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There
is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated
relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers’
compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination
matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.
(o) There
is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate
any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited
to, Section 4999 or Section 409A of the Code.
(p) Neither
Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder
approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with
any other event) (i) result in the payment of any “parachute payment” within the meaning of Section 280G of the
Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any
payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.
4.18 Environmental
Matters. Since January 1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which
compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental
Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate,
would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January 1, 2023,
any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee
or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge
of Parent, there are no circumstances that may prevent or interfere with Parent’s or any of its Subsidiaries’ compliance
with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material
Adverse Effect. To the Knowledge of Parent: (i) no current or prior owner of any property leased or controlled by Parent or any
of its Subsidiaries has received since January 1, 2023, any written notice or other communication relating to property owned or
leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise,
that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental
Law relating to such property and (ii) neither Parent nor any of its Subsidiaries has any material liability under any Environmental
Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in
the Parent’s possession or control relating to the Parent and its Subsidiaries, including the Parent’s and its Subsidiaries’
business and current or former facilities.
4.19 Insurance.
Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs
and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs).
Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance
in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1,
2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation
or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material
claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the
appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary
has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal
Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.
4.20 Transactions
with Affiliates. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent’s
last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of
Regulation S-K promulgated by the SEC. Section 4.20 of the Parent Disclosure Letter identifies each Person who is (or
who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.
4.21 No
Financial Advisors. Except as set forth on Section 4.21 of the Parent Disclosure Letter, no broker, finder or investment
banker is entitled to any brokerage fee, finder’s fee, opinion fee, success fee, transaction fee or other fee or commission in
connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.
4.22 Valid
Issuance. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion thereof) to be issued in the Merger
will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common
Stock issuable upon conversion of any Parent Capital Stock has been duly reserved for issuance, and upon issuance in accordance with
the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.
4.23 Privacy
and Data Security. Parent and its Subsidiaries are and since January 1, 2023, have been in compliance with all applicable Privacy
Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data
loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies
or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal
Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers
or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with
Parent or any of its Subsidiaries in connection with the operation of Parent’s and its Subsidiaries’ business), except, in
each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent
Material Adverse Effect. To the Knowledge of Parent, Parent (i) has implemented and maintains reasonable Privacy Policies that materially
comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii) has complied
with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened
against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts
governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization,
sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling,
use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have
been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access,
use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service
provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to
any Person under applicable Law or pursuant to the terms of any Parent Contract.
4.24 No
Other Representations or Warranties. Parent hereby acknowledges and agrees that, except for the representations and warranties contained
in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries
makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other
information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated
Transactions, and (subject to the express representations and warranties of the Company set forth in Section 3
(in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective
Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).
Section 5.
Certain Covenants of the Parties.
5.1 Operation
of Parent’s Business.
(a) Except
(i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii) as set forth in Section 5.1(a) of
the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) unless the Company shall otherwise consent in writing
(which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement
and continuing until the earlier to occur of the termination of this Agreement pursuant to Section 10 and the First Effective
Time (the “Pre-Closing Period”), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts
to (x) conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law
and the requirements of all Contracts that constitute Parent Material Contracts and (y) continue to pay material outstanding accounts
payable and other material current Liabilities (including payroll) when due and payable.
(b) Except
(i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii) as set forth in Section 5.1(b) of
the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) with the prior written consent of the Company (which
consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor
shall it cause or permit any of Subsidiaries to, do any of the following:
(i) declare,
accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem
or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated
employees, directors or consultants of Parent);
(ii) except
as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a
party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split,
reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;
(iii) sell,
issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except
for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units,
as applicable), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible
into or exchangeable for any capital stock or other security;
(iv) form
any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;
(v) (A) lend
money to any Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others
or (D) make any capital expenditure or commitment in excess of $25,000;
(vi) (A) adopt,
establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B) cause or permit
any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with
Section 409A of the Code, (C) pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations
in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the
wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees
or consultants, (D) increase the severance or change of control benefits offered to any current or new employees, directors or consultants,
or (E) hire any officer, employee or consultant;
(vii) acquire
any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance
with respect to such assets or properties;
(viii) sell,
assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses
in the Ordinary Course of Business);
(ix) other
than in the Ordinary Course of Business: (A) make, change or revoke any material Tax election; (B) file any amended income
or other material Tax Return; (C) adopt or change any material accounting method in respect of Taxes; (D) enter into any material
Tax closing agreement, settle any material Tax claim or assessment; (E) consent to any extension or waiver of the limitation period
applicable to or relating to any material Tax claim or assessment; or (F) surrender any material claim for refund;
(x) waive,
settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements
or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance
policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of Parent or
its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;
(xi) delay
or fail to repay when due any material obligation, including accounts payable and accrued expenses;
(xii) forgive
any loans to any Person, including its employees, officers, directors or Affiliate;
(xiii) terminate
or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;
(xiv) (A) materially
change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B) agree
to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent
or any of Subsidiaries;
(xv) enter
into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or
(xvi) agree,
resolve or commit to do any of the foregoing.
Nothing contained in this Agreement shall give
the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior
to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control
and supervision over its business operations.
5.2 Operation
of the Company’s Business.
(a) Except
(i) as expressly contemplated or permitted by this Agreement, (ii) as set forth in Section 5.2(a) of
the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to any Interim Financing or Company Acquisition,
which are expressly permitted, or (v) unless Parent shall otherwise consent in writing (which consent shall not be unreasonably
withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially
reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable
Law and the requirements of all Contracts that constitute Company Material Contracts.
(b) Except
(i) as expressly contemplated or permitted by this Agreement, (ii) as set forth in Section 5.2(b) of
the Company Disclosure Letter, (iii) as required by applicable Law, (iv) in connection with any Interim Financing or Company
Acquisition, which are expressly permitted, or (v) with the prior written consent of Parent (which consent shall not be unreasonably
withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any
of its Subsidiaries to, do any of the following:
(i) declare,
accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem
or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated
employees, directors or consultants of the Company);
(ii) except
as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries’ Organizational Documents,
or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares,
stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;
(iii) other
than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of
the shares of Company Capital Stock outstanding as of the date of this Agreement: (A) any capital stock or other security of the
Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options
or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument
convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;
(iv) other
than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture
with any other Entity;
(v) (A) lend
money to any Person, (B) incur or guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;
(vi) sell,
lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets
or properties, except in the Ordinary Course of Business;
(vii) sell,
assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses
in the Ordinary Course of Business);
(viii) waive,
settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A) for
an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof)
and (B) that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on,
or the admission of wrongdoing by the Company;
(ix) enter
into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business;
or
(x) agree,
resolve or commit to do any of the foregoing.
Nothing contained in this Agreement shall give
Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior
to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral
control and supervision over its business operations.
5.3 Access
and Investigation.
(a) Subject
to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement,
during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use
commercially reasonable efforts to cause such Party’s Representatives to: (a) provide the other Party and such other Party’s
Representatives with reasonable access during normal business hours to such Party’s Representatives, personnel, property and assets
and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries,
(b) provide the other Party and such other Party’s Representatives with such copies of the existing books, records, Tax Returns,
work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional
financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request,
(c) permit the other Party’s officers and other employees to meet, upon reasonable notice and during normal business hours,
with the chief financial officer and other officers and managers of such Party responsible for such Party’s financial statements
and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d) make available to
the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority
in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this Section 5.3
shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.
(b) Notwithstanding
anything herein to the contrary in this Section 5.3, no access or examination contemplated by this Section 5.3
shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney
work product privilege, or violate any applicable Law; provided, that such Party or its Subsidiary (i) shall be entitled
to withhold only such information that may not be provided without causing such violation or waiver, (ii) shall provide to the other
Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted
versions of any such information) and (iii) shall enter into such effective and appropriate joint-defense agreements or other protective
arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party
without causing such violation or waiver.
5.4 No
Solicitation.
(a) Each
of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any
of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly,: (i) solicit, initiate or knowingly
encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry
or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii) furnish any
non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition
Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry,
(iv) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction
or (v) publicly propose to do any of the foregoing; provided, however, that, (x) any public disclosures made
in compliance with Section 6.3(e) shall not constitute a violation of this Section 5.4 and (y) notwithstanding anything
contained in this Section 5.4 and subject to compliance with this Section 5.4, prior
to the approval of this Agreement by a Party’s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company
and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding
such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition
Proposal by such Person which such Party’s board of directors determines in good faith, after consultation with such Party’s
financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn)
if: (A) such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B) the
board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such
action would reasonably be expected to be inconsistent with the board of directors’ fiduciary duties under applicable Law, (C) at
least two (2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with,
such Person, such Party gives the other Party written notice of the identity of such Person and of such Party’s intention to furnish
nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable
Confidentiality Agreement and (E) at least two (2) Business Days prior to furnishing any such nonpublic information to
such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously
furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that,
in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this Section 5.4
by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this Section 5.4
by such Party for purposes of this Agreement.
(b) If
any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing
Period, then such Party shall promptly (and in no event later than one (1) Business Day after such Party becomes aware of such
Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including
the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party
shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry
and any material modification or material proposed modification thereto.
(c) Each
Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that
relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any
nonpublic information provided to such Person.
(d) For
the avoidance of doubt and notwithstanding anything to the contrary in this Section 5.4, the Company shall be
expressly permitted to take any action with respect to an Interim Financing or a Company Acquisition.
5.5 Notification
of Certain Matters. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly
notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a) any notice or other communication is
received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions,
(b) any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge
of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c) such
Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d) the failure
of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely
satisfaction of any of the conditions set forth in 6.19, Section 8 or Section 9,
as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter
or the Parent Disclosure Letter for the purpose of (x) determining the accuracy of any of the representations and warranties made
by the Company in this Agreement or (y) determining whether any condition set forth in 6.19, Section 8
or Section 9 has been satisfied. Any failure by either Party to provide notice pursuant
to this Section 5.5 shall not be deemed to be a breach for purposes of Section 8.2 or Section 9.2,
as applicable, unless such failure to provide such notice was knowing and intentional.
Section 6.
Additional Agreements of the Parties.
6.1 Proxy
Statement.
(a) On
or prior to February 14, 2025, Parent shall prepare and file with the SEC a proxy statement relating to the Parent Stockholder Meeting
to be held in connection with the Parent Stockholder Matters (together with any amendments thereof or supplements thereto, the “Proxy
Statement”). Parent shall use its commercially reasonable efforts to (i) cause the Proxy Statement to comply with applicable
rules and regulations promulgated by the SEC and (ii) respond promptly to any comments or requests of the SEC or its staff
related to the Proxy Statement.
(b) Parent
covenants and agrees that the Proxy Statement (and the letters to stockholders, notice of meeting and form of proxy included therewith)
will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities Laws and the DGCL,
and (ii) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
(c) Parent
shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent’s stockholders as promptly as practicable
after the Proxy Statement has been filed with the SEC and either (i) the SEC has indicated that it does not intend to review the
Proxy Statement or that its review of the Proxy Statement has been completed or (ii) at least ten (10) days shall have passed
since the Proxy Statement was filed with the SEC without receiving any correspondence from the SEC commenting upon, or indicating that
it intends to review, the Proxy Statement, all in compliance with applicable U.S. federal securities laws and the DGCL. If Parent, First
Merger Sub, Second Merger Sub or the Surviving Entity (1) become aware of any event or information that, pursuant to the Securities
Act or the Exchange Act, should be disclosed in an amendment or supplement to the Proxy Statement, (2) receives notice of any SEC
request for an amendment or supplement to the Proxy Statement or for additional information related thereto, or (3) receives SEC
comments on the Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof
and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC and, if appropriate, in mailing
such amendment or supplement to the Parent stockholders. The Company and its legal counsel shall be given reasonable opportunity to review
and comment on the Proxy Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on
the response to any comments of the SEC on the Proxy Statement, prior to the filing thereof with the SEC. Parent may file the Proxy Statement,
or any amendment or supplement thereto, without the prior consent of the Company.
(d) As
promptly as reasonably practicable following December 31, 2024, the Company will use commercially reasonable efforts to furnish
to Parent audited financial statements for the year ended December 31, 2024 (the “Company Financial Statements”)
required to be included in the Proxy Statement.
6.2 Company
Stockholder Written Consent.
(a) Promptly
after the date hereof, and in any event no later than two (2) Business Days thereafter, the Company shall obtain the approval by
written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section 228
of the DGCL, for purposes of (i) adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging
that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant
to Section 262 of the DGCL, and that such stockholder has received and read a copy of Section 262 of the DGCL and (iii) acknowledging
that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and
thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the “Company Stockholder
Written Consents”). Under no circumstances shall the Company assert that any other approval or consent is necessary by its
stockholders to approve this Agreement and the Contemplated Transactions.
(b) Reasonably
promptly following receipt of the Required Company Stockholder Vote, the Company shall prepare and mail a notice (the “Stockholder
Notice”) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder
Notice shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with
Section 251(b) of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement,
the Merger and the other Contemplated Transactions, (ii) provide the stockholders of the Company to whom it is sent with notice
of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and
the other Contemplated Transactions in accordance with Section 228(e) of the DGCL and the certificate of incorporation and
bylaws of the Company and (iii) include a description of the appraisal rights of the Company’s stockholders available under
the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments
thereto) submitted to the stockholders of the Company in accordance with this Section 6.2(b) shall be subject
to Parent’s advance review and reasonable approval.
(c) The
Company agrees that, subject to Section 6.2(d): (i) the Company Board shall recommend that the Company’s
stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts
to solicit such approval within the time set forth in Section 6.2(a) (the recommendation of the Company
Board that the Company’s stockholders vote to adopt and approve this Agreement being referred to as the “Company Board
Recommendation”) and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall
not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the
Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt,
approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed.
(d) Notwithstanding
anything to the contrary contained in Section 6.2(c), and subject to compliance with Section 5.4
and Section 6.2, if at any time prior to approval and adoption of this Agreement by the Required Company
Stockholder Vote, (i) the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following
consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii) as a result of a material development
or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal,
Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B) the fact, in and of itself, that the Company meets
or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that
affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a “Company
Intervening Event”), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly
propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a “Company
Board Adverse Recommendation Change”) if, but only if, (x) in the case of a Superior Offer, following the receipt of and
on account of such Superior Offer, (i) the Company Board determines in good faith, based on the advice of its outside legal counsel,
that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent
with its fiduciary duties under applicable Law, (ii) the Company has, during the Notice Period (as defined below), negotiated with
Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases
to constitute a Superior Offer and (iii) if, Parent has delivered to the Company a written offer to alter the terms or conditions
of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside
legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably
be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms
and conditions of this Agreement); provided that (1) Parent receives written notice from the Company confirming that the
Company Board has determined to change its recommendation at least four (4) Business Days in advance of the Company Board Adverse
Recommendation Change (the “Notice Period”), which notice shall include a description in reasonable detail of the
reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with
any party making a potential Superior Offer, (2) during any Notice Period, Parent shall be entitled to deliver to the Company one
or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in
good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that
the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any
Superior Offer (including any revision in the amount, form or mix of consideration the Company’s stockholders would receive as
a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and
the Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period
following such notification during which the parties shall comply again with the requirements of this Section 6.2(d) and
the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended
(it being understood that there may be multiple extensions) or (y) in the case of a Company Intervening Event, the Company promptly
notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall
state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends
to make a Company Board Adverse Recommendation Change.
(e) The
Company’s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with
Section 6.2(a) shall not be limited or otherwise affected by the commencement, disclosure, announcement
or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation
Change.
6.3 Parent
Stockholder Meeting.
(a) Parent
shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock
to consider and vote to approve (I) the issuance of shares of Parent Capital Stock (including shares of Parent Capital Stock issuable
upon conversion thereof) in connection with the Contemplated Transactions for purposes of the listing rules of Nasdaq, and (II) the
Parent Charter Amendment (collectively, the “Parent Stockholder Matters” and such meeting, the “Parent Stockholder
Meeting”). The Parent Stockholder Meeting shall be held as promptly as practicable after the filing of the Proxy Statements
in accordance with Section 6.1(a), and in any event, no later than 60 days after the date thereof. Parent shall
take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance
with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting,
or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i) it will not
receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii) it will
not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct
the business of the Parent Stockholder Meeting or (iii) that the failure to postpone or adjourn the Parent Stockholder Meeting would
reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make
one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder
Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.
(b) Parent
agrees that (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder
Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in Section 6.3(a) above
and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent’s stockholders
vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the “Parent Board
Recommendation”).
(c) Notwithstanding
anything to the contrary contained in Section 6.3(b), and subject to compliance with Section 5.4
and Section 6.3, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation
(or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company (a “Parent
Board Adverse Recommendation Change”) if, at any time prior to approval and adoption of this Agreement by the Required Parent
Stockholder Vote, (i) Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation
with its outside legal counsel and financial advisor, to be a Superior Offer or (ii) as a result of a material development or change
in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition
Inquiry, Acquisition Transaction or the consequences thereof, or (B) the fact, in and of itself, that Parent meets or exceeds internal
budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business,
assets or operations of Parent that occurs or arises after the date of this Agreement (a “Parent Intervening Event”),
if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the
Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw
or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable
Law, (ii) Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined
below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such
Acquisition Proposal ceases to constitute a Superior Offer, and (iii) if, after the Company has delivered to Parent a written offer
to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith,
based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent
Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into
account such alterations of the terms and conditions of this Agreement); provided that (1) the Company receives written notice
from Parent confirming that the Parent Board has determined to change its recommendation at least four (4) Business Days in advance
of the Parent Board Adverse Recommendation Change (the “Parent Notice Period”), which notice shall include a description
in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed
transaction agreements with any party making a potential Superior Offer, (2) during any Parent Notice Period, the Company shall
be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives
to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and
conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event
of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent’s
stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice
of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3) Business
Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements
of this Section 6.3(c) and the Parent Board shall not make a Parent Board Adverse Recommendation Change
prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in
the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making
a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the
applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.
(d) Parent’s
obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with Section 6.3(a) shall
not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal
or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.
(e) Nothing
contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules 14d-9 and 14e-2(a) promulgated
under the Exchange Act; provided, however, that any disclosure made by Parent or the Parent Board pursuant to Rules 14d-9
and 14e-2(a) shall be limited to a statement that Parent is unable to take a position with respect to the bidder’s tender
offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would
reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii) complying with Item 1012(a) of
Regulation M-A promulgated under the Exchange Act; (iii) informing any Person of the existence of the provisions contained in Section 5.4;
or (iv) making any disclosure that the Parent Board (or a committee thereof), after consultation with its outside legal counsel,
has determined in good faith is required by applicable Law or by any listing or trading rules or regulations of Nasdaq; provided
that, in the case of (iv), Parent shall provide the Company with a reasonable opportunity to review any such disclosure not less than
two (2) Business Days prior to the making thereof (or, if two Business Days is not reasonably practicable under the circumstances,
such shorter period of time as is reasonably practicable under the circumstances) and shall consider in good faith any comments from
the Company thereto.
6.4 Efforts;
Regulatory Approvals.
(a) The
Parties shall use commercially reasonable efforts to obtain all regulatory approvals required by applicable Law to consummate the Contemplated
Transactions. Without limiting the generality of the foregoing, each Party (i) shall make all filings and other submissions (if
any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall
use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law
or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force
and effect, (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated
Transactions and (iv) shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this
Agreement.
(b) Notwithstanding
the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable
after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party
with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit
promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the
Parties shall prepare and file, if required, (a) the notification and report forms required to be filed under the Hart–Scott–Rodino
Antitrust Improvements Act of 1976 and (b) any notification or other document required to be filed in connection with the Merger
under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10) Business Days after the date
the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any
state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection
with antitrust or competition matters.
(c) Without
limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation
against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (“Transaction Litigation”)
(including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status
thereof. Parent will (i) give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution
of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; provided
that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely
affect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult
with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii) consider in good
faith the Company’s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company
(such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.
6.5 Company
Options; Company Warrants.
(a) At
the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option (including any Service Provider Grants),
whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease
to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to
purchase shares of Parent Common Stock (an “Assumed Option”), on the same terms and conditions (including any vesting
provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as
of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board
(or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject
to each such Assumed Option shall be equal to (i) the number of shares of Company Common Stock subject to the respective Company
Option immediately prior to the First Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest
whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent)
equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option
immediately prior to the First Effective Time divided by (B) the Exchange Ratio; provided, that in the case of any Company
Option to which Section 421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect
of any accelerated vesting thereof, if applicable) by reason of its qualification under Section 422 of the Code, the exercise price,
the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined
in a manner consistent with the requirements of Section 424(a) of the Code; provided further, that in the case of any
Assumed Option to which Section 409A of the Code applies as of the First Effective Time, the exercise price, the number of shares
of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner
consistent with the requirements of Section 409A of the Code in order to avoid the imposition of any additional taxes thereunder.
The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.
(b) At
the First Effective Time, each Company Warrant, whether vested or unvested, that is outstanding immediately prior to the First Effective
Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted,
at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an “Assumed Warrant”), on the
same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events)
as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common
Stock subject to each such Assumed Warrant shall be equal to (i) the number of shares of the Company Common Stock subject to each
Assumed Warrant immediately prior to the First Effective Time multiplied by (ii) the Exchange Ratio (rounded up to the next whole
share of Parent Common Stock to the extent the aggregate amount of fractional shares of Parent Common Stock such holder of Assumed Warrants
would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down), and such Assumed Warrant shall have an exercise
price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise
purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B) the Exchange Ratio.
6.6 Employee
Benefits.
(a) Parent
shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on Section 4.17(d) or
contemplated by Section 5.1(b) of the Parent Disclosure Letter, subject to the provisions of such agreements.
The parties acknowledge and agree that the Merger shall not constitute a “change in control” (or term of similar import)
under any Company Employee Plan.
(b) From
and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an “employee
welfare benefit plan” as defined in Section 3(1) of ERISA (each, a “Post-Closing Welfare Plan”) in
which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving
Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i) waive all limitations as to
pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements
applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the
same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied
or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant
immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii) provide each such current
or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that
includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such
Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for
the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.
(c) Parent
401(k) Plan. Unless directed otherwise by the Company in writing no less than three (3) Business Days before the Closing
Date, Parent shall, at least one (1) Business Day prior to the Closing Date, (i) ceased contributions to, and adopted written
resolutions (or taken other necessary and appropriate action(s)) to terminate any Parent Employee Plan that is intended to qualify under
Section 401(a) of the Code with a cash or deferred arrangement described in Section 401(k) of the Code (collectively,
the “401(k) Plans”) in compliance with such 401(k) Plan’s terms and the requirements of applicable
Law, (ii) made all employee and employer contributions to the 401(k) Plans for all periods of service prior to the Closing
Date, including such contributions that would have been made on behalf of 401(k) Plan participants had the Merger not occurred (regardless
of any service or end-of-year employment requirements) but prorated for the portion of the plan year that ends on the Closing Date, and
(iii) 100% vested all participants under the 401(k) Plans, with such termination, contributions and vesting effective no later
than one (1) day prior to the Closing Date. Parent shall provide the Company copies of all such corporate actions or documentation
related to the same at least three (3) Business Days before their adoption or approval for the Company’s reasonable review
and comment.
(d) Parent
Options. As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or
exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that
is then outstanding shall be canceled and the holder thereof shall be entitled to receive, immediately prior to the First Effective Time
a number of shares of Parent Common Stock equal to the number of shares underlying such Parent Option. Notwithstanding anything herein
to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding
sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying
the legally-required withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock
to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in
cash to the appropriate taxing authorities. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no
consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary
and appropriate to provide for the foregoing.
(e) Parent
Restricted Stock Units. As of immediately prior to the First Effective Time, the Parent Board shall have adopted appropriate resolutions
and taken all other actions necessary and appropriate to provide that (i) the vesting of each outstanding and unvested Parent Restricted
Stock Unit shall be accelerated in full effective as of immediately prior to the First Effective Time, contingent on the occurrence of
the Closing and (ii) for each outstanding and unsettled Parent Restricted Stock Unit (including any Parent Restricted Stock Units
accelerated under Section 6.6(e)(i) above) the holder thereof shall be entitled to receive, immediately
prior to the First Effective Time a number of shares of Parent Common Stock equal to the number of vested and unsettled shares underlying
such Parent Restricted Stock Units. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder
receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance
that number of shares of Parent Common Stock calculated by multiplying the legally-required withholding rate for such holder in connection
with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding
up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. Prior to the Closing, the
Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.
6.7 Indemnification
of Officers and Directors.
(a) From
the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving
Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior
to the First Effective Time, a director or officer of Parent or the Company, respectively (the “D&O Indemnified Parties”),
against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys’
fees and disbursements (collectively, “Costs”), incurred in connection with any claim, action, suit, proceeding or
investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&O Indemnified
Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective
Time, in each case, to the fullest extent permitted under the DGCL. Each D&O Indemnified Party will be entitled to advancement of
expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity,
jointly and severally, upon receipt by Parent or the Surviving Entity from the D&O Indemnified Party of a request therefor; provided
that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to
repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the
D&O Indemnified Parties’ rights with regards to counsel, following the First Effective Time, the D&O Indemnified Parties
shall be entitled to continue to retain Sidley Austin LLP or such other counsel selected by the D&O Indemnified Parties.
(b) The
certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation
and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses
and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws
of Parent.
(c) From
and after the First Effective Time, (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company
to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company’s
Organizational Documents and pursuant to any indemnification agreements between the Company and such D&O Indemnified Parties, with
respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii) Parent shall fulfill and honor
in all respects the obligations of Parent to its D&O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification
provisions under Parent’s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&O
Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.
(d) From
and after the First Effective Time, Parent shall maintain directors’ and officers’ liability insurance policies, with an
effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public
companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a
six (6) year prepaid “D&O tail policy” for the non-cancelable extension of the directors’ and officers’
liability coverage of Parent’s existing directors’ and officers’ insurance policies for a claims reporting or discovery
period of at least six (6) years from and after the First Effective Time with respect to any claim related to any period of time
at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the
coverage provided under Parent’s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except
that Parent will not commit or spend on such “D&O Tail policy” annual premiums in excess of 250% of the annual premiums
paid by Parent in its last full fiscal year prior to the date hereof for Parent’s current policies of directors’ and officers’
liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific
amount), and if such premiums for such “D&O tail policy” would exceed 250% of such annual premium, then Parent shall
purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company
shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such “D&O tail
policy.”
(e) From
and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys’ fees, that are incurred by the
persons referred to in this Section 6.7 in connection with their enforcement of the rights provided to such persons
in this Section 6.7.
(f) The
provisions of this Section 6.7 are intended to be in addition to the rights otherwise available to the current
and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit
of, and shall be enforceable by, each of the D&O Indemnified Parties, their heirs and their Representatives.
(g) In
the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any
other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers
all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that
the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this
Section 6.7. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity
under this Section 6.7.
6.8 Disclosure.
The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent’s Form 8-K
announcing the execution and delivery of this Agreement. Without limiting any Party’s obligations under the Confidentiality Agreement,
no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any
public disclosure regarding the Contemplated Transactions unless: (a) the other Party shall have approved such press release or
disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined
in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable,
before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding,
the text of such press release or disclosure; provided, however, that each of the Company and Parent may make any public
statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst
conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements
made by the Company or Parent in compliance with this Section 6.8. Notwithstanding the foregoing, a Party need not consult
with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant
to Section 6.2(d) or pursuant to Section 6.3(e).
6.9 Listing.
At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq
until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required
by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent
Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject
to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required)
and to submit a copy of the amendment to Parent’s certificate of incorporation effecting the Nasdaq Reverse Split, certified by
the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d) to the extent required by Nasdaq Marketplace
Rule 5110, assist the Company in preparing and filing an initial listing application for the Parent Capital Stock on Nasdaq (including
any Parent Common Stock issuable upon conversion thereof) (the “Nasdaq Listing Application”) and to cause such Nasdaq
Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other
Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially
reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing
Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application
and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested
in connection with any action contemplated by this Section 6.9. All Nasdaq fees associated with any action contemplated
by this Section 6.9, including any fees related to the engagement of a consultant (the “Nasdaq Fees”),
shall be paid by the Company.
6.10 Tax
Matters.
(a) The
Parties shall use reasonable efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment.
No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or
impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner
that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment
during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination
within the meaning of Section 1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting
requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section 1.368-3.
(b) Parent
shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that
would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify
Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be
expected to prevent, cause a failure of, or impede the Intended Tax Treatment.
(c) If
the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Proxy Statement,
(i) the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized
law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions
and limitations), (ii) Parent shall use its reasonable best efforts to cause Sidley Austin LLP (or such other nationally recognized
law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions
and limitations), and (iii) Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally
recognized law or accounting firm reasonably satisfactory to the Company) and Sidley Austin LLP (or such other nationally recognized
law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Proxy Statement shall have been
declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations
and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to
enable such advisors to render such opinions (the “Tax Certificates”). Each of Parent and the Company shall use its
commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not
to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax
Certificates.
(d) Parent
and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications
or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer,
recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted
to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration
or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such
Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.
6.11 Legends.
Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital
Stock to be received in the Merger by equityholders of the Company who may be considered “affiliates” of Parent for purposes
of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate
stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.
6.12 Officers
and Directors. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall
use commercially reasonable efforts and take all necessary action so that the Persons listed on Section 6.12 of the
Parent Disclosure Letter are elected or appointed, as applicable, to the positions of officers or directors of Parent and the Surviving
Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on Section 6.12
of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set
forth therein, the Party appointing such Person (as set forth on Section 6.12 of the Parent Disclosure Letter) shall
designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers
of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.
6.13 Termination
of Certain Agreements and Rights. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration
rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent
Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first
refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without
any liability being imposed on the part of Parent or the Surviving Entity.
6.14 Section 16
Matters. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent
Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who
is reasonably expected to become subject to the reporting requirements of Section 16(a) of the Exchange Act with respect to
Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act.
6.15 Allocation
Information. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior
to the First Effective Time) (a) each holder of Company Capital Stock, (b) such holder’s name and address, (c) the
number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d) the number of shares
of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder
as of immediately prior to the First Effective Time (the “Allocation Certificate”).
6.16 Parent
SEC Documents. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely
file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents
required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (“SEC Documents”). As of
its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by
Parent with the SEC (a) shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities
Act, and (b) shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
6.17 Notice
of Certain Transactions. As reasonably practicable following the closing of any Interim Financing or Company Acquisition, the Company
shall provide notice to Parent (email being sufficient) setting forth in reasonable detail the terms of such Interim Financing or Company
Acquisition, including (i) in the case of any Interim Financing, the amount of proceeds actually received by the Company in connection
with such Interim Financing and (ii) in the case of any Company Acquisition, the Fair Market Value associated therewith.
6.18 Obligations
of Merger Subs. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and
to consummate the Merger on the terms and conditions set forth in this Agreement.
6.19 Parent
Financing. To the extent requested by the Company prior to the Closing, Parent shall use reasonable best efforts to amend, restate
and/or supersede the Subscription Agreement, in the manner determined by the Company at the Company’s cost and expense, to allow
for the purchase of additional shares (up to $200,000,000 of such additional shares at a price per share no less than the Nasdaq official
closing price (as reflected on Nasdaq.com) immediately preceding the signing of such amendment or restatement of the Subscription Agreement
or other or superseding subscription agreement) of Parent Common Stock (whether in a second tranche or otherwise) by new or existing
investors.
Section 7.
Conditions Precedent to Obligations of Each Party.
The obligations of each Party to effect the Merger
and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent
permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:
7.1 Regulatory
Approvals. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise
been terminated.
7.2 No
Restraints. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with
the Contemplated Transactions (including any Parent Common Stock issuable upon conversion thereof) shall have been complied with and
no Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent
jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated
Transactions illegal.
7.3 Stockholder
Approval. (a) Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are
necessary to consummate the transactions contemplated by this Agreement) and (b) the Company shall have obtained the Required Company
Stockholder Vote.
7.4 Listing.
The Nasdaq Listing Application shall have been approved by Nasdaq.
7.5 Lock-Up
Agreements. The Lock-Up Agreements shall be in full force and effect.
7.6 Parent
Charter Amendment. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware,
containing at least such amendments as are necessary to consummate the transactions contemplated by this Agreement.
7.7 Certificate
of Designation. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.
Section 8.
Additional Conditions Precedent to Obligations of Parent and Merger Subs.
The obligations of Parent and Merger Subs to
effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written
waiver by Parent, at or prior to the Closing, of each of the following conditions:
8.1 Accuracy
of Representations. The Company Fundamental Representations shall have been true and correct in all material respects as of the date
of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of
such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such
representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been
true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually
or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations
and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular
date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations
and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and
correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or
in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect
(without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b) for
those representations and warranties which address matters only as of a particular date (which representations shall have been true and
correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that,
for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure
Letter made or purported to have been made after the date of this Agreement shall be disregarded).
8.2 Performance
of Covenants. The Company shall have performed or complied with in all material respects all agreements and covenants required to
be performed or complied with by it under this Agreement at or prior to the First Effective Time.
8.3 Documents.
Parent shall have received the following documents, each of which shall be in full force and effect:
(a) a
certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions
set forth in Sections 8.1, 8.2, 8.4, 8.5
and 8.6 have been duly satisfied and (ii) that the information (other than emails and addresses) set forth in the
Allocation Certificate delivered by the company in accordance with Section 6.15 is true and accurate in all respects
as of the Closing Date;
(b) a
certificate pursuant to Treasury Regulations Sections 1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance
with the requirements of Treasury Regulations Section 1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;
(c) the
Company Valuation Schedule; and
(d) the
Allocation Certificate.
8.4 No
Company Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect
that is continuing.
8.5 Company
Stockholder Written Consent. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full
force and effect.
8.6 Parent
Financing. The Subscription Agreement shall be in full force and effect and proceeds of not less than the Minimum Concurrent Investment
Amount shall have been received by Parent or will be received by Parent substantially concurrently with the Closing in connection with
the consummation of the transactions contemplated by the Subscription Agreement.
Section 9.
Additional Conditions Precedent to Obligation of the Company.
The obligations of the Company to effect the
Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver
by the Company, at or prior to the Closing, of each of the following conditions:
9.1 Accuracy
of Representations. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date
of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of
such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such
representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been
true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the
same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually
or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations
and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular
date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations
and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and
correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or
in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect
(without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b) for
those representations and warranties which address matters only as of a particular date (which representations shall have been true and
correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that,
for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure
Letter made or purported to have been made after the date of this Agreement shall be disregarded).
9.2 Performance
of Covenants. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants
required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.
9.3 Documents.
The Company shall have received the following documents, each of which shall be in full force and effect:
(a) a
certificate executed by an executive officer of Parent certifying that the conditions set forth in Sections 9.1, 9.2
and 9.4 have been duly satisfied;
(b) written
resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers
and directors of Parent who are not to continue as officers or directors of Parent pursuant to Section 6.12 hereof;
and
(c) the
Parent Net Cash Schedule.
9.4 No
Parent Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect
that is continuing.
Section 10.
Termination.
10.1 Termination.
This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company’s
stockholders and whether before or after approval of the Parent Stockholder Matters by Parent’s stockholders, unless otherwise
specified below):
(a) by
mutual written consent of Parent and the Company;
(b) by
either Parent or the Company if the Merger shall not have been consummated by September 30, 2025 (subject to possible extension
as provided in this Section 10.1(b), the “End Date”); provided, however, that
the right to terminate this Agreement under this Section 10.1(b) shall not be available to the Company or
Parent if such Party’s (or in the case of Parent, Merger Subs’) action or failure to act has been a principal cause of the
failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement;
(c) by
either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable
Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;
(d) by
Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the date hereof; provided,
however, that once the Required Company Stockholder Vote has been obtained (whether timely or not), Parent may not terminate this
Agreement pursuant to this Section 10.1(d);
(e) by
either Parent or the Company if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall
have been held and completed and Parent’s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii) the
Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof)
by the Required Parent Stockholder Vote; provided, however, that the right to terminate this Agreement under this Section 10.1(e) shall
not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure
to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;
(f) by
the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent
Triggering Event shall have occurred;
(g) by
Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company
Stockholder Vote) if a Company Triggering Event shall have occurred;
(h) by
the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs
or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions
set forth in Section 9.1 or Section 9.2 would not be satisfied as of the time of such
breach or as of the time such representation or warranty shall have become inaccurate; provided, that the Company is not then
in material breach of any representation, warranty, covenant or agreement under this Agreement; provided further, that if such
inaccuracy in Parent’s or Merger Subs’ representations and warranties or breach by Parent or Merger Subs is curable by Parent
or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this Section 10.1(h) as
a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing
upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate
pursuant to this Section 10.1(h) and (ii) Parent or Merger Subs (as applicable) ceasing to exercise
commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of
such breach or inaccuracy and its intention to terminate pursuant to this Section 10.1(h) (it being understood
that the Company shall not be permitted to terminate this Agreement pursuant to this Section 10.1(h) as
a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming
effective);
(i) by
Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation
or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in Section 8.1
or Section 8.2 would not be satisfied as of the time of such breach or as of the time such representation
or warranty shall have become inaccurate; provided that Parent is not then in material breach of any representation, warranty,
covenant or agreement under this Agreement; provided, further, that if such inaccuracy in the Company’s representations
and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant
to this Section 10.1(i) as a result of such particular breach or inaccuracy until the earlier of (i) the
expiration of a thirty (30) day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy
and its intention to terminate pursuant to this Section 10.1(i) and (ii) the Company ceasing to exercise
commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or
inaccuracy and its intention to terminate pursuant to this Section 10.1(i) (it being understood that Parent
shall not be permitted to terminate this Agreement pursuant to this Section 10.1(i) as a result of such
particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or
(j) by
Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance
with all of the requirements set forth in the proviso to this Section 10.1(j), upon the Parent Board authorizing
Parent to enter into a Permitted Alternative Agreement; provided, however, that Parent shall not enter into any Permitted
Alternative Agreement unless: (i) Parent shall have complied in all material respects with its obligations under Section 5.4
and Section 6.3, (ii) the Parent Board shall have determined in good faith, after consultation with
its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent
with its fiduciary obligations under applicable Law and (iii) Parent shall concurrently pay to the Company the Company Termination
Fee in accordance with Section 10.3(d).
The Party desiring to terminate this Agreement
pursuant to this Section Section 10 (other than pursuant to Section 10.1(a)) shall give a notice
of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor
described in reasonable detail.
10.2 Effect
of Termination. In the event of the termination of this Agreement as provided in Section Section 10, this Agreement
shall be of no further force or effect; provided, however, that (a) this Section 10.2, Section 10.3
and Error! Reference source not found.11 (other than Section 11.8) and the related definitions
of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b) the
termination of this Agreement and the provisions of Section 10.3 shall not relieve any Party of any liability for fraud
or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.
10.3 Expenses;
Termination Fees.
(a) Except
as set forth in this Section 10.3 and Section 6.9, all fees and expenses incurred in
connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the
Merger is consummated.
(b) If
(i) this Agreement is terminated by Parent or the Company pursuant to Section 10.1(e) or by the Company
pursuant to Section 10.1(f), (ii) at any time after the date of this Agreement and prior to the Parent Stockholder
Meeting, a bona fide third party Acquisition Proposal for a change of control transaction with respect to Parent shall have been publicly
announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii) within twelve (12)
months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates
a Subsequent Transaction (excluding in each case any transactions occurring in connection with the liquidation, dissolution and winding
up of Parent), then Parent shall pay to the Company, within ten (10) Business Days after termination (or, if applicable, upon such
entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $320,000 (the
“Company Termination Fee”).
(c) If
this Agreement is terminated by the Company (other than pursuant to Section 10.1(e) or Section 10.1(f)),
the Company shall pay to Parent, within ten (10) Business Days of such termination, a non-refundable fee in an amount equal to $500,000
for each month (or portion thereof) that has elapsed after May 30, 2025 at the time of such payment; provided that in no
event shall the amount of the fee payable by the Company pursuant to this Section 10.3(c) exceed $2,000,000.
(d) If
this Agreement is terminated by Parent pursuant to Section 10.1(d), the Company shall pay to Parent, within ten
(10) Business Days of such termination, a nonrefundable fee in an amount equal to $2,000,000. If (i) this Agreement is terminated
by Parent pursuant to Section 10.1(g), (ii) at any time after the date of this Agreement and before obtaining
the Required Company Stockholder Vote, a, Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise
communicated to the Company Board (and shall not have been withdrawn) and (iii) within twelve (12) months after the date of such
termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction,
then the Company shall pay to Parent, within ten (10) Business Days after termination (or, if applicable, upon such entry into a
definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $2,000,000.
(e) If
either Party fails to pay when due any amount payable by it under this Section 10.3, then (i) such Party
shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in
connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this Section 10.3
and (ii) such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such
overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full)
at a rate per annum equal to the “prime rate” (as announced by Bank of America or any successor thereto) in effect on the
date such overdue amount was originally required to be paid plus three percent.
(f) The
Parties agree that, subject to Section 10.2, the payment of the fees and expenses set forth in this Section 10.3
shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described
in this Section 10.3, it being understood that in no event shall either Parent or the Company be required to
pay the individual fees or damages payable pursuant to this Section 10.3 on more than one occasion. Subject to
Section 10.2, following the payment of the fees and expenses set forth in this Section 10.3
by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement
or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated
Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other
claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or
any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in
connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination
or the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall
be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising
out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated
Transactions to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this Section 10.3
are an integral part of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement
and (z) any amount payable pursuant to this Section 10.3 is not a penalty, but rather is liquidated damages
in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that
nothing in this Section 10.3(f) shall limit the rights of the Parties under Section 11.10.
Section 11.
Miscellaneous Provisions.
11.1 Non-Survival
of Representations and Warranties. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement
or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants
that by their terms survive the First Effective Time and this Section 11 shall survive
the First Effective Time.
11.2 Amendment.
This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time
(whether before or after the adoption and approval of this Agreement by the Company’s stockholders or before or after obtaining
the Required Parent Stockholder Vote); provided, however, that after any such approval of this Agreement by a Party’s
stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of
such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger
Subs and Parent.
11.3 Waiver.
(a) Any
provision hereof may be waived by the waiving Party solely on such Party’s own behalf, without the consent of any other Party.
No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part
of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right,
privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further
exercise thereof or of any other power, right, privilege or remedy.
(b) No
Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement,
unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered
on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is
given.
11.4 Entire
Agreement; Counterparts; Exchanges by Electronic Transmission. This Agreement and the other schedules, exhibits, certificates, instruments
and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both
written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided, however,
that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; provided,
further, that only Exhibit D (including Exhibit A to such Exhibit) is incorporated by reference and made a part hereof
for purposes of Section 251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an
original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or
otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions
of this Agreement.
11.5 Applicable
Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of
the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably
and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or,
to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States
District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and
determined exclusively in accordance with clause (a) of this Section 11.5, (c) waives any objection to laying
venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient forum or do
not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall
be effective if notice is given in accordance with Section 11.7 of this Agreement and (f) irrevocably and unconditionally
waives the right to trial by jury.
11.6 Assignability.
This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective
successors and permitted assigns; provided, however, that neither this Agreement nor any of a Party’s rights or obligations
hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment
or delegation of this Agreement or any of such rights or obligations by such Party without the other Party’s prior written consent
shall be void and of no effect.
11.7 Notices.
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder
(a) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international
overnight courier service, (b) upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery
if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the
next succeeding Business Day, in each case to the intended recipient as set forth below:
if to Parent or Merger Subs:
GlycoMimetics Inc.
9708 Medical Center Drive
Rockville, Maryland 20850
Attention: Christian Dinneen-Long
Email: cdinneen-long@glycomimetics.com
with a copy to (which shall not constitute notice):
Sidley Austin LLP
787
Seventh Avenue
New York, NY 10019
Attention: Asher M. Rubin; John Butler
Email: arubin@sidley.com; john.butler@sidley.com
if to the Company:
Crescent Biopharma, Inc.
221 Crescent Street, Building 23, Suite 105
Waltham, Massachusetts 02453
Attention: Jonathan Violin
Email: jviolin@crescentbiopharma.com
with a copy to (which shall not constitute notice):
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
Attention: Ryan Murr, Branden Berns, Chris Trester
Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com
11.8 Cooperation.
Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements
and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated
Transactions and to carry out the intent and purposes of this Agreement.
11.9 Severability.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or
provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that
any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall
have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term
or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or
provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted
to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable
term or provision.
11.10 Other
Remedies; Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party
will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise
by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which
monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement
were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to
consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery
of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware
or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled
at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with
respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other
equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an
appropriate remedy for any reason at law or in equity.
11.11 No
Third-Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than
the Parties and the D&O Indemnified Parties to the extent of their respective rights pursuant to Section 6.7) any
right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
[Remainder of page intentionally left
blank]
In
Witness Whereof, the Parties have caused this Agreement to be executed as of the date first above written.
| |
GlycoMimetics Inc. |
| |
|
| |
By: |
/s/ Harout Semerjian |
| |
Name: |
Harout Semerjian |
| |
Title: |
President and Chief Executive Officer |
| |
|
| |
Gemini MERGER SUB CORP. |
| |
|
| |
By: |
/s/ Harout Semerjian |
| |
Name: |
Harout Semerjian |
| |
Title: |
President and Chief Executive Officer |
| |
|
| |
Gemini MERGER SUB II, LLC |
| |
|
| |
By: |
/s/ Harout Semerjian |
| |
Name: |
Harout Semerjian |
| |
Title: |
President and Chief Executive Officer |
In
Witness Whereof, the Parties have caused this Agreement to be executed as of the date first above written.
| |
Crescent Biopharma, Inc. |
| |
|
| |
By: |
/s/ Jonathan Violin |
| |
Name: |
Jonathan Violin |
| |
Title: |
Chief Executive Officer |
Exhibit 3.1
Glycomimetics,
inc.
CERTIFICATE OF DESIGNATION OF PREFERENCES,
RIGHTS AND LIMITATIONS
OF
SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK
Pursuant to Section 151 of the
General Corporation Law of the State of Delaware
THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf
of GlycoMimetics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly
adopted by the Board of Directors of the Corporation (the “Board of Directors”), in accordance with the provisions
of Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), at a meeting duly
called and held on [·], which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value
$0.001 per share, which is designated as “Series A Non-Voting Convertible Preferred Stock,” with the preferences, rights
and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.
WHEREAS: the
Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the “Certificate of Incorporation”),
provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the
“Preferred Stock”), issuable from time to time in one or more series.
RESOLVED: that,
pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock
of the Corporation be, and hereby is, authorized by the Board of Directors, (ii) the Board of Directors hereby authorizes the issuance
of [·] shares of “Series A Non-Voting Convertible Preferred Stock” pursuant to the terms of the Agreement and Plan
of Merger and Reorganization, dated October 28, 2024, by and among the Corporation, Gemini Merger Sub Corp., a Delaware corporation
and wholly owned subsidiary of the Corporation, Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary
of the Corporation, and Crescent Biopharma, Inc. (the “Merger Agreement”), and (iii) the Board of
Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications,
limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of
Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:
TERMS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED
STOCK
1. Definitions.
For the purposes hereof, the following terms shall have the following meanings:
“Buy-In”
shall have the meaning set forth in Section 6.4.3.
“Closing Sale
Price” means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00
p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or
an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter
market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such
security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by
OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of
Directors of the Corporation.
“Commission”
means the United States Securities and Exchange Commission.
“Common Stock”
means the Corporation’s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities
may hereafter be reclassified or changed.
“Conversion Shares”
means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A Non-Voting Preferred Stock in
accordance with the terms hereof.
“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Holder”
means a holder of shares of Series A Non-Voting Preferred Stock.
“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Trading Day”
means a day on which the principal Trading Market is open for business.
“Trading Market”
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or
any successors to any of the foregoing).
2. Designation,
Amount and Par Value. The series of Preferred Stock shall be designated as the Corporation’s Series A Non-Voting Convertible
Preferred Stock (the “Series A Non-Voting Preferred Stock”) and the number of shares so designated shall
be [·]. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.001 per share.
3. Dividends.
Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series A Non-Voting Preferred Stock
(on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in
the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common
Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common
Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares
of Series A Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common
Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.
4. Voting
Rights.
4.1 Except
as otherwise provided herein or as otherwise required by the DGCL, the Series A Non-Voting Preferred Stock shall have no voting rights.
However, as long as any shares of Series A Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative
vote of the holders of a majority of the then outstanding shares of the Series A Non-Voting Preferred Stock: (i) alter or change
adversely the powers, preferences or rights given to the Series A Non-Voting Preferred Stock or alter or amend this Certificate of
Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (the “Certificate
of Designation”), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended
and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations
and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges
or powers of, or restrictions provided for the benefit of the Series A Non-Voting Preferred Stock, regardless of whether any of the
foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification,
conversion or otherwise, (ii) issue further shares of Series A Non-Voting Preferred Stock or increase or decrease (other than
by conversion) the number of authorized shares of Series A Non-Voting Preferred Stock, (iii) at any time while at least 30%
of the originally issued Series A Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental
Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into another entity or any stock sale
to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least
a majority of the capital stock of the Corporation immediately after such transaction, (iv) increase the authorized number of directors
constituting the Board of Directors or change the number of votes entitled to be cast by any director or directors on any matter or (v) enter
into any agreement with respect to any of the foregoing. Holders of shares of Common Stock acquired upon the conversion of shares of Series A
Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.
4.2 Any
vote required or permitted under Section 4.1 may be taken at a meeting of the Holders or through the execution of an
action by written consent in lieu of such meeting, provided that the consent is executed by Holders representing a majority of the outstanding
shares of Series A Non-Voting Preferred Stock.
4.3 Election
of Directors.
4.3.1 At
all times when at least 30% of the originally issued Series A Non-Voting Preferred Stock remains issued and outstanding, (i) the
holders of record of the shares of Series A Non-Voting Preferred Stock, exclusively and voting together as a separate class on an
as-converted to Common Stock basis, shall be entitled to elect 2 directors of the Corporation (the “Preferred Directors”);
and (iii) the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series A
Non-Voting Preferred Stock), exclusively and voting together as a single class on an as-converted to Common Stock basis, shall be entitled
to elect the balance of the total number of directors of the Corporation (the “At-Large Directors”); provided,
however, for administrative convenience, the initial Preferred Directors may also be appointed by the Board of Directors in connection
with the approval of the initial issuance of Series A Non-Voting Preferred Stock without a separate action by the holders of Series A
Non-Voting Preferred Stock.
4.3.2 Any
Preferred Director elected as provided in Section 4.3.1 may be removed without cause by, and only by, the affirmative vote
of the holders of a majority of the shares of the Series A Non-Voting Preferred Stock, given either at a special meeting of such
stockholders duly called for that purpose or pursuant to a written consent of stockholders.
4.3.3 If
the holders of shares of the Series A Non-Voting Preferred Stock fail to elect a sufficient number of directors to fill all directorships
for which they are entitled to elect directors pursuant to Section 4.3.1 (and to the extent any of such directorships is not
otherwise filled by a director appointed in accordance with the proviso in Section 4.3.1), then any directorship not so filled
shall remain vacant until such time as the holders of the Series A Non-Voting Preferred Stock fill such directorship in accordance
with Section 4.3.1.
4.3.4 At
any meeting held for the purpose of electing a Preferred Director, the presence in person or by proxy of the holders of a majority of
the outstanding shares of the Series A Non-Voting Preferred Stock shall constitute a quorum for the purpose of electing such Preferred
Director.
4.3.5 Each
Preferred Director shall be entitled to three votes on each matter presented to the Board of Directors.
5. Rank;
Liquidation.
5.1 The
Series A Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution
or winding up of the Corporation, whether voluntarily or involuntarily.
5.2 Upon
any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”),
each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder
of Common Stock would receive if the Series A Non-Voting Preferred Stock were fully converted (disregarding for such purpose any
Beneficial Ownership Limitations) to Common Stock which amounts shall be paid pari passu with all holders of Common Stock, plus
an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation
shall be insufficient to pay the Holders of shares of the Series A Non-Voting Preferred Stock the amount required under the preceding
sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in
accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full.
For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares
that such Fundamental Transaction shall be treated as if it were a Liquidation.
6. Conversion.
6.1 Conversion
at Option of Holder. Subject to Section 6.3, each share of Series A Non-Voting Preferred Stock then outstanding
shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock
equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an “Optional Conversion”).
Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Annex A
(a “Notice of Conversion”), duly completed and executed. Provided the Corporation’s transfer agent is
participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer program, the Notice
of Conversion may specify, at the Holder’s election, whether the applicable Conversion Shares shall be credited to the account of
the Holder’s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a “DWAC Delivery”).
The date on which an Optional Conversion shall be deemed effective (the “Conversion Date”) shall be the Trading
Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation;
provided, that the original certificate(s) (if any) representing such shares of Series A Non-Voting Preferred Stock being converted,
duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter.
In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing
such shares of Series A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are
received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical
error.
6.2 Conversion
Ratio. The “Conversion Ratio” for each share of Series A Non-Voting Preferred Stock shall be 1,000
shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series A Non-Voting
Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.
6.3 Beneficial
Ownership Limitation. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share
of Series A Non-Voting Preferred Stock, and a Holder shall not have the right to convert any portion of the Series A Non-Voting
Preferred Stock pursuant to Section 6.1, to the extent that, after giving effect to such attempted conversion set forth
on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series A Non-Voting Preferred
Stock, such Holder (or any of such Holder’s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially
owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations
of the Commission, including any “group” of which the Holder is a member (the foregoing, “Attribution Parties”))
would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing
sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the
number of shares of Common Stock issuable upon conversion of the Series A Non-Voting Preferred Stock subject to the Notice of Conversion
with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon
(A) conversion of the remaining, unconverted Series A Non-Voting Preferred Stock beneficially owned by such Holder or any of
its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the
Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would
exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence,
for purposes of this Section 6.3, beneficial ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the applicable rules and regulations of the Commission, and the terms “beneficial ownership” and
“beneficially own” have the meanings ascribed to such terms therein. In addition, for purposes hereof, “group”
has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission.
For purposes of this Section 6.3, in determining the number of outstanding shares of Common Stock, a Holder may rely
on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation’s most
recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation
that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation’s transfer agent to the
Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email),
the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to any actual conversion or exercise of securities of the Corporation, including shares of Series A Non-Voting Preferred Stock,
by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly
reported or confirmed to the Holder. The “Beneficial Ownership Limitation” shall initially be 19.99% of the
number of shares of Common Stock outstanding or deemed to be outstanding as of the applicable measurement date. The Corporation shall
be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation.
Notwithstanding the foregoing, by written notice to the Corporation, (i) the Holder may reset the Beneficial Ownership Limitation
percentage to a higher percentage, not to exceed 19.99%, which increase will not be effective until the sixty-first (61st) day after such
written notice is delivered to the Corporation, and (ii) the Holder may reset the Beneficial Ownership Limitation percentage to a
lower percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the
Beneficial Ownership Limitation pursuant to clause (i), not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended
by such Holder without first providing the minimum notice required by this Section 6.3. Notwithstanding the foregoing,
(x) at any time following notice of a Fundamental Transaction, the Holder may waive and/or change the Beneficial Ownership Limitation
effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter
effective immediately upon written notice to the Corporation (y) at any time that the beneficial ownership of shares of Common Stock
of a Holder (together with any of such Holder’s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common
Stock outstanding as of any given date, then such Holder’s Beneficial Ownership Limitation shall automatically be set to 9.99%.
The provisions of this Section 6.3 shall be construed, corrected and implemented in a manner so as to effectuate the
intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series A Non-Voting Preferred
Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including
for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.
6.4 Mechanics
of Conversion.
6.4.1 Delivery
of Certificate or Electronic Issuance. Upon Conversion not later than two (2) Trading Days after the applicable Conversion Date,
or if the Holder requests the issuance of physical certificate(s), two (2) Trading Days after receipt by the Corporation of the original
certificate(s) representing such shares of Series A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying
Notice of Conversion (the “Share Delivery Date”), the Corporation shall either: (a) deliver, or cause to
be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired
upon the conversion of shares of Series A Non-Voting Preferred Stock, or (b) in the case of a DWAC Delivery (if so requested
by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder’s prime broker with DTC through
its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered
to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable
Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice
to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt
of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A Non-Voting
Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates
or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares
of Series A Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.
6.4.2 Obligation
Absolute. Subject to Section 6.3 and subject to Holder’s right to rescind a Notice of Conversion pursuant to
Section 6.4.1, the Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series A
Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction
by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any
Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged
breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder
or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such
Holder in connection with the issuance of such Conversion Shares. Subject to Section 6.3 and subject to Holder’s
right to rescind a Notice of Conversion pursuant to Section 6.4.1, in the event a Holder shall elect to convert any or
all of its Series A Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or
anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an
injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series A Non-Voting Preferred
Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of
such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series A Non-Voting Preferred
Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying
dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction,
the Corporation shall, subject to Section 6.3 and subject to Holder’s right to rescind a Notice of Conversion pursuant
to Section 6.4.1, issue Conversion Shares upon a properly noticed conversion.
6.4.3 Buy-In
on Failure to Timely Deliver Certificates. If the Corporation fails to deliver to a Holder the applicable certificate or certificates
or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to Section 6.4.1 (other than a failure
caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership
Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction
or otherwise), or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by
such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date
(a “Buy-In”), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies
available to or elected by such Holder) the amount by which (x) such Holder’s total purchase price (including any brokerage
commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common
Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the
sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such
Holder, either reissue (if surrendered) the shares of Series A Non-Voting Preferred Stock equal to the number of shares of Series A
Non-Voting Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been
issued if the Corporation had timely complied with its delivery requirements under Section 6.4.1. For example, if a Holder
purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of
shares of Series A Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving
rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall
be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after
the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations
and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder’s right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to the Corporation’s failure to timely deliver certificates representing shares of Common Stock upon conversion of
the shares of Series A Non-Voting Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder shall
not be entitled to both (i) require the reissuance of the shares of Series A Non-Voting Preferred Stock submitted for conversion
for which such conversion was not timely honored and (ii) receive the number of shares of Common Stock that would have been issued
if the Corporation had timely complied with its delivery requirements under Section 6.4.1.
6.4.4 Reservation
of Shares Issuable Upon Conversion. The Corporation covenants that at all times it will reserve and keep available out of its authorized
and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A Non-Voting Preferred Stock,
free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A Non-Voting
Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments
of Section 7) upon the conversion of all outstanding shares of Series A Non-Voting Preferred Stock. The Corporation
covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid
and non-assessable.
6.4.5 Fractional
Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series A Non-Voting Preferred Stock, no certificates
or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares
of Common Stock that a Holder of Series A Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with
all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole
share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of
shares of Series A Non-Voting Preferred Stock the Holder is at the time converting into Common Stock and the aggregate number of
shares of Common Stock issuable upon such conversion.
6.4.6 Transfer
Taxes. The issuance of certificates for shares of the Common Stock upon conversion of the Series A Non-Voting Preferred Stock
shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery
of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer
involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of
such shares of Series A Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates
unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall
have established to the satisfaction of the Corporation that such tax has been paid.
6.5 Status
as Stockholder. Upon each Conversion Date, (i) the shares of Series A Non-Voting Preferred Stock being converted shall be
deemed converted into shares of Common Stock and (ii) the Holder’s rights as a holder of such converted shares of Series A
Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock
and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation
to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for
the Corporation’s failure to convert Series A Non-Voting Preferred Stock.
7. Certain
Adjustments.
7.1 Stock
Dividends and Stock Splits. If the Corporation, at any time while this Series A Non-Voting Preferred Stock is outstanding: (A) pays
a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt,
shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series A Non-Voting Preferred Stock)
with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number
of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of
shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock
(excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment
made pursuant to this Section 7.1 shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision
or combination.
7.2 Fundamental
Transaction. If, at any time while this Series A Non-Voting Preferred Stock is outstanding, (A) the Corporation effects
any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person
(other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for
or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license
of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange
offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the
Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects
any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision
or combination covered by Section 7.1) to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (in any such case, a “Fundamental Transaction”), then, upon any subsequent conversion
of this Series A Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion
Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of
such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock
(the “Alternate Consideration”). For purposes of any such subsequent conversion, the determination of the Conversion
Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same
choice as to the Alternate Consideration it receives upon any conversion of this Series A Non-Voting Preferred Stock following such
Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving
entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the
Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders’ right to convert such preferred
stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental
Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 7.2
and insuring that this Series A Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any
subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last
address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar
days prior to the date on which such Fundamental Transaction is expected to become effective or close.
7.3 Calculations.
All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of
a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.
8. Redemption.
The shares of Series A Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit
the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.
9. Transfer.
A Holder may transfer any shares of Series A Non-Voting Preferred Stock together with the accompanying rights set forth herein, held
by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The
Corporation shall in good faith (i) do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute
and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series A Non-Voting
Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this Section 9.
The transferee of any shares of Series A Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable
to the transferor as of the time of such transfer.
10. Series A
Non-Voting Preferred Stock Register. The Corporation shall maintain at its principal executive offices (or such other office or agency
of the Corporation as it may designate by notice to the Holders in accordance with Section 11), a register for the Series A
Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder
in whose name the shares of Series A Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic
mail address of each transferee of any shares of Series A Non-Voting Preferred Stock. The Corporation may deem and treat the registered
Holder of shares of Series A Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and
for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by
any holder of Series A Non-Voting Preferred Stock or his, her or its legal representatives.
11. Notices.
Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series A
Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation,
or given by electronic communication in compliance with the provisions of the Delaware General Corporation Law, and shall be deemed sent
upon such mailing or electronic transmission.
12. Book-Entry;
Certificates. The Series A Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests
that such Holder’s shares of Series A Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead
issue a stock certificate to such Holder representing such Holder’s shares of Series A Non-Voting Preferred Stock. To the extent
that any shares of Series A Non-Voting Preferred Stock are issued in book-entry form, references herein to “certificates”
shall instead refer to the book-entry notation relating to such shares.
13. Lost
or Mutilated Series A Non-Voting Preferred Stock Certificate. If a Holder’s Series A Non-Voting Convertible Preferred
Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution
for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a
new certificate for the shares of Series A Non-Voting Convertible Preferred Stock so mutilated, lost, stolen or destroyed, but only
upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to
the Corporation.
14. Waiver.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver
by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation
on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist
upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must
be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any
right of the Holders of Series A Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series A Non-Voting
Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series A
Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any
provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without
the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially
adverse effect on any Holder shall require the consent of such Holder(s).
15. Severability.
Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any
provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent
of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.
16. Status
of Converted Series A Non-Voting Preferred Stock. If any shares of Series A Non-Voting Preferred Stock shall be converted
or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such
acquisition, and shall not be reissued as a share of Series A Non-Voting Preferred Stock. Any share of Series A Non-Voting Preferred
Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the
status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Non-Voting Preferred Stock.
[Remainder of Page Intentionally Left Blank]
IN
WITNESS WHEREOF, GlycoMimetics, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations
of Series A Non-Voting Convertible Preferred Stock to be duly executed by its [·] on [·], 202[5].
ANNEX A
NOTICE OF CONVERSION
(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER
TO CONVERT SHARES OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK)
The undersigned Holder hereby irrevocably elects
to convert the number of shares of Series A Non-Voting Preferred Stock indicated below, represented in book-entry form, into shares
of common stock, par value $0.001 per share (the “Common Stock”), of GlycoMimetics, Inc., a Delaware corporation
(the “Corporation”), as of the date written below. If securities are to be issued in the name of a Person other
than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined
herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations
of Series A Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) filed by the Corporation
with the Secretary of State of the State of Delaware on [·], 202[5].
As of the date hereof, the number of shares of
Common Stock beneficially owned by the undersigned Holder (together with such Holder’s Attribution Parties), including the number
of shares of Common Stock issuable upon conversion of the Series A Non-Voting Preferred Stock subject to this Notice of Conversion,
but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series A
Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of
the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such
Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained
in Section 6.3 of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes
hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of
the Commission.
CONVERSION CALCULATIONS:
| Date to Effect Conversion: |
|
|
| Number of shares of Series A Non-Voting Preferred Stock owned prior to Conversion: |
|
|
| Number of shares of Series A Non-Voting Preferred Stock to be Converted: |
|
|
| Number of shares of Common Stock to be Issued: |
|
|
| Address for delivery of physical certificates: |
|
|
For DWAC Delivery, please provide the following:
[HOLDER]
Exhibit 10.1
SUPPORT AGREEMENT
This
Support Agreement (this “Agreement”) is made and entered into as of October [·], 2024, by and among
Crescent Biopharma, Inc., a Delaware corporation (the “Company”), GlycoMimetics, Inc., a Delaware corporation
(“Parent”), and the undersigned stockholder (the “Stockholder” and each of the Stockholder, Company,
and Parent a “Party” and, collectively, the “Parties”) of the Company. Capitalized terms used herein
but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).
RECITALS
WHEREAS, concurrently with
the execution and delivery hereof, Parent, the Company and Gemini Merger Sub Corp., a Delaware
corporation and a wholly owned subsidiary of Parent (the “First Merger Sub”), and Gemini
Merger Sub II, LLC, a Delaware limited liability company (the “Second Merger Sub”) have entered into an Agreement
and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof,
the “Merger Agreement”), pursuant to which (i) the First Merger Sub will merge with and into the Company, with
the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge
with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject
to the conditions set forth in the Merger Agreement (together, the “Merger”).
WHEREAS,
as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number
of shares of Company Capital Stock as indicated in Appendix A.
WHEREAS,
as an inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into
this Agreement.
NOW, THEREFORE, intending
to be legally bound, the Parties hereby agree as follows:
1. Certain
Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement.
For all purposes of this Agreement, the following terms shall have the following respective meanings:
(a) “Constructive
Sale” means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative
contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering
into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic
benefits or risks of ownership of such security.
(b) “Shares”
means (i) all shares of Company Capital Stock beneficially owned by the Stockholder as of the date hereof, (ii) all additional
shares of Company Capital Stock acquired and beneficially owned by the Stockholder during the period commencing with the execution and
delivery of this Agreement and expiring on the Closing Date, and (iii) all convertible notes, promissory notes, warrants, options,
rights or other securities or instruments directly or indirectly held by the Stockholder as of the date hereof that are convertible into
or exercisable or exchangeable for shares of Company Capital Stock, whether or not currently convertible, exercisable or exchangeable.
(c) “Transfer”
or “Transferred” means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange,
pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant
or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate
succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein
(including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or
otherwise), or the beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and
each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.
2. Transfer
and Voting Restrictions. The Stockholder covenants to Parent and the Company as follows:
(a) Except
as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement
and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder’s Shares, or publicly
announce its intention to Transfer any of its Shares.
(b) Except
as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental
Authority, the Stockholder will not commit any act that would restrict the Stockholder’s legal power, authority and right to vote
all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations
under this Agreement. Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement,
the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder’s Shares,
grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares
in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case which has the effect of
limiting or affecting the Stockholder’s legal power, authority or right to execute and deliver the Company Stockholder Written Consents.
(c) Notwithstanding
anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document
or by intestacy, (ii) to such Stockholder’s Affiliates (in each case, directly or indirectly) (iii) to any member of the
Stockholder’s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member
of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit
of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for
the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise
for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions
from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder’s organizational documents, (vi) purchased
from Parent pursuant to the Parent Financing on or about the Closing Date (including any shares of Parent issued upon conversion of any
pre-funded warrants of Parent), and (vii) to the extent required by applicable Law; provided, that in the cases of clauses
(i)-(v),1 (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct
transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially
identical to this Agreement upon consummation of the Transfer if not already a party thereto.
1 Note to Draft: PIPE shares have historically been
carved out this obligation in these transactions as PIPE shares are not in issuance when voting take place. To the extent a transfer
is required by applicable Law, we could purport to impose additional obligations, but we presume any such law overrides the obligations
set forth herein.
(d) Notwithstanding
anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to
acquire any shares of Company Capital Stock.
3. Agreement
to Vote Shares. The Stockholder covenants to the Company as follows:
(a) Until
the Expiration Date (as defined below), at any meeting of the stockholders of the Company, however called, and at every adjournment or
postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be
present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in
favor of the adoption and approval of the Merger Agreement, (B) in favor of approval of the Contemplated Transactions, and (C) against
any Acquisition Proposal.
(b) If
the Stockholder is not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and
any nominees to be present (in person or by proxy) and vote all the Stockholder’s Shares in accordance with this Section 3.
(c) In
the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up,
reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term “Shares”
shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which
or for which any or all of such shares may be changed or exchanged or which are received in such transaction.
4. Action
in Stockholder Capacity Only. The Stockholder is entering into this Agreement solely in the Stockholder’s capacity as the beneficial
owner of its Shares and not in the Stockholder’s capacity as a director or officer of the Company. Nothing herein shall limit or
affect the Stockholder’s ability to act as an officer or director of the Company.
5. Irrevocable
Proxy. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with
respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with Section 3
at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the
Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in
writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and
in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting
of the Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, Section 3
of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this
Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable
proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to
be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate
on the Expiration Date.
6. No
Solicitation. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take
any action that the Company is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the
Merger Agreement is hereby incorporated by reference mutatis mutandis.
7. Documentation
and Information. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents
and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines
to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder’s
identity and ownership of the Shares and the nature of the Stockholder’s commitments and obligations under this Agreement; provided,
that, Parent and the Company provide such documents, schedules, press release or other disclosure document to the Stockholder in advance
for its review and comment. Each of Parent and the Company is an intended third-party beneficiary of this Section 7.
8. No
Exercise of Appraisal Rights; Waivers. The Stockholder hereby irrevocably and unconditionally (a) waives, and agrees to cause
to be waived and to prevent the exercise of, any rights of appraisal, any dissenters’ rights and any similar rights (including any
notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including
all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain,
prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before
any Governmental Authority, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement
or (ii) alleges that the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has
(or may be alleged to have) to the Company or to the other Company stockholders; provided, that (x) the Stockholder may defend
against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the
Stockholder’s capacity as a director, officer or securityholder of the Company and (y) the foregoing shall not limit or restrict
in any manner the Stockholder from enforcing the Stockholder’s rights under this Agreement and the other agreements entered into
by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder’s right to receive
the Merger Consideration pursuant to the terms of the Merger Agreement.
9. Representations
and Warranties of the Stockholder. The Stockholder hereby represents and warrants to Parent and the Company as follows:
(a) (i) The
Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in Appendix A (each of which shall be deemed
to be “held” by the Stockholder for purposes of Section 3 unless otherwise expressly stated with respect
to any shares in Appendix A), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant
to this Agreement, any lock-up agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising
under applicable securities or community property laws); and (ii) the Stockholder does not beneficially own any securities of the
Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in Appendix
A.
(b) Except
as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms
of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or
any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of
the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any
of the Stockholder’s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of
the Stockholder’s Shares, deposited any of the Stockholder’s Shares in a voting trust or entered into any arrangement or agreement
with any person limiting or affecting the Stockholder’s legal power, authority or right to vote the Stockholder’s Shares on
any matter.
(c) This
Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery
by the other Parties) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with
its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance
by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or
constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate
of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder’s
assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would
not reasonably be expected to materially impair or adversely affect the Stockholder’s ability to perform its obligations under this
Agreement.
(d) The
execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization
or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization,
permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not
materially impair the Stockholder’s ability to perform its obligations under this Agreement.
(e) The
Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder’s own choosing.
The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions.
The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the
Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions.
The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Entity) shall be responsible for such
Stockholder’s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands
and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder’s
execution, delivery and performance of this Agreement.
(f) With
respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge
of the Stockholder, threatened against, the Stockholder or any of the Stockholder’s properties or assets (including the Shares)
that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder
or to consummate the transactions contemplated hereby.
10. Certain
Agreements. Each Stockholder, by this Agreement, and with respect to such Stockholder’s Shares, severally and not jointly, hereby
agrees to terminate, subject to the occurrence of, and effective immediately prior to, the First Effective Time any rights under any letter
agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management,
inspection rights, preemptive rights, board of directors observer rights or rights to receive information delivered to the board of directors
or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, but excluding,
for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment
agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance
with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of
the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon,
the First Effective Time.
11. Termination.
This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time
as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without
giving effect to any amendments thereto unless consented to by the Stockholder), (b) the First Effective Time and (c) the time
this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the “Expiration Date”);
provided, however, that (i) Section 12 shall survive the termination of this Agreement
and (ii) the termination of this Agreement shall not relieve any Party from any liability for any material and willful breach of
this Agreement prior to the First Effective Time.
12. Miscellaneous
Provisions.
(a) Amendments.
No amendment of this Agreement shall be effective against any Party unless it shall be in writing and signed by each of the Parties.
(b) Entire
Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile. This Agreement constitutes the entire agreement between
the Parties and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the Parties with
respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise)
by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions
of this Agreement.
(c) Applicable
Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the
Parties arising out of or relating to this Agreement, each of the Parties: (i) irrevocably and unconditionally consents and submits
to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject
matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees
that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of
this Section 12(c), (iii) waives any objection to laying venue in any such action or proceeding in such
courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (v) agrees
that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with Section 12(h) of
this Agreement and (vi) irrevocably and unconditionally waives the right to trial by jury.
(d) Assignment.
This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective
successors and permitted assigns; provided, however, that neither this Agreement nor any of a Party’s rights or obligations
hereunder may be assigned or delegated (except pursuant to the Merger) by such Party without the prior written consent of the other Parties,
and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Parties’
prior written consent shall be void and of no effect.
(e) No
Third-Party Rights. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit
or remedy of any nature whatsoever under or by reason of this Agreement.
(f) Severability.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or
provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power
to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior
sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision
that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.
(g) Specific
Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative
with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one
remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even
if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement)
or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the
extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District
Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each
of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties
further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that
any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at
law or in equity.
(h) Notices.
All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day
after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon
delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with
a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business
Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger
Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder’s
address, electronic mail address or facsimile shown below Stockholder’s signature to this Agreement.
(i) Confidentiality.
Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company,
this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person
until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that
the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided
that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder
nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the
publication of any press release or other public announcement with respect to the Company, this Agreement, the Merger, the Merger Agreement
or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be
required by applicable Law in which circumstance such announcing Party shall make reasonable efforts to consult with the Company and Parent
to the extent practicable.
(j) Interpretation.
The words “hereof,” “herein” and “hereunder” and words of like import used in this Agreement shall
refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience
of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections
and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein
shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any
plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine
and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words “include,” “includes”
or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation,”
whether or not they are in fact followed by those words or words of like import. The word “or” is not exclusive. “Writing,”
“written” and comparable terms refer to printing, typing and other means of reproducing words (including electronic media)
in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from
time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of
that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case
as amended, modified, re-enacted thereof, substituted, from time to time. References to “$” and “dollars” are
to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder
will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise
specified, from and including or through and including, respectively. All references to “days” shall be to calendar days unless
otherwise indicated as a “Business Day.” Except as otherwise specifically indicated, for purposes of measuring the beginning
and ending of time periods in this Agreement (including for purposes of “Business Day” and for hours in a day or Business
Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United
States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party
shall not be applied in the construction or interpretation of this Agreement.
[Remainder of Page Left Intentionally Blank]
IN WITNESS WHEREOF, the undersigned
have caused this Agreement to be duly executed as of the date first above written.
COMPANY:
Crescent
Biopharma, Inc.
[Signature Page to Company
Stockholder Support Agreement]
Parent:
GlycoMimetics, Inc.,
[Signature Page to Company Stockholder Support Agreement]
[STOCKHOLDER],
in his/her capacity as the Stockholder:
[Signature
Page to Company Stockholder Support Agreement]
Appendix A
Exhibit 10.2
SUPPORT AGREEMENT
This
Support Agreement (this “Agreement”) is made and entered into as of [·],
2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the “Company”), GlycoMimetics, Inc.,
a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder” and each
of the Stockholder, Company, and Parent a “Party” and, collectively, the “Parties”) of the Parent.
Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement
(as defined below).
RECITALS
WHEREAS, concurrently with
the execution and delivery hereof, Parent, the Company and Gemini Merger Sub Corp., a
Delaware corporation and a wholly owned subsidiary of Parent (the “First Merger Sub”), and Gemini
Merger Sub II, LLC, a Delaware limited liability company (the “Second Merger Sub”) have entered into an Agreement
and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof,
the “Merger Agreement”), pursuant to which (i) the First Merger Sub will merge with and into the Company, with
the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will
merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and
subject to the conditions set forth in the Merger Agreement (together, the “Merger”).
WHEREAS,
as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such
number of shares of Parent Common Stock as indicated in Appendix A.
WHEREAS,
as an inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that Stockholder
enter into this Agreement.
NOW, THEREFORE, intending
to be legally bound, the Parties hereby agree as follows:
1. Certain
Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement.
For all purposes of this Agreement, the following terms shall have the following respective meanings:
(a) “Constructive
Sale” means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative
contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering
into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic
benefits or risks of ownership of such security.
(b) “Parent
Stockholder Matters” means the approval of (i) the issuance of Parent Capital Stock (including shares of Parent Common
Stock issuable upon conversion thereof) in connection with the Contemplated Transactions for purposes of the listing rules of Nasdaq
and (ii) the Parent Charter Amendment.
(c) “Shares”
means (i) all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, (ii) all
additional shares of Parent Common Stock acquired by the Stockholder, beneficially owned or of record, during the period commencing with
the execution and delivery of this Agreement and expiring on the Closing Date, and (iii) all convertible notes, promissory notes,
warrants, options, rights or other securities or instruments directly or indirectly held by the Stockholder as of the date hereof that
are convertible into or exercisable or exchangeable for shares of Parent Common Stock, whether or not currently convertible, exercisable
or exchangeable.
(d) “Transfer”
or “Transferred” means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange,
pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant
or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate
succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein
(including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or
otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition,
and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.
2. Transfer
and Voting Restrictions. The Stockholder covenants to Parent and the Company as follows:
(a) Except
as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement
and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder’s Shares, or
publicly announce its intention to Transfer any of its Shares.
(b) Except
as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental
Authority, the Stockholder will not commit any act that would restrict the Stockholder’s legal power, authority and right to vote
all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations
under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this
Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder’s
Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit
any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case which has the
effect of limiting or affecting the Stockholder’s legal power, authority or right to vote the Stockholder’s Shares in favor
of the Parent Stockholder Matters and against any competing proposals.
(c) Notwithstanding
anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document
or by intestacy, (ii) to such Stockholder’s Affiliates (in each case, directly or indirectly) (iii) to any member of
the Stockholder’s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family
member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect
benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other
entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder)
or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata
distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder’s organizational documents,
(vi) purchased from Parent on or about the Closing Date (including any shares of Parent issued upon conversion of any pre-funded
warrants of Parent), (vii) to the extent required by applicable Law and (viii) pursuant to the exercise of any option to purchase
any Parent Common Stock, including in order to pay the exercise price of such option or satisfy taxes applicable thereto; provided,
that in the cases of clauses (i)-(v),1
(x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any)
of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to
this Agreement upon consummation of the Transfer if not already a party thereto.
1 Note to Draft: PIPE shares have historically been
carved out this obligation in these transactions as PIPE shares are not in issuance when voting take place. To the extent a transfer
is required by applicable Law, we could purport to impose additional obligations, but we presume any such law overrides the obligations
set forth herein.
(d) Notwithstanding
anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to
acquire any shares of Parent Common Stock.
3. Agreement
to Vote Shares. The Stockholder covenants to the Company as follows:
(a) Until
the Expiration Date (as defined below), at any meeting of the stockholders of Parent called to vote upon the Parent Stockholder Matters,
however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders
of Parent, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares
held by the Stockholder (A) in favor of the Parent Stockholder Matters, and (B) against any Acquisition Proposal.
(b) If
the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to
cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder’s Shares in accordance
with this Section 3.
(c) In
the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse
stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term “Shares”
shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which
or for which any or all of such shares may be changed or exchanged or which are received in such transaction.
4. Action
in Stockholder Capacity Only. The Stockholder is entering into this Agreement solely in the Stockholder’s capacity as a record
holder and beneficial owner, as applicable, of its Shares and not in the Stockholder’s capacity as a director or officer of Parent.
Nothing herein shall limit or affect the Stockholder’s ability to act as an officer or director of Parent.
5. Irrevocable
Proxy. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted
with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with Section 3
at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent,
the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it,
and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name,
place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent stockholders
called with respect to any of the matters specified in, and in accordance and consistent with, Section 3 of this Agreement.
Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as
otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no
circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions
of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.
6. No
Solicitation. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take
any action that Parent is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger
Agreement is hereby incorporated by reference mutatis mutandis.
7. Documentation
and Information. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents
and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines
to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder’s
identity and ownership of the Shares and the nature of the Stockholder’s commitments and obligations under this Agreement. Each
of Parent and the Company is an intended third-party beneficiary of this Section 7.
8. Representations
and Warranties of the Stockholder. The Stockholder hereby represents and warrants to Parent and the Company as follows:
(a) (i) The
Stockholder is the beneficial or record owner of the shares of Parent Common Stock indicated in Appendix A (each of which shall
be deemed to be “held” by the Stockholder for purposes of Section 3 unless otherwise expressly stated with
respect to any shares in Appendix A), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed
pursuant to this Agreement and Encumbrances arising under applicable securities or community property laws); and (ii) the Stockholder
does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares of Parent
Common Stock set forth in Appendix A.
(b) Except
as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the
terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval
of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality
of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect
to any of the Stockholder’s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to
any of the Stockholder’s Shares, deposited any of the Stockholder’s Shares in a voting trust or entered into any arrangement
or agreement with any person limiting or affecting the Stockholder’s legal power, authority or right to vote the Stockholder’s
Shares on any matter.
(c) This
Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery
by the other Parties) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance
with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance
by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or
constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate
of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder’s
assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would
not reasonably be expected to materially impair or adversely affect the Stockholder’s ability to perform its obligations under
this Agreement.
(d) The
execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization
or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization,
permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not
materially impair the Stockholder’s ability to perform its obligations under this Agreement.
(e) The
Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder’s own choosing.
The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions.
The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the
Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated
Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Entity) shall be responsible
for such Stockholder’s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder
understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder’s
execution, delivery and performance of this Agreement.
(f) With
respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the
knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder’s properties or assets (including the
Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations
hereunder or to consummate the transactions contemplated hereby.
9. Termination.
This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time
as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without
giving effect to any amendments thereto unless consented to by the Stockholder), (b) the First Effective Time and (c) the time
this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the “Expiration Date”);
provided, however, that (i) Section 10 shall survive the termination of this Agreement,
and (ii) the termination of this Agreement shall not relieve any Party from any liability for any material and willful breach of
this Agreement prior to the First Effective Time.
10. Miscellaneous
Provisions.
(a) Amendments.
No amendment of this Agreement shall be effective against any Party unless it shall be in writing and signed by each of the Parties.
(b) Entire
Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile. This Agreement constitutes the entire agreement between
the Parties and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the Parties with
respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise)
by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions
of this Agreement.
(c) Applicable
Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of
the Parties arising out of or relating to this Agreement, each of the Parties: (i) irrevocably and unconditionally consents and
submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not
have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of
Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance
with clause (i) of this Section 10(c), (iii) waives any objection to laying venue in any such action
or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over
any Party, (v) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given
in accordance with Section 10(h) of this Agreement and (vi) irrevocably and unconditionally waives the
right to trial by jury.
(d) Assignment.
This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective
successors and permitted assigns; provided, however, that neither this Agreement nor any of a Party’s rights or obligations
hereunder may be assigned or delegated (except pursuant to the Merger) by such Party without the prior written consent of the other Parties,
and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Parties’
prior written consent shall be void and of no effect.
(e) No
Third-Party Rights. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit
or remedy of any nature whatsoever under or by reason of this Agreement.
(f) Severability.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or
provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that
any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall
have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term
or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or
provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted
to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable
term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable
term or provision.
(g) Specific
Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative
with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any
one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages,
even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement)
or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the
extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District
Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each
of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the
Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis
that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason
at law or in equity.
(h) Notices.
All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business
Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon
delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with
a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business
Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the
Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder’s
address, electronic mail address or facsimile shown below Stockholder’s signature to this Agreement.
(i) Confidentiality.
Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company,
this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person
until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however,
that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided
that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder
nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication
of any press release or other public announcement with respect to Parent, this Agreement, the Merger, the Merger Agreement or the other
transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by
applicable Law in which circumstance such announcing Party shall make reasonable efforts to consult with the Company and Parent to the
extent practicable.
(j) Interpretation.
The words “hereof,” “herein” and “hereunder” and words of like import used in this Agreement shall
refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience
of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections
and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein
shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any
plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine
and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words “include,” “includes”
or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation,”
whether or not they are in fact followed by those words or words of like import. The word “or” is not exclusive. “Writing,”
“written” and comparable terms refer to printing, typing and other means of reproducing words (including electronic media)
in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from
time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of
that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case
as amended, modified, re-enacted thereof, substituted, from time to time. References to “$” and “dollars” are
to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder
will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise
specified, from and including or through and including, respectively. All references to “days” shall be to calendar days
unless otherwise indicated as a “Business Day.” Except as otherwise specifically indicated, for purposes of measuring the
beginning and ending of time periods in this Agreement (including for purposes of “Business Day” and for hours in a day or
Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of
the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the
drafting Party shall not be applied in the construction or interpretation of this Agreement.
[Remainder of Page Left Intentionally
Blank]
IN WITNESS WHEREOF, the undersigned
have caused this Agreement to be duly executed as of the date first above written.
COMPANY:
Crescent
Biopharma, Inc.
[Signature
Page to Company Stockholder Support Agreement]
Parent:
[Gemini]
INC.
[Signature Page to
Company Stockholder Support Agreement]
[STOCKHOLDER],
in his/her capacity as the Stockholder:
[Signature
Page to Company Stockholder Support Agreement]
Appendix A
Exhibit 10.3
SECURITIES PURCHASE AGREEMENT
This SECURITIES PURCHASE
AGREEMENT (this “Agreement”) is dated as of October 28, 2024, by and among GlycoMimetics, Inc., a Delaware
corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each,
an “Investor” and together, the “Investors”).
WHEREAS, the Company
and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by
Section 4(a)(2) of the U.S. Securities Act of 1933, as amended (the “Securities Act”);
WHEREAS, the Company
desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon the terms and
subject to the conditions stated in this Agreement, (A) shares (the “Initial Shares”) of the Company’s
common stock, par value $0.001 per share (the “Common Stock”), including Common Stock being issued pursuant to any
cancellation or conversion of Convertible Securities (as defined below) at a per share purchase price equal to the Share Price, and/or
(B) the pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) substantially in the
form attached hereto as Exhibit B at a per warrant price equal to the Pre-Funded Warrant Price (as defined below);
WHEREAS, contemporaneously
with the sale of the Initial Shares and/or the Pre-Funded Warrants, the parties hereto will execute and deliver a Registration Rights
Agreement, in the form attached hereto as Exhibit C, pursuant to which the Company will agree to provide certain registration
rights in respect of the Shares (as defined below) under the Securities Act and applicable state securities laws; and
WHEREAS,
the Company is party to that certain Agreement and Plan of Merger by and among the Company, Gemini Merger Sub Corp., a Delaware corporation
and wholly-owned subsidiary of the Company (“First Merger Sub”), Gemini Merger Sub II, LLC, a Delaware limited liability
company and wholly-owned subsidiary of the Company (“Second Merger Sub”) and Crescent Biopharma, Inc. (“Crescent”),
dated on or about the date hereof (the “Merger Agreement”), pursuant to which (i) First Merger Sub will merge
with and into Crescent, with Crescent surviving and becoming a wholly-owned subsidiary of the Company, and (ii) Crescent will merge
with and into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly-owned subsidiary of the Company (together,
the “Merger”).
NOW
THEREFORE, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and
each Investor, severally and not jointly, agree as follows:
1. Definitions.
As used in this Agreement, the following terms shall have the following respective meanings:
“2024
SEC Reports” means (a) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2023 and (b) any Quarterly Reports on Form 10-Q or any Current Reports on Form 8-K filed or furnished (as applicable)
by the Company after January 1, 2024 and prior to the Business Day immediately preceding the date hereof, together in each case
with any documents incorporated by reference therein or exhibits thereto.
“Additional
Securities” has the meaning set forth in Section 8.15 hereof.
“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with such Person.
“Aggregate Purchase
Amount” has the meaning set forth in Section 2.2 hereof.
“Agreement”
has the meaning set forth in the recitals hereof.
“Amended and Restated
Bylaws” means the bylaws of the Company, as currently in effect and as in effect on the Closing Date.
“Amended and Restated
Certificate of Incorporation” means the Certificate of Incorporation of the Company, as currently in effect and as in effect
on the Closing Date.
“Beneficial Ownership
Limitation” has the meaning set forth in Section 2.1 hereof.
“Benefit Plan”
or “Benefit Plans” means employee benefit plans as defined in Section 3(3) of ERISA and all other employee
benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave,
vacation pay, salary continuation for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options
or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements,
maintained by the Company or to which the Company or any of its Subsidiaries is obligated to contribute for employees or former employees
of the Company and its Subsidiaries.
“Board of Directors”
means the board of directors of the Company.
“Business Day”
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.
“Closing”
has the meaning set forth in Section 2.2 hereof.
“Closing Date”
has the meaning set forth in Section 2.2 hereof.
“Code”
means the U.S. Internal Revenue Code of 1986, as amended.
“Commitment Amount”
has the meaning set forth in Section 2.1 hereof.
“Common Stock”
has the meaning set forth in the recitals hereof.
“Company”
has the meaning set forth in the recitals hereof.
“Confidential Data”
has the meaning set forth in Section 3.30 hereof.
“Contribution”
has the meaning set forth in Section 2.2 hereof.
“Convertible Security”
means a convertible note issued by the Company or any of its Subsidiaries.
“Crescent”
has the meaning set forth in the recitals hereof.
“Disclosure Document”
has the meaning set forth in Section 5.3 hereof.
“Disclosure Time”
has the meaning set forth in Section 5.3 hereof.
“Drug Regulatory
Agency” means the U.S. Food and Drug Administration (“FDA”) or other foreign, state, local or comparable
governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling,
sale, marketing, advertising, distribution and importation or exportation of drug or biological products and drug or biological product
candidates.
“Environmental Laws”
has the meaning set forth in Section 3.15 hereof.
“ERISA”
means the U.S. Employee Retirement Income Security Act of 1974, as amended.
“Exchange Act”
means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder.
“Financial Statements”
has the meaning set forth in Section 3.8(b) hereof.
“GAAP”
has the meaning set forth in Section 3.8(b) hereof.
“GDPR”
has the meaning set forth in Section 3.31 hereof.
“Governmental Authorizations”
has the meaning set forth in Section 3.11 hereof.
“Health Care Laws”
has the meaning set forth in Section 3.21 hereof.
“HIPAA”
has the meaning set forth in Section 3.30 hereof.
“Indemnified Persons”
has the meaning set forth in Section 5.10(a).
“Initial Shares”
has the meaning set forth in the recitals hereof.
“Intellectual Property”
has the meaning set forth in Section 3.12 hereof.
“Investor”
and “Investors” have the meanings set forth in the recitals hereof.
“Investor Majority”
means, (i) prior to the Closing, the Investors committed to purchase at least a majority of the Securities, which majority shall
include any Investor who, together with any affiliated funds or commonly managed funds, has committed to purchase at least $18.0 million
of the Securities, and (ii) following the Closing, the Investors who hold (as of such time) at least a majority of the Securities
(including any Pre-Funded Warrant Shares).
“IT Systems”
has the meaning set forth in Section 3.30 hereof.
“Material Adverse
Effect” means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate,
(a) was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets,
liabilities, stockholders’ equity or results of operations of the Company and its Subsidiaries, taken as a whole, or (b) materially
delays or materially impairs the ability of the Company to timely comply, or prevents the Company from complying, with its obligations
under this Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so; provided,
however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the
following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under subclause (a) of
this definition:
(i) any
change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any
other geographic region in which the Company or its Subsidiaries conducts business, provided that the Company or its Subsidiaries are
not disproportionately affected thereby;
(ii) general
financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the
Company or its Subsidiaries are not disproportionately affected thereby;
(iii) any
change that generally affects industries in which the Company and its Subsidiaries conduct business, provided that the Company and its
Subsidiaries are not disproportionately affected thereby;
(iv) earthquakes,
hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including
the COVID-19 pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States
or any other location, provided that the Company and its Subsidiaries are not disproportionately affected thereby;
(v) national
or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national
emergency or war, or the occurrence of any military or terrorist attack, provided that the Company and its Subsidiaries are not disproportionately
affected thereby;
(vi) material
changes in laws after the date of this Agreement; and
(vii) in
and of itself, any material failure by the Company or its Subsidiaries to meet any published or internally prepared estimates of drug
development timelines (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute,
and may be taken into account in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances
are not otherwise described in clauses (i)-(v) of this definition).
“Nasdaq”
means the Nasdaq Stock Market LLC.
“National Exchange”
means (i) on and prior to the Closing Date, the Nasdaq Global Market, and (ii) following the Closing Date, any of the following
markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question, together with any successor thereto:
the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market and the Nasdaq Capital Market.
“Person”
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated
association, joint venture or any other entity or organization.
“Personal Data”
has the meaning set forth in Section 3.30 hereof.
“Placement Agent”
means each of Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and LifeSci Capital LLC.
“Pre-Funded Warrant
Price” means an amount equal to (i) the Share Price minus (ii) $0.001.
“Pre-Funded Warrant
Shares” has the meaning set forth in Section 2.1 hereof.
“Pre-Funded Warrants”
has the meaning set forth in the recitals hereof.
“Privacy Laws”
has the meaning set forth in Section 3.31 hereof.
“Privacy Statements”
has the meaning set forth in Section 3.31 hereof.
“Process”
or “Processing” has the meaning set forth in Section 3.31 hereof.
“Registration Rights
Agreement” has the meaning set forth in Section 6.1(j) hereof.
“Regulatory Agencies”
has the meaning set forth in Section 3.20 hereof.
“Rule 144”
means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such rule may be amended from time to time, or any
similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such rule.
“SEC”
means the U.S. Securities and Exchange Commission.
“SEC Reports”
has the meaning set forth in Section 3.8(a) hereof.
“Securities”
has the meaning set forth in Section 2.1 hereof.
“Securities Act”
has the meaning set forth in the recitals hereof.
“Share Price”
means an amount equal to (i) the Parent Valuation (as defined in the Merger Agreement), (ii) divided by the number of Parent
Outstanding Shares (as defined in the Merger Agreement) as of immediately prior to the Closing.
“Shares”
means the Initial Shares and the Pre-Funded Warrant Shares.
“Short Sales”
include, without limitation, (i) all “short sales” as defined in Rule 200 promulgated under Regulation SHO under
the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options,
puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act)
and similar arrangements (including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers
or non-U.S. regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock),
in each case, solely to the extent it has the same economic effect as a “short sale” (as defined in Rule 200 promulgated
under Regulation SHO under the Exchange Act).
“Subsidiaries”
has the meaning set forth in Section 3.1 hereof and, for the avoidance of doubt, as of the Closing Date includes Crescent.
“Tax”
or “Taxes” means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges
of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto),
whether or not imposed on the Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or
gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding,
employment, social security, workers’ compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation,
premium, windfall profits, transfer and gains taxes and customs duties.
“Tax Returns”
means returns, reports, information statements and other documentation (including any additional or supporting material) filed or maintained,
or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall
include any amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.
“Transaction
Agreements” means this Agreement, the Pre-Funded Warrants, the Registration Rights Agreement and any other documents or agreements
explicitly contemplated hereunder.
“Transfer
Agent” means, with respect to the Common Stock, American Stock Transfer & Trust Company, or such other financial institution
that provides transfer agent services as the Company may engage from time to time.
“Transfer
Taxes” means all real property transfer, sales, use, value added, stamp, documentary, recording, registration, conveyance,
stock transfer, intangible property transfer, personal property transfer, gross receipts, registration, duty, securities transactions
or similar fees or Taxes (together with any interest, penalty, or addition thereto) incurred in connection with the transactions contemplated
by this Agreement.
“Wire”
has the meaning set forth in Section 2.2 hereof.
2. Purchase
and Sale of Securities.
2.1 Purchase
and Sale. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Investors, severally and not jointly, agree to purchase, the number of Initial Shares equal to (rounded down to the nearest whole Initial
Share) (i) the aggregate commitment amount set forth under the heading “Commitment
Amount” and opposite such Investor’s name on the Exhibit A (the “Commitment Amount”) divided
by (ii) the Share Price; provided, however, for any Investor that has provided notice to the Company at least ten
(10) Business Days prior to the Closing that such Investor would beneficially own (when aggregated with all Securities then beneficially
owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated
thereunder)) in excess of the Beneficial Ownership Limitation, or as such Investor may otherwise choose, in lieu of purchasing Initial
Shares such Investor may elect to purchase Pre-Funded Warrants to purchase a number of shares of Common Stock issuable upon exercise
of the Pre-Funded Warrants (the “Pre-Funded Warrant Shares”) equal to (rounded down to the nearest whole Pre-Funded
Warrant Share) (i) the Commitment Amount (or any remainder thereof) divided by (ii) the Pre-Funded Warrant Price in lieu of
Initial Shares in such manner to result in the same Aggregate Purchase Amount being paid by such Investor in the aggregate (including
upon exercise of such Pre-Funded Warrants). The “Beneficial Ownership Limitation” shall initially be set at the discretion
of each Investor to a percentage designated by such Investor on its signature page hereto between 0% and 9.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of the Initial Shares and Pre-Funded Warrants
on the Closing Date (collectively, the “Securities”); provided that such percentage shall be set at 9.99% for
any Investor that does not make such designation on its signature page hereto. Notwithstanding the foregoing, by written notice
to the Company, any Investor may reset the Beneficial Ownership Limitation percentage to a higher or lower percentage, not to exceed
9.99%; provided that any increase prior to the Closing will not be effective until the sixty-first (61st) day after such written
notice is delivered to the Company. Upon such a change by an Investor of the Beneficial Ownership Limitation, the Beneficial Ownership
Limitation may not be further amended by such Investor without first providing the minimum notice required by this Section 2.1.
Notwithstanding anything to the contrary set forth in this Agreement, for any Investor that has provided notice to the Company that this
sentence shall apply to it, (i) the Investor shall not be required to purchase Pre-Funded Warrants and (ii) the Company shall
not issue or sell, and the Investor shall not purchase or acquire, any Initial Shares which, when aggregated with all shares of Common
Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act
and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more than 9.99% of the outstanding
shares of Common Stock immediately after giving effect to the Closing and the consummation of the transactions contemplated hereby, and
the number of Initial Shares and the Aggregate Purchase Amount for such Investor shall be reduced accordingly.
2.2 Closing.
Subject to the satisfaction or waiver of the conditions set forth in Section 6, the closing of the purchase and sale
of the Securities (the “Closing” and the date on which the Closing occurs, the “Closing Date”)
shall occur remotely via the exchange of documents and signatures immediately following the Second Effective Time (as defined in the
Merger Agreement), or at such other time as agreed to by the Company and the Investor Majority. Not less than three (3) Business
Days prior to the anticipated Closing Date, the Company shall provide written notice to the Investors (the “Closing Notice”)
of the anticipated Closing Date and the wire instructions for delivery of the Aggregate Purchase Amount. At the Closing, the Securities
shall be issued and registered in the name of such Investor, or in such nominee name(s) as
designated by such Investor, representing the number of Securities to be purchased by such Investor at such Closing as set forth in Exhibit A,
in each case against payment to the Company of the purchase price therefor (the “Aggregate Purchase Amount”) in full,
either by (x) wire transfer to the Company of immediately available funds (a “Wire”), at or prior to the Closing,
in accordance with wire instructions provided by the Company to the Investors in the Closing Notice; (y) the cancellation of Convertible
Securities or other debt of the Company or its Subsidiaries (including any outstanding principal, interest or any other amounts due thereon)
set forth under the heading “Convertible Securities Amount” and opposite such Investor’s name in Exhibit A
(any such cancellation, a “Contribution”); or (z) a combination of such methods. On the Closing Date, the
Company will (A) cause the Transfer Agent to issue the Initial Shares in book-entry form, free and clear of all restrictive and
other legends (except as expressly provided in Section 4.10 hereof) and the Company shall provide evidence of such issuance
from the Company’s Transfer Agent as soon as reasonably practical following the Closing Date to each Investor and (B) deliver
to such Investor (or such Investor’s designated custodian per its delivery instructions), or in such nominee name(s) as designated
by such Investor, a Pre-Funded Warrant exercisable for a number of shares of Common Stock as set forth in Exhibit A with
respect to such Investor. If the Closing has not occurred within two (2) Business Days after the expected Closing Date, unless otherwise
agreed by the Company and such Investor, the Company shall promptly (but no later than one (1) Business Day thereafter) return the
previously wired Aggregate Purchase Amount to each respective Investor by wire transfer of United States dollars in immediately available
funds to the account specified by each Investor, and any book entries for the Securities shall be deemed cancelled; provided that,
unless this Agreement has been terminated pursuant to Section 7, such return of funds shall not terminate this Agreement
or relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and sell, the Securities at the Closing.
Notwithstanding the foregoing and anything in this Agreement to the contrary, (i) the Company may amend Exhibit A up
to three (3) Business Days prior to the Closing, without the consent of the other parties hereto, to reflect the number of Securities
purchased, the Aggregate Purchase Amount to be paid and the Convertible Securities Amount to be Contributed, in each case, by each applicable
Investor, and shall provide such updated Exhibit A to an Investor upon request, and (ii), as may be agreed to among the Company
and one or more Investors, if an Investor is (a) an investment company registered under the Investment Company Act of 1940, as amended,
(b) advised by an investment adviser subject to regulation under the Investment Advisers Act of 1940, as amended, or (c) otherwise
subject to internal policies and/or procedures relating to the timing of funding and issuance of securities, such Investor shall not
be required to wire its Aggregate Purchase Amount until it confirms receipt of evidence of the issuance of such Investor’s Initial
Shares from the Transfer Agent in form and substance reasonably acceptable to the Investor (and the Company shall use reasonable best
efforts to cause the Transfer Agent to deliver such evidence) and, if applicable, copies of such Investor’s Pre-Funded Warrants.
2.3 Conversion
and Termination of Convertible Securities. Notwithstanding anything in this Agreement to the contrary, by executing and delivering
this Agreement, each Investor holding one or more Convertible Securities prior to the Closing hereby irrevocably agrees that:
(a) the
aggregate amount of all such Convertible Securities (including any outstanding principal, interest or any other amounts) held by such
Investor is set forth under the heading “Convertible Securities Amount” and opposite such Investor’s name in Exhibit A;
(b) such
Investor is the sole owner of all right, title and interest in and to the Convertible Securities corresponding to the amounts set forth
under the heading “Convertible Securities Amount” and opposite such Investor’s name in Exhibit A;
(c) at
the Closing, (i) all of such Investor’s Convertible Securities will automatically and without any action on the part of such
Investor convert into that number of Securities as is calculated in accordance with Section 2.1 based on such
Investor’s Aggregate Purchase Amount (whether paid via Wire or Contribution), regardless of whether any such Convertible Securities
or an affidavit of loss therefor is actually delivered in original or other form to the Company, and (ii) any original Convertible
Securities held by (or delivered, electronically or otherwise, to) the Company or any Subsidiary, as applicable, shall be cancelled (and
marked cancelled) by the Company or any Subsidiary, as applicable, upon or following the Closing;
(d) with
respect to any Contribution by such Investor, (i) such Investor (on behalf of itself and all beneficial owners of such Investor’s
Convertible Securities) and Company (on behalf of itself and its Subsidiaries) hereby agree that any Convertible Securities that are
Contributed hereby are and will be deemed for all purposes to have been amended and modified by virtue hereof to the full extent necessary
to permit and facilitate their conversion as provided in this Agreement into Securities and (ii) such Investor’s Securities
are issued in full and complete discharge and satisfaction of all obligations of the Company or its Subsidiaries, as applicable, (including
any outstanding principal, interest or any other amounts) under such Investor’s Convertible Securities, and such Convertible Securities
will be terminated in full and will be null, void and of no further force or effect automatically immediately upon the Closing, provided
that the foregoing will not impair the right of such Investor to receive the applicable number of Securities calculated in accordance
with Section 2.1 above; and
(e) the
Company and its Subsidiaries, affiliates, and agents shall be entitled to deduct and withhold from the amounts deliverable in satisfaction
of such Investor’s Convertible Securities (including any Securities otherwise issuable with respect thereto) such amounts, if any,
as are required to be deducted and withheld under the Code or any other applicable tax law. To the extent that amounts are so deducted
and withheld and duly paid over to the appropriate tax authority, such withheld amounts shall be treated for all purposes of this Agreement
as having been delivered to the person in respect of whom such deduction and withholding was made. Each person holding Convertible Securities
shall, upon request, use its commercially reasonable efforts to provide the applicable withholding
agent with all necessary tax forms, including a duly executed IRS Form W-9 or appropriate version of IRS Form W-8, as applicable.
Prior to withholding any amounts pursuant to this Section 2.3(e), the Company (and its Subsidiaries, affiliates,
and agents) shall use commercially reasonable efforts to notify such Investor, and the Company and such Investor shall cooperate in good
faith to reduce or eliminate any such withholding.
3. Representations
and Warranties of the Company. Except as disclosed or reflected in the 2024 SEC Reports (but excluding any risk factor disclosures
contained under the heading “Risk Factors,” any disclosure of risks included in any “forward-looking statements”
disclaimer or any other statements that are similarly predictive or forward-looking in nature, in each case, other than any specific
factual information contained therein), the Company hereby represents and warrants to each of the Investors and the Placement Agents
that the statements contained in this Section 3 are true and correct as of the date hereof and as of the Closing Date
(except for the representations and warranties that speak as of a specific date, which shall be made as of such date):
3.1 Organization
and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware,
has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described
in the 2024 SEC Reports and is qualified to do business in each jurisdiction in which the character of its properties or the nature of
its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to
so qualify would not reasonably be expected to have a Material Adverse Effect. Each of the Company’s subsidiaries (collectively,
the “Subsidiaries”) is wholly owned by the Company. Each of the Subsidiaries is duly incorporated and validly existing
and in good standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on their
business as now conducted and to own or lease its properties. Each of the Subsidiaries is duly qualified to do business as a foreign
corporation and is in good standing in each jurisdiction in which such qualification is required unless the failure to so qualify has
not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
3.2 Capitalization.
The authorized capital stock of the Company consists of 100,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par
value $0.001 per share. The Company’s disclosure of its issued and outstanding capital stock in the 2024 SEC Reports containing
such disclosure was accurate in all material respects as of the date indicated in such 2024
SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid
and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other
similar rights of any securityholder of the Company which have not been waived, and such shares were issued in compliance in all material
respects with applicable state and federal securities law and any rights of third parties. There are no securities or instruments issued
by or to which the Company is a party containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities
pursuant to this Agreement. There are no securities or instruments issued by or to which the Company is a party containing anti-dilution
or similar provisions that will be triggered (which, for the avoidance of doubt, excludes any such
anti-dilution or similar provision that will be waived in connection with the transactions contemplated by this Agreement and the Merger
Agreement) by the issuance of the Securities pursuant to this Agreement.
3.3 Registration
Rights. Except as set forth in the Transaction Agreements (including in Section 3.7), the Company is presently not
under any obligation, and has not granted any rights, to register under the Securities Act any of the Company’s presently outstanding
securities or any of its securities that may hereafter be issued that have not expired or been satisfied or waived.
3.4 Authorization.
The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its
obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the
Pre-Funded Warrant Shares. Except for the Required Parent Stockholder Vote (as defined in the Merger Agreement), all corporate action
on the part of the Company, its officers, directors and stockholders necessary for the authorization
of the Securities and the Pre-Funded Warrant Shares, the authorization, execution, delivery and performance of the Transaction Agreements
and the consummation of the transactions contemplated herein, including the issuance and sale of the Securities and the Pre-Funded Warrant
Shares and the reservation of the Pre-Funded Warrant Shares, has been taken. This Agreement has been duly executed and delivered by the
Company and assuming the due authorization, execution and delivery by each Investor and that this Agreement constitutes the legal, valid
and binding agreement of each Investor, this Agreement and each of the Pre-Funded Warrants constitutes a legal, valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles
(regardless of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the Company and
the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration
Rights Agreement will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance
with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating
to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding
in equity or at law).
3.5 Valid
Issuance. The Initial Shares being purchased by the Investors hereunder have been duly and validly authorized and, upon issuance
pursuant to the terms hereof, against full payment therefor in accordance with the terms of this Agreement, will be duly and validly
issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than those as provided
in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws) and the holder of the Initial
Shares shall be entitled to all rights accorded to a holder of Common Stock. The Pre-Funded Warrant Shares have been duly and validly
authorized and reserved for issuance and, upon issuance pursuant to the terms of the Pre-Funded Warrants, against full payment therefor
in accordance with the terms of the Pre-Funded Warrants, will be duly and validly issued, fully paid and non-assessable and will be issued
free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer
under applicable state and federal securities laws) and the holder of the Pre-Funded Warrant Shares shall be entitled to all rights accorded
to a holder of Common Stock. Subject to the accuracy of the representations and warranties made by the Investors in Section 4
hereof, the offer and sale of the Securities to the Investors is and will be in compliance with applicable exemptions from (i) the
registration and prospectus delivery requirements of the Securities Act and (ii) the registration and qualification requirements
of applicable securities laws of the states of the United States.
3.6 No
Conflict. The execution, delivery and performance of the Transaction Agreements by the Company, the issuance and sale of the Securities
and the consummation of the other transactions contemplated by the Transaction Agreements will not (i) violate any provision of
the Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws, (ii) conflict with or result in a violation
of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration
of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise,
license, judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company or any Subsidiary or their respective
properties or assets, or (iii) result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or any Subsidiary is subject (including federal and state securities laws and regulations) and the rules and
regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property or asset
of the Company or any Subsidiary is bound or affected, except, in the case of clauses (ii) and (iii), as would not, individually
or in the aggregate, be reasonably expected to have a Material Adverse Effect.
3.7 Consents.
Assuming the accuracy of the representations and warranties of the Investors in Section 4, no consent, approval, authorization,
filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization,
execution or delivery by the Company of the Transaction Agreements, the issuance and sale of the Securities and the performance by the
Company of its other obligations under the Transaction Agreements, except such as (a) have been or will be obtained or made under
the Securities Act or the Exchange Act, (b) the filing of any requisite notices and/or
application(s) to the National Exchange for the issuance and sale of the Shares and the listing of the Shares for trading or quotation,
as the case may be, thereon in the time and manner required thereby, (c) customary post-closing filings with the SEC or pursuant
to state securities laws in connection with the offer and sale of the Shares by the Company in the manner contemplated herein, which
will be filed on a timely basis, (d) the filing of the registration statement required to be filed by the Registration Rights Agreement,
or (e) such that the failure of which to obtain would not have a Material Adverse Effect.
All notices, consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to
the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain
in full force and effect, on or prior to the Closing.
3.8 SEC
Filings; Financial Statements.
(a) Since
January 1, 2024, the Company has timely filed or furnished, as applicable, all forms, statements, certifications, reports and documents
required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (such forms, statements, certifications,
reports or documents filed since January 1, 2024, the “SEC Reports”). As of the time it was filed with, or furnished
to, the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of
the SEC Reports complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the
case may be), and the rules and regulations promulgated thereunder, and, as of the time they were filed or furnished, none of the
SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. There are no outstanding
or unresolved comments from the SEC staff with respect to the SEC Reports. None of the SEC Reports is the subject of an ongoing SEC review.
As of and prior to the date hereof, the Company is not, and never has been, an issuer identified in Rule 144(i)(1).
(b) The
financial statements of the Company included in the SEC Reports (collectively, the “Financial Statements”) comply
in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as
in effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects
the financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods therein
specified, all in accordance with United States generally accepted accounting principles (“GAAP”) (except as otherwise
noted therein, and in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited
financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments) applied on a consistent
basis unless otherwise noted therein throughout the periods therein specified. Except as set forth in the Financial Statements filed
prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except (i) those incurred in the
ordinary course of business, consistent with past practices since the date of such Financial Statements or (ii) liabilities not
required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have
had or would reasonably be expected to have a Material Adverse Effect.
3.9 Absence
of Changes. Except as otherwise stated or disclosed in the 2024 SEC Reports, since January 1, 2024: (a) the Company has
conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company
(except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, including
the Merger Agreement); (b) no material change to any material contract or arrangement by which the Company is bound or to which
any of its assets or properties is subject has been entered into that has not been disclosed in the 2024 SEC Reports; and (c) there
has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect.
3.10 Absence
of Litigation. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or,
to the Company’s knowledge, threatened against the Company or any Subsidiary which, individually or in the aggregate, has had or
would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or decrees outstanding
of any court or government agency or instrumentality and binding upon the Company or any Subsidiary
that have had or would reasonably be expected to have a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any Subsidiary, is, or within the
last ten (10) years has been, the subject of any action involving a claim of violation of or liability under federal or state securities
laws relating to the Company or such Subsidiary or a claim of breach of fiduciary duty relating to the Company or such Subsidiary.
3.11 Compliance
with Law; Permits. None of the Company or any Subsidiary is in violation of, or has received any notices of violations with respect
to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality,
except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse
Effect. The Company and its Subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, “Governmental
Authorizations”) from such federal, state or local government or governmental agency, department or body that are currently
necessary for the operation of the business of the Company and its Subsidiaries as currently conducted, except where the failure to possess
currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. None of the
Company or any Subsidiary has received any written (or, to the Company’s knowledge, oral) notice regarding any revocation or material
modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.
3.12 Intellectual
Property. The Company and its Subsidiaries own, or have rights to use, all material inventions, patent applications, patents, trademarks,
trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary
of confidential information, systems or procedures) and other intellectual property as described in the SEC Reports necessary for, or
used in the conduct of their respective businesses (including as described in the SEC Reports) (collectively, “Intellectual
Property”), except where any failure to own, possess or acquire such Intellectual Property has not had, and would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its Subsidiaries
has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company’s
knowledge: (i) there are no third parties who have rights to any Intellectual Property, including no liens, security interests,
or other encumbrances; and (ii) there is no infringement by third parties of any Intellectual Property. No action, suit, or other
proceeding is pending, or, to the Company’s knowledge, is threatened: (A) challenging the Company’s or its Subsidiaries’
rights in or to any Intellectual Property; (B) challenging the validity, enforceability or scope of any Intellectual Property; or
(C) alleging that the Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark,
trade name, service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or
in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries
have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to
the Company or any of its Subsidiaries in all material respects, and to the Company’s knowledge all such agreements are in full
force and effect. To the Company’s knowledge, there are no material defects in any of the patents or patent applications included
in the Intellectual Property. The Company and its Subsidiaries have taken all reasonable steps to protect, maintain and safeguard their
Intellectual Property.
3.13 Employee
Benefits. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established
and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection
and Affordable Care Act of 2010, as amended, and other applicable laws, rules and regulations.
The Company and its Subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding
employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse
Effect. There is no labor dispute, strike or work stoppage against the Company or its Subsidiaries pending or, to the knowledge
of the Company, threatened which may interfere with the business activities of the Company, except where such dispute, strike or work
stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.
3.14 Taxes.
The Company and its Subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have
been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except
for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal
tax returns has been made against the Company. The charges, accruals and reserves on the books of the Company in respect of any income
and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional
income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.
No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its Subsidiaries are presently
in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on
any of the assets of the Company. The Company, at all times since inception, has been and continues to be each classified as a corporation
for U.S. federal income tax purposes. Neither the Company nor any of its Subsidiaries has been a United States real property holding
corporation within the meaning of Code Section 897(c)(2) during the period specified in Code Section 897(c)(1)(A)(ii).
3.15 Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (“Environmental Laws”), (ii) have received all permits and other Governmental Authorizations
required under applicable Environmental Laws to conduct its business and (iii) are in compliance with all terms and conditions of
any such permit, license or approval, except where such noncompliance with Environmental Laws, failure
to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses
or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company
or any Subsidiary has received since January 1, 2024, any written notice or other communication (in writing or otherwise), whether
from a governmental authority or other Person, that alleges that the Company or any Subsidiary is not in compliance with any Environmental
Law and, to the knowledge of the Company, there are no circumstances that may prevent or interfere with the Company’s or any Subsidiary’s
compliance with any Environmental Law in the future, except where such failure to comply would
not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company: (i) no current or (during the time
a prior property was leased or controlled by the Company) prior property leased or controlled by the Company or any Subsidiary has received
since January 1, 2024, any written notice or other communication relating to property owned or leased at any time by the Company,
whether from a governmental authority, or other Person, that alleges that such current or prior owner or the Company or any Subsidiary
is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability
under any Environmental Law.
3.16 Title.
Each of the Company and its Subsidiaries has good and marketable title to all personal property owned by it that is material to the business
of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property
and do not materially and adversely interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries,
as the case may be. Any real property and buildings held under lease by the Company or its
Subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially and
adversely interfere with the use made and proposed to be made of such property and buildings by the Company or its Subsidiaries, as the
case may be. The Company does not own any real property.
3.17 Insurance.
The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably
situated companies and is adequate for the conduct of its and its Subsidiaries’ businesses and the value of its and its Subsidiaries’
properties (owned or leased) and assets, and each of such insurance policies is in full force and effect and the Company is in compliance
in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1,
2024, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation
of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under
any insurance policy.
3.18 Nasdaq
Stock Market. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange
Act and are listed for trading on the Nasdaq Global Market under the symbol “GLYC.” Except as set forth in the SEC Reports,
the Company is in compliance with all listing requirements of Nasdaq applicable to the Company except where such failure to be in compliance
would not reasonably be expected to have a Material Adverse Effect. There is no suit, action, proceeding or investigation pending or,
to the knowledge of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit or terminate the listing
of the Common Stock on the Nasdaq Global Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action
that is designed to terminate the registration of the Common Stock under the Exchange Act.
3.19 Sarbanes-Oxley
Act. The Company is, and since January 1, 2024 has been, in compliance in all material respects with all applicable requirements
of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder.
3.20 Clinical
Data and Regulatory Compliance. Except as would not reasonably be expected to result in a Material Adverse Effect: (i) the preclinical
tests and clinical trials, and other studies used to support regulatory approval (collectively, “studies”) being conducted
by the Company that are described in, or the results of which are referred to in, SEC Reports were and, if still pending, are being conducted
in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard
medical and scientific research procedures; (ii) each description of the results of such studies is accurate and complete in all
material respects and fairly presents the data derived from such studies, and the Company and its Subsidiaries have no knowledge of any
other studies the results of which are required to be disclosed in accordance with the Exchange Act and are inconsistent with, or otherwise
call into question, the results described or referred to in the SEC Reports; (iii) the Company and its Subsidiaries have made all
such filings and obtained all such approvals as may be required by the FDA or from any other U.S. federal, state or local government
or foreign government or Drug Regulatory Agency, or Institutional Review Board, each having jurisdiction over biopharmaceutical products
(collectively, the “Regulatory Agencies”) for the conduct of its business as described in the SEC Reports; (iv) neither
the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination
or suspension of or imposing any clinical hold on any clinical trials that are described or referred to in the SEC Reports; and (v) the
Company and its Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations
and policies of the Regulatory Agencies.
3.21 Compliance
with Health Care Laws. The Company and its Subsidiaries are in compliance in all material respects with all Health Care Laws to the
extent applicable to the Company’s current business and research use only products. For purposes of this Agreement, “Health
Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.) and the Public Health
Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state,
local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b));
(iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921
et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation
Act of 2010; (v) the European Union (“EU”) Clinical Trials Regulation (Regulation (EU) No. 536/2014); (vi) the
EU Regulation regarding community procedures for authorization and supervision of medicinal products for human and veterinary use and
establishing a European Medicines Agency (Regulation (EC) No. 726/2004); (vii) licensure, quality, safety
and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; (viii) all other local,
state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its Subsidiaries, and (ix) the
regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its Subsidiaries
has received written or, to the Company’s knowledge, oral notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging
that any product operation or activity is in material violation of any Health Care Laws nor, to the Company’s knowledge, is any
such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its
Subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected
or supplemented by a subsequent submission). Neither the Company nor any of its Subsidiaries is a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company, any of its Subsidiaries nor any of their respective employees, officers, directors, or, to the knowledge
of the Company, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action
that could reasonably be expected to result in debarment, suspension, or exclusion.
3.22 Accounting
Controls and Disclosure Controls and Procedures. The Company maintains a system of internal control over financial reporting (as
defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including
policies and procedures sufficient to provide reasonable assurance (i) that the Company maintains records that in reasonable detail
accurately and fairly reflect the Company’s transactions and dispositions of assets, (ii) that transactions are recorded as
necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only
in accordance with authorizations of management and the Board of Directors and (iv) regarding prevention or timely detection of
the unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Company’s
financial statements. Since the end of the Company’s most recent audited fiscal year, there has been (a) no material weaknesses
in the design or operation of the Company’s internal control over financial reporting (whether or not remediated) and (b) no
change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting. The Company’s “disclosure controls and procedures”
(as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to provide reasonable assurance that all
information (both financial and non-financial) required to be disclosed by the Company in the reports that it files or submits under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the
SEC, and that all such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions
regarding required disclosure.
3.23 Price
Stabilization of Common Stock. The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize
or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares.
3.24 Investment
Company Act. The Company is not, and immediately after receipt of payment for the Securities will not be, an “investment company”
within the meaning of the U.S. Investment Company Act of 1940, as amended.
3.25 General
Solicitation; No Integration or Aggregation. Neither the Company nor any other person or entity authorized by the Company to act
on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act)
of investors with respect to offers or sales of the Securities pursuant to this Agreement. The Company has not, directly or indirectly,
sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act)
which, to its knowledge, is or will be (i) integrated with the Securities sold pursuant to this Agreement for purposes of the Securities
Act or (ii) aggregated with prior offerings by the Company for the purposes of the rules and regulations of Nasdaq. Assuming
the accuracy of the representations and warranties of the Investors set forth in Section 4, neither the Company nor any of its Affiliates,
its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security
or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) of
the Securities Act for the exemption from registration for the transactions contemplated hereby.
3.26 Brokers
and Finders. Other than the Placement Agents, neither the Company nor any other Person authorized by the Company to act on its behalf
has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement.
3.27 Reliance
by the Investors. The Company has a reasonable basis for making each of the representations set forth in this Section 3.
The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company’s compliance with,
the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.
3.28 No
Additional Agreements. There are no agreements or understandings between the Company, on one hand, and any Investor, on the other
hand, with respect to the transactions contemplated by the Transaction Agreements other than as specified in the Transaction Agreements.
3.29 Anti-Bribery
and Anti-Money Laundering Laws; Sanctions. Each of the Company, its Subsidiaries and, to the knowledge of the Company, any of their
respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its
participation in the offering will not violate: (A) anti-bribery laws, including but
not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated
to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17,
1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or
regulation of similar purposes and scope, (B) anti-money laundering laws, including, but not limited to, applicable federal, state,
international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation,
Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or
procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United
States is a member and with which designation the United States representative to the group or organization continues to concur, all
as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses
issued thereunder, or (C) except as would not reasonably be expected, individually or in the aggregate, to result in a Material
Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S. Export Administration Regulations,
the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S.
Department of the Treasury Office of Foreign Asset Control.
3.30 Cybersecurity.
The Company and its Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted,
and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its Subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect
the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (“Confidential
Data”) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability
continuous operation, redundancy and security of all IT Systems. “Personal Data” means the following data used in
connection with the Company’s and its Subsidiaries’ businesses and in their possession or control: (i) a natural person’s
name, street address, telephone number, e-mail address, photograph, social security number or other tax identification number, driver’s
license number, passport number, credit card number or bank information; (ii) information that identifies or may reasonably be used
to identify an individual; (iii) any information that would qualify as “protected health information” under the Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health
Act (collectively, “HIPAA”); and (iv) any information that would qualify as “personal data,” “personal
information” (or similar term) under the Privacy Laws. To the Company’s knowledge, there have been no breaches, outages or
unauthorized uses of or accesses to the Company’s IT Systems, Confidential Data, or Personal Data that would require notification
under Privacy Laws (as defined below).
3.31 Compliance
with Data Privacy Laws. The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable
state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure,
transfer, disposal, or any other processing (collectively “Process” or “Processing”) of Personal
Data, including without limitation HIPAA, the EU General Data Protection Regulation (“GDPR”) (Regulation (EU) No. 2016/679),
all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its Subsidiaries,
and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively, the “Privacy
Laws”). To ensure material compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and
take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data
privacy and security, and the Processing of Personal Data and Confidential Data (the “Privacy Statements”). The Company
and its Subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse
Effect, at all times since inception provided accurate notice of its Privacy Statements then in effect to its customers, employees, third
party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate,
misleading, incomplete, or in material violation of any Privacy Laws.
3.32 Transactions
with Affiliates and Employees. No relationship, direct or indirect, exists between or among the Company, on the one hand, and any
director, officer, stockholder, customer or supplier of the Company, on the other hand, that is required to be described in the SEC Reports
that is not so described or will not be so described in accordance with the Exchange Act.
3.33 Additional
Representations and Warranties.
(a) As
of the date hereof and as of the Closing Date, the representations and warranties of the Company contained in Section 4 of the Merger
Agreement and in any certificate or other writing delivered by the Company pursuant thereto are true and correct as though given in accordance
with Section 8.1 of the Merger Agreement.
(b) As
of the date hereof and as of the Closing Date, to the Company’s knowledge, the representations and warranties of Crescent contained
in Section 3 of the Merger Agreement and in any certificate or other writing delivered by Crescent pursuant thereto are true and
correct as though given in accordance with Section 9.1 of the Merger Agreement.
(c) The
information supplied by or on behalf of the Company for inclusion or incorporation by reference in the Proxy Statement (as defined in
the Merger Agreement) will not, as of the date the proxy statement is first mailed to stockholders of the Company, at the time of the
related meeting of the stockholders of Parent or at the Closing Date, contain any statement that, at such time and in light of the circumstances
under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary
in order to make the statements made in the Proxy Statement not false or misleading; or omit to state any material fact necessary to
correct any statement in any earlier communication with respect to the solicitation of proxies for such stockholder meeting that has
become false or misleading.
4. Representations
and Warranties of Each Investor. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants
to the Company and the Placement Agents that the statements contained in this Section 4 are true and correct as of the
date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made
as of such date):
4.1 Organization.
Such Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has
the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.
4.2 Authorization.
Such Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements
to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership
action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and
performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions
contemplated herein has been taken. The signature of the Investor on this Agreement is genuine and the signatory to this Agreement, if
the Investor is an individual, has the legal competence and capacity to execute the same or, if the Investor is not an individual, the
signatory has been duly authorized to execute the same on behalf of the Investor. Assuming this Agreement constitutes the legal and binding
agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such
Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by
general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).
4.3 No
Conflicts. The execution, delivery and performance of the Transaction Agreements by such Investor, the purchase of the Securities
in accordance with their terms and the consummation by such Investor of the other transactions contemplated hereby will not conflict
with or result in any violation of, breach or default by such Investor (with or without notice or lapse of time, or both) under, conflict
with, or give rise to a right of termination, cancellation or acceleration of any obligation,
a change of control right or to a loss of a material benefit under (i) any provision of the organizational documents of such Investor,
including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement,
as may be applicable or (ii) any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling,
statute, law, ordinance, rule or regulations, applicable to such Investor or its respective properties or assets, except, in the
case of clause (ii), as would not, individually or in the aggregate, be reasonably expected to materially delay or materially hinder
the ability of such Investor to perform its obligations under the Transaction Agreements.
4.4 Residency.
Such Investor’s residence (if an individual) or offices in which its investment decision with respect to the Securities was made
(if an entity) are located at the address immediately below such Investor’s name on Exhibit A, except as otherwise
communicated by such Investor to the Company.
4.5 Brokers
and Finders. Such Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions
contemplated by this Agreement whose fees the Company would be required to pay.
4.6 Investment
Representations and Warranties. Each Investor hereby represents and warrants that, it (i) as of the date hereof is, if an entity,
a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an “accredited investor”
as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii) if an individual,
is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the Securities Act and has
such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment
in the Securities. Each Investor further represents and warrants that (x) it is capable of evaluating the merits and risk of such
investment, and (y) that it has not been organized for the purpose of acquiring the Securities and is an “institutional account”
as defined by FINRA Rule 4512(c). Such Investor understands and agrees that the offering and sale of the Securities has not been
registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions
for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent
and the accuracy of such Investor’s representations as expressed herein.
4.7 Intent.
Each Investor is purchasing the Securities solely for investment purposes, for such Investor’s own account and not for the account
of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor
has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities
Act without prejudice, however, to the Investor’s right at all times to sell or otherwise dispose of all or any part of such Securities
in compliance with applicable federal and state securities laws. Notwithstanding the foregoing, if such Investor is purchasing the Securities
as a fiduciary or agent for one or more investor accounts, such Investor has full investment discretion with respect to each such account,
and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each
such account. Each Investor has no present arrangement to sell the Securities to or through any person or entity. Each Investor understands
that the Securities must be held indefinitely unless such Securities are resold pursuant to a registration statement under the Securities
Act or an exemption from registration is available. Nothing contained herein shall be deemed a representation or warranty by such Investor
to hold the Securities for any period of time.
4.8 Investment
Experience; Ability to Protect Its Own Interests and Bear Economic Risks. Each Investor acknowledges that it can bear the economic
risk and complete loss of its investment in the Securities and has knowledge and experience
in finance, securities, taxation, investments and other business matters as to be capable of evaluating the merits and risks of investments
of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such
accounting, legal, business and tax advice as such Investor has considered necessary to make an informed investment decision.
Each Investor
acknowledges that such Investor (i) is a sophisticated investor, experienced in investing in private placements of equity securities
and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies
involving a security or securities and (ii) has exercised independent judgment in evaluating its participation in the purchase of
the Securities. Each Investor acknowledges that such Investor is aware that there are substantial risks incident to the purchase and
ownership of the Securities, including those set forth in the Company’s filings with the SEC. Alone, or together with any professional
advisor(s), such Investor has adequately analyzed and fully considered the risks of an investment in the Securities and determined that
the Securities are a suitable investment for the Investor. Each Investor is, at this time and in the foreseeable future, able to afford
the loss of such Investor’s entire investment in the Securities and such Investor acknowledges specifically that a possibility
of total loss exists.
4.9 Independent
Investment Decision. Such Investor understands that nothing in the Transaction Agreements or any other materials presented by or
on behalf of the Company to such Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice.
Such Investor has consulted such legal, tax and investment advisors as it, in their sole discretion, has deemed necessary or appropriate
in connection with its purchase of the Securities.
4.10 Securities
Not Registered; Legends. Such Investor acknowledges and agrees that the Securities are being offered in a transaction not involving
any public offering within the meaning of the Securities Act, and such Investor understands that the Securities have not been registered
under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the
Securities Act, and that the Securities must continue to be held and may not be offered, resold,
transferred, pledged or otherwise disposed of by such Investor unless a subsequent disposition thereof is registered under the Securities
Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any state of the United
States. Such Investor understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known
to it) promulgated under the Securities Act depend on the satisfaction of various conditions including, but not limited to, the time
and manner of sale, the holding period and on requirements relating to the Company which are outside of such Investor’s control
and which the Company may not be able to satisfy, and that, if applicable, Rule 144 may afford the basis for sales only in limited
amounts. Such Investor acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer,
pledge or disposition of any of the Securities. Such Investor acknowledges that no federal or state agency has passed upon or endorsed
the merits of the offering of the Securities or made any findings or determination as to the fairness of this investment.
Each Investor understands
that any certificates or book entry notations evidencing the Securities may bear one or more legends in substantially the following form
and substance:
“THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS
(I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT
TO RULE 144 UNDER THE SECURITIES ACT, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH
TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES ARE TRANSFERRED WITHOUT
CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR
THE DELIVERY OF AN OPINION). NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”
In
addition, the Securities may contain a legend regarding affiliate status of the Investor, if applicable, provided that the Company will
notify the Investor in advance of Closing if such a legend is to be placed on its Securities.
4.11 Placement
Agents. Each Investor hereby acknowledges and agrees that (a) each Placement Agent is acting solely as placement agent in connection
with the execution, delivery and performance of the Transaction Agreements and the issuance of the Securities to the Investor and neither
any Placement Agent nor any of their respective affiliates have acted as an underwriter or in any other capacity and is not and shall
not be construed as a fiduciary or financial advisor for such Investor, the Company or any other person or entity in connection with
the execution, delivery and performance of the Transaction Agreements and the issuance and purchase of the Securities, (b) no Placement
Agent has made and no Placement Agent makes any representation or warranty, whether express or implied, of any kind or character, and
no Placement Agent has provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction
Agreements or with respect to the Securities, nor is such information or advice necessary or desired, (c) no Placement Agent will
have any responsibility with respect to (i) any representations, warranties or agreements made by any person or entity under or
in connection with the execution, delivery and performance of the Transaction Agreements, or the execution, legality, validity or enforceability
(with respect to any person) thereof, or (ii) the business, affairs, financial condition, operations, properties or prospects of,
or any other matter concerning the Company, and (d) no Placement Agent will have any liability or obligation (including without
limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses
or disbursements incurred by such Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to such
Investor, or to any person claiming through it, in respect of the execution, delivery and performance of the Transaction Agreements,
except in each case for such party’s own gross negligence, willful misconduct or bad faith. No disclosure or offering document
has been prepared by any Placement Agent or any of their respective affiliates in connection with the offer and sale of the Securities.
Neither any of the Placement Agents nor any of their respective affiliates have made or make any representation as to the quality or
value of the Securities and the Placement Agents and their respective affiliates may have acquired non-public information with respect
to the Company which the Investor agrees need not be provided to it.
4.12 No
General Solicitation. Each Investor acknowledges and agrees that the Investor is purchasing the Securities directly from the Company.
Such Investor became aware of this offering of the Securities solely by means of direct contact from the Placement Agents or directly
from the Company as a result of a pre-existing, substantive relationship with the Company or the Placement Agents, and/or their respective
advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons,
representatives, affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons. The
Securities were offered to such Investor solely by direct contact between such Investor and the Company, the Placement Agents and/or
their respective representatives. Such Investor did not become aware of this offering of the Securities, nor were the Securities offered
to such Investor, by any other means, and none of the Company, any of the Placement Agents and/or their respective representatives acted
as investment advisor, broker or dealer to such Investor. Such Investor is not purchasing the Securities as a result of any general or
public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding
the Securities published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented
at any seminar or any other general solicitation or general advertisement, including any of the
methods described in Section 502(c) of Regulation D under the Securities Act.
4.13 Access
to Information. In making its decision to purchase the Securities, each Investor has relied solely upon independent investigation
made by such Investor, upon the SEC Reports and upon the representations, warranties and covenants set forth herein. Such Investor acknowledges
and agrees that such Investor has received such information as such Investor deems necessary in order to make an investment decision
with respect to the Securities, including, with respect to the Company. Without limiting the generality of the foregoing, each Investor
acknowledges that copies of the 2024 SEC Reports are available on EDGAR at www.sec.gov. Each Investor acknowledges and agrees that such
Investor and such Investor’s professional advisor(s), if any, have had the opportunity to ask such questions, receive such answers
and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of the
Securities as such Investor and such Investor’s professional advisor(s), if any, have deemed necessary to make an investment decision
with respect to the Securities and that such Investor has independently made its own analysis and decision to invest in the Company.
Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such
Investor’s right to rely on the Company’s representations and warranties contained in this Agreement.
4.14 Certain
Trading Activities. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting
on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short
Sales, of the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company
or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date hereof. Notwithstanding the
foregoing, (i) in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions made
by the portfolio managers managing other portions of such Investor’s assets, the representation set forth above shall only apply
with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Securities
covered by this Agreement and (ii) in the case of an Investor whose investment adviser utilized an information barrier with respect
to the information regarding the transactions contemplated hereunder after first being contacted by the Company or such other Person
representing the Company, the representation set forth above shall only apply after the point
in time when the portfolio manager who manages such Investor’s assets was informed of the information regarding the transactions
contemplated hereunder and, with respect to the Investor’s investment adviser, the representation set forth above shall only apply
with respect to any purchases or sales, including Short Sales, of the securities of the Company on behalf of other funds or investment
vehicles for which the Investor’s investment adviser is also an investment adviser or subadviser after the point in time when the
portfolio manager who manages the assets of such other funds or investment vehicles for which the Investor’s investment adviser
is also an investment adviser or sub-adviser was informed of the information regarding the transactions contemplated hereunder. Other
than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information, such Investor has
maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of
this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation
or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to
borrow in order to effect Short Sales or similar transactions in the future.
5. Covenants.
5.1 Further
Assurances. Prior to the Closing, each party agrees to cooperate with each other and their respective officers, employees, attorneys,
accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate
the intents and purposes of this Agreement, subject to the terms and conditions hereof and compliance with applicable law, including
taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto
in complying with the terms hereof. Each Investor acknowledges that the Company and the Placement Agents will rely on the acknowledgments,
understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the Investor agrees to
promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in Section 4
are no longer accurate and the Company agrees to promptly notify each Investor and the Placement Agents if any of the acknowledgments,
understandings, agreements, representations and warranties set forth in Section 3 are no longer accurate.
5.2 Listing.
The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Global Market
and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company’s reporting,
filing and other obligations under the rules and regulations of Nasdaq, and to obtain approval of the listing of the Shares.
5.3 Disclosure
of Transactions.
(a) The
Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the date hereof (provided
that, if this Agreement is executed between midnight and 9:00 a.m., New York City time on
any Business Day, no later than 9:01 a.m. on the date hereof), issue a press release and/or file with the SEC a Current Report on
Form 8-K (including all exhibits thereto, the “Disclosure Document” and the actual filing of such press release
and/or Current Report on Form 8-K, the “Disclosure Time”) disclosing (i) all material terms of the transactions
contemplated hereby and by the other Transaction Agreements and attaching this Agreement and the other Transaction Agreements as exhibits
to such Disclosure Document, and (ii) all material non-public information concerning the Company, the transactions contemplated
hereby or the transactions contemplated by the Merger Agreement disclosed to the Investors prior to the Disclosure Time. Following the
Disclosure Time, no Investor shall be in possession of any material non-public information received from the Company, its subsidiaries
or any of their respective officers, directors, employees or agents (including the Placement Agents). The Company understands and confirms
that the Investors will rely on the foregoing representation in effecting securities transactions. Notwithstanding anything in this Agreement
to the contrary, the Company shall not disclose the name of any Investor or any of its affiliates or advisers, or include the name of
any Investor or any of its affiliates or advisers in any marketing materials (whether or not made publicly available), press release,
public announcement or filing with the SEC (other than any registration statement contemplated by the Registration Rights Agreement,
which shall be subject to review of the Investors in accordance with the terms of the Registration Rights Agreement) or any regulatory
agency, without the prior written consent of such Investor, except (i) as required by the federal securities law in connection with
(A) any registration statement contemplated by the Registration Rights Agreement and (B) the filing of final Transaction Agreements
with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii) to the extent such disclosure is required
by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Global Market, provided that
the Company shall use commercially reasonable efforts to provide the Investors with prior written notice of and a reasonable opportunity
to review such disclosure permitted under foregoing clauses (i) and (ii).
5.4 Integration.
The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer
for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act)
that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities
Act of the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes
of the rules and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such
other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.
5.5 Removal
of Legends.
(a) In
connection with any sale, assignment, transfer or other disposition of Shares by an Investor pursuant to Rule 144 or pursuant to
any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor
with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company shall instruct the Transfer
Agent to remove any restrictive legends related to the book entry account holding such Shares
and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends as soon as reasonably practicable
(expected to be within three (3) Business Days) following any such request therefor from such Investor, provided that the Company
has timely received from the Investor a completed Investor representation letter in substantially the form attached hereto as Exhibit D
and such other customary representations as may be reasonably required in accordance with applicable law in connection therewith.
The Company shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal.
(b) In
addition, without limiting Section 5.5(a), and subject to receipt from the Investor by the Company and the Transfer Agent of customary
representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the
earliest of such time as the Initial Shares or any other Shares (i) have been registered under the Securities Act pursuant to an
effective registration statement, (ii) have been sold pursuant to Rule 144 (in which case the provisions of Section 5.5(a) shall
apply), or (iii) are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance
with the current public information requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance
with the provisions of this Section 5.5(b) (A) upon effectiveness of the registration statement registering
the resale of such Initial Shares or Other Shares as set forth in clause (i), provide a “blanket” opinion to the Transfer
Agent for the removal of legends in connection with any sale pursuant to the effective registration statement, and (B) with respect
to clauses (i), (ii) and (iii), as soon as reasonably practicable and no later than three (3) Business Days following any request
therefor from an Investor accompanied by a completed Investor representation letter in substantially the form attached hereto as Exhibit E
deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry
shares. If, as a condition to the removal of any legends of any of the Securities, the Transfer Agent requires that the request for removal
be accompanied by a certificate and/or an opinion of counsel reasonably satisfactory to the Transfer Agent, to the effect that the proposed
transfer does not result in a violation of the Securities Act, the Company and/or its legal counsel shall provide such certificate or
opinion with respect to any such transfer. Any shares subject to legend removal under this Section 5.5 may be transmitted by the
Transfer Agent to the Investor by crediting the account of the Investor’s prime broker with the DTC System as directed by such
Investor. The Company shall be responsible for the fees of its Transfer Agent, DTC and its legal counsel associated with such legend
removal.
5.6 Withholding
Taxes. Each Investor agrees to furnish the Company with any information, representations and forms as shall reasonably be requested
by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations).
5.7 Fees
and Taxes. The Company shall be solely responsible for the payment of any placement agent’s fees, financial advisory fees,
or broker’s commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated
hereby, including, without limitation, any fees or commissions payable to the Placement Agents.
5.8 No
Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict
or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Agreements.
5.9 Reporting
Status. The Company shall timely file all reports required to be filed with the SEC pursuant to the Exchange Act, and the Company
shall not terminate its status as an issuer required to file reports under the Exchange Act
even if the Exchange Act or the rules and regulations thereunder would otherwise permit such termination.
5.10 Indemnification.
(a) The
Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members,
managers, employees, investment advisers and agents (collectively, the “Indemnified Persons”), from and against any
and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements
and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action,
claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Indemnified Person may become subject
(i) as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company
under the Transaction Agreements or (ii) as a result of or arising out of any action, claim or proceeding, pending or threatened,
against an Indemnified Person in any capacity by any stockholder of the Company (whether directly or in a derivative capacity) who is
not an Affiliate of the Indemnified Person with respect to the transactions contemplated by the Transaction Agreements, and in each case
will reimburse any such Indemnified Person for all such amounts as they are incurred by such Indemnified Person.
(b) Any
person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ
separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of
such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party
shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable
judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying
party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to
employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense
of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided
herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall
materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying
party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate
firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified
party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement
unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof
the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the
indemnified party in respect of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability,
wrongdoing, or wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent
of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment
or enter into any settlement.
5.11 Stockholder
Approval. The Company shall use its best efforts to obtain the Required Parent Stockholder Vote to approve the issuance of the Shares
for purposes of the listing rules of Nasdaq at the Parent Stockholder Meeting (as defined in the Merger Agreement), which shall
be held as promptly as practicable after the filing of the Proxy Statements (as defined in the Merger Agreement) in accordance with the
terms and conditions of the Merger Agreement and, in any event, no later than 60 days after the date thereof. The Company shall use its
best efforts to solicit its stockholders’ approval of such resolution and to cause the Board of Directors to recommend to the stockholders
that they approve such resolution.
5.12 Reservation
of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Pre-Funded Warrant Shares that are issuable upon the exercise of the Pre-Funded Warrants, if any.
5.13 No
Amendment or Waiver of Merger Agreement Terms. The Company shall not amend, modify or waive (or approve an amendment, modification
or a waiver requested by Crescent of, or fail to contest an action regarding a breach of) any provision of the Merger Agreement in a
manner that would reasonably be expected to materially and adversely affect the benefits that an Investor would reasonably expect to
receive pursuant to this Agreement without the prior written consent of the Investor Majority, it being agreed that any amendment or
modification to the definition of “Parent Valuation” or “Parent Outstanding Stock” shall be deemed to materially
and adversely affect the benefits that the Investors would reasonably expect to receive under this Agreement.
6. Conditions
of Closing.
6.1 Conditions
to the Obligation of the Investors. The several obligations of each Investor to consummate the transactions to be consummated at
the Closing, and to purchase and pay for the Securities being purchased by it at the Closing
pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent:
(a) Representations
and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all respects as of
the date hereof except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation
or warranty shall be true and correct in all respects as of such earlier date, and the representations and warranties of the Company
contained herein shall be true and correct in all material respects as of the Closing Date, as though made on and as of such date, except
for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all
respects and except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation
or warranty shall be true and correct in all material respects as of such earlier date.
(b) Performance.
The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed
by the Company on or prior to the Closing Date.
(c) No
Injunction. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental
or court order or regulation and no such prohibition shall have been threatened in writing.
(d) Consents.
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of
the purchase and sale of the Securities, including the Required Parent Stockholder Vote, all of which shall be in full force and effect.
(e) Transfer
Agent. The Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Initial Shares
at the Closing.
(f) Adverse
Changes. Since the date hereof, no event or series of events shall have occurred that has had or would reasonably be expected to
have a Material Adverse Effect or a Company Material Adverse Effect (as defined in the Merger Agreement).
(g) Opinion
of Company Counsel. The Company shall have delivered to the Investors and the Placement Agents the opinion of Sidley Austin LLP,
dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Placement Agents and addressing such
legal matters as the Placement Agents and the Company reasonably agree.
(h) Compliance
Certificate. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a certificate, in form
and substance reasonably acceptable to the Investor Majority, certifying that the conditions specified in Sections 6.1(a) (Representations
and Warranties), 6.1(b) (Performance), 6.1(c) (No Injunction), 6.1(d) (Consents),
6.1(f) (Adverse Changes), 6.1(k) (No Stop Order) 6.1(l) (Nasdaq),
6.1(m) (Minimum Financing Amount), and 6.1(n) (Merger) of this Agreement
have been fulfilled.
(i) Secretary’s
Certificate. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate certifying (i) the
Amended and Restated Certificate of Incorporation, (ii) the Amended and Restated Bylaws, and (iii) resolutions of the Company’s
Board of Directors (or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions
contemplated by this Agreement and the issuance of the Securities and the Pre-Funded Warrant Shares.
(j) Registration
Rights Agreement. The Company shall have executed and delivered the Registration Rights Agreement in the form attached hereto as
Exhibit C (the “Registration Rights Agreement”) to the Investors.
(k) No
Stop Orders. No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock. The Common Stock shall be listed on the National Exchange and shall not have
been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the
National Exchange have been threatened, as of the Closing Date, in writing by the SEC or the National Exchange.
(l) Nasdaq.
The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and Nasdaq shall
have raised no objection to such notice and the transactions contemplated hereby.
(m) Minimum
Financing Amount. The Company shall receive at Closing aggregate proceeds from the purchase of Securities pursuant to this Agreement
of not less than (i) $100,000,000 (including in such proceeds any Convertible Securities Contributed as consideration in accordance
with this Agreement) minus (ii) the amount of proceeds actually received by Crescent in connection with any Interim Financing (as
defined in the Merger Agreement) prior to the Closing (excluding in such proceeds any Convertible Securities Contributed as consideration
in accordance with this Agreement).
(n) Merger.
The Merger shall have been consummated as of the Second Effective Time. The Merger Agreement shall not have been amended or modified,
and the Company shall not have waived any provision thereunder, in each case in a manner that would reasonably be expected to materially
and adversely affect the benefits that an Investor would reasonably expect to receive under this Agreement without having received the
prior written consent of the Investor Majority.
(o) Parent
Stockholder Approval. The Company shall have obtained Required Parent Stockholder Vote, including approval of the issuance of the
Shares pursuant to this Agreement.
6.2 Conditions
to the Obligation of the Company. The obligation of the Company to consummate the transactions to be consummated at the Closing,
and to issue and sell to each Investor the Securities to be purchased by it at the Closing pursuant to this Agreement, is subject to
the satisfaction or waiver in writing of the following conditions precedent:
(a) Representations
and Warranties. The representations and warranties of each Investor in Section 4 hereto shall be true and
correct in all respects as of the date hereof and as of the Closing Date, with the same force and effect as though made on and as of
the Closing Date, except to the extent that any such representation or warranty expressly speaks as of an earlier date, in which case
such representation and warranty shall be true and correct in all respects as of such earlier date, and consummation of the Closing shall
constitute a reaffirmation by the Investor of each of the representations, warranties, covenants and agreements of the Investor contained
in this Agreement as of the Closing Date.
(b) Performance.
Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed
or observed by such Investor on or prior to the Closing Date.
(c) Injunction.
The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court
order or regulation.
(d) Registration
Rights Agreement. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached
as Exhibit C.
(e) Payment.
Except as may be agreed to among the Company and one or more Investors in accordance with Section 2.2, the Company
shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the number
of Securities being purchased by each Investor at the Closing as set forth in Exhibit A.
7. Termination.
7.1 Termination.
The obligations of the Company, on the one hand, and each Investor, on the other hand, to effect the Closing shall terminate as follows:
(i) Upon
the mutual written consent of the Company and the Investor Majority prior to the Closing;
(ii) By
the Company, if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment and
shall not have been waived by the Company;
(iii) By
an Investor, solely as to itself, if any of the conditions set forth in Section 6.1 shall have become incapable
of fulfillment and shall not have been waived by such Investor; or
(iv) By
either the Company or an Investor, solely as to itself, if the Closing has not occurred on or before September 30, 2025;
provided,
however, that, except in the case of clauses (ii) through (iv) above, the party seeking to terminate its obligation
to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the
Transaction Agreements if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation
to effect the Closing.
7.2 Notice.
In the event of termination pursuant to Section 7.1, written notice thereof shall be given to each other Investor. Nothing
in this Section 7 shall be deemed to release any party from any liability for any breach by such party of the other
terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party
of its other obligations under the Transaction Agreements.
8. Miscellaneous
Provisions.
8.1 Public
Statements or Releases. Except as set forth in Section 5.3, neither the Company nor any Investor shall make any
public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior
consent of the other party (which consent shall not be unreasonably withheld) other than filings pursuant to Section 13 and/or Section 16
of the Exchange Act, which, for avoidance of doubt, shall not require the Company’s consent; provided that, the Company
shall not publicly disclose the name of any Investor or any affiliate or investment adviser of any Investor without such Investor’s
prior written consent (email being sufficient).
8.2 Interpretation.
The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement
will refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and subsection references
are to this Agreement unless otherwise specified. The headings in this Agreement are included for convenience of reference only and will
not limit or otherwise affect the meaning or interpretation of this Agreement. Whenever the words “include,” “includes”
or “including” are used in this Agreement, they will be deemed to be followed by the words “without limitation.”
The phrases “the date of this Agreement,” “the date hereof” and terms of similar import, unless the context otherwise
requires, will be deemed to refer to the date set forth in the first paragraph of this Agreement. The meanings given to terms defined
herein will be equally applicable to both the singular and plural forms of such terms. All matters to be agreed to by any party hereto
must be agreed to in writing by such party unless otherwise indicated herein. References to agreements, policies, standards, guidelines
or instruments, or to statutes or regulations, are to such agreements, policies, standards, guidelines or instruments, or statutes or
regulations, as amended or supplemented from time to time (or to successors thereto).
8.3 Notices.
Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when
delivered if personally delivered to the party for whom it is intended, (b) when delivered,
if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next Business Day, provided no rejection or undeliverable notice is received, (c) three (3) days after having been sent by
certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1) Business Day after deposit with
a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:
(a) If
to the Company, addressed as follows:
GlycoMimetics Inc.
9708 Medical Center Drive
Rockville, Maryland 20850
Attention: Christian Dinneen-Long
Email: cdinneen-long@glycomimetics.com
with a copy to (which shall not constitute
notice), prior to the Closing:
Sidley Austin, LLP
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Attention: Asher Rubin
Email: arubin@sidley.com
with a copy to (which shall not constitute notice),
following the Closing:
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
Attention: Ryan Murr, Branden Berns, Chris Trester
Email: rmurr@gibsondunn.com, bberns@gibsondunn.com,
ctrester@gibsondunn.com
(b) If
to any Investor, at its address set forth on Exhibit A or to such e-mail address or address as subsequently modified by written
notice given in accordance with this Section 8.3.
Any
Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.
8.4 Severability.
If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding
upon the parties hereto.
8.5 Governing
Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury.
(a) This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to choice of laws
or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction.
(b) The
Company and each of the Investors hereby irrevocably and unconditionally:
(i) submits
for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby,
to the general jurisdiction of the any state court or United States Federal court sitting in the City of Wilmington in the State of Delaware;
(ii) consents
that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue
of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees
not to plead or claim the same to the extent permitted by applicable law;
(iii) agrees
that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or
any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in Section 8.3
or at such other address of which the other party shall have been notified pursuant thereto;
(iv) agrees
that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right
to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing
clause (i) are not available despite the intentions of the parties hereto;
(v) agrees
that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction
to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner
specified herein or as otherwise permitted by law;
(vi) agrees
that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal
process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under
this Agreement, to the extent permitted by law; and
(vii) irrevocably
and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.
8.6 Waiver.
No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall
be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other
term, provision or condition of this Agreement.
8.7 Expenses.
Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses,
including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed
investment in the Securities and the consummation of the transactions contemplated thereby; provided, however, that the Company shall
pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered
by the Company), Transfer Taxes, stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery
of any Securities to the Investors.
8.8 Assignment.
None of the parties may assign its rights or obligations under this Agreement or designate another person (i) to perform all or
part of its obligations under this Agreement or (ii) to have all or part of its rights and benefits under this Agreement, in each
case without the prior written consent of (x) the Company, in the case of an Investor,
and (y) the Investors, in the case of the Company, provided that an Investor may, without the prior consent of the Company,
assign its rights to purchase the Securities hereunder to any of its affiliates or to any other investment funds or accounts managed
or advised by the investment manager who acts on behalf of such Investor (provided each such assignee agrees to be bound by the
terms of this Agreement and makes the same representations and warranties set forth in Section 4 hereof). In the event
of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions
of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an
executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an
assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this
Agreement unless expressly consented to by the Company.
8.9 Confidential
Information.
(a) Each
Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided
to such Investor are publicly disclosed by the Company in accordance with Section 5.3, such Investor will maintain
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction),
other than to such Investor’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit
evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks
and services and other than as may be required by law.
(b) The
Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate
the eligibility of the Investor to acquire the Securities, and the Investor shall promptly provide such information as may reasonably
be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor
confidential, except (i) as required by the federal securities laws, rules or regulations and (ii) to the extent such
disclosure is required by other laws, rules or regulations, at the request of the staff of the SEC or regulatory agency or under
the regulations of Nasdaq, in which case of clause (ii) or (iii), the Company will use commercially reasonable efforts to notify
the Investor and provide the Investor the opportunity to review such disclosure. The Investor acknowledges that the Company may file
a form of this Agreement and the Registration Rights Agreement with the SEC as exhibits to a periodic report or a registration statement
of the Company.
8.10 Reliance
by and Exculpation of Placement Agents.
(a) Each
Investor agrees for the express benefit of the Placement Agents and their respective affiliates and representatives that (i) the
Placement Agents and their respective affiliates and representatives have not made, and will not make any representations or warranties
with respect to the Company or the offer and sale of the Securities, and such Investor will not rely on any statements made by any Placement
Agent, orally or in writing, to the contrary, (ii) such Investor will be responsible for conducting its own due diligence investigation
with respect to the Company and the offer and sale of the Securities, (iii) such Investor will be purchasing Securities
based on the results of its own due diligence investigation of the Company and the Placement Agents and each of their respective directors,
officers, employees, representatives, and controlling persons have made no independent investigation with respect to the Company, the
Securities, or the accuracy, completeness, or adequacy of any information supplied to the Investor by the Company, and (iv) such
Investor has negotiated the offer and sale of the Securities directly with the Company, and the Placement Agents will not be responsible
for the ultimate success of any such investment. Each Investor further represents and warrants to the Placement Agents that it, including
any fund or funds that it manages or advises that participates in the offer and sale of the Securities, is permitted under its constitutive
documents (including, without limitation, all limited partnership agreements, charters, bylaws, limited liability company agreements,
all applicable side letters with investors, and similar documents) to make investments of the type contemplated by this Agreement. This
Section 8.10 shall survive any termination of this Agreement.
(b) The
Company agrees and acknowledges that the Placement Agents may rely on its representations, warranties, agreements and covenants contained
in this Agreement and each Investor agrees that the Placement Agents may rely on such Investor’s representations and warranties
contained in this Agreement as if such representations and warranties, as applicable, were made directly to the Placement Agents.
(c) Neither
the Placement Agents nor any of their respective affiliates or representatives (1) shall be liable for any improper payment made
in accordance with the information provided by the Company; (2) makes any representation or warranty, or has any responsibilities
as to the validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the
Company pursuant to the Transaction Agreements or in connection with any of the transactions contemplated therein; or (3) shall
be liable (x) for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or
within the discretion or rights or powers conferred upon them by the Transaction Agreements or (y) for anything which any of them
may do or refrain from doing in connection with the Transaction Agreements, except in each case for such party’s own gross negligence,
willful misconduct or bad faith.
(d) The
Company agrees that the Placement Agents and their respective affiliates and representatives shall be entitled to (1) rely on, and
shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of
them by or on behalf of the Company, and (2) be indemnified by the Company for acting as the Placement Agents hereunder pursuant
to the indemnification provisions set forth in the applicable letter agreement between the Company and the Placement Agents.
8.11 Third
Parties. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement
any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a
party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial
owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement)
shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby, except as
expressly set forth in this Agreement. Notwithstanding the foregoing, each Placement Agent is an intended third-party beneficiary of
the representations and warranties of the Company set forth in Section 3, the representations and warranties of each
Investor set forth in Section 4, Section 6.1(g) and Section 8.10 of this Agreement.
8.12 Independent
Nature of Investors’ Obligations and Right. The obligations of each Investor under this Agreement are several and not joint
with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any other
Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute
the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group (including a “group”
within the meaning of Section 13(d)(3) of the 1934 Act), and the Company will not assert any such claim with respect to such
obligations or the transactions contemplated by this Agreement and the Company acknowledges that the Investors are not acting in concert
or as a group with respect to such obligations or the transactions contemplated by this Agreement. It is expressly understood that each
provision contained in this Agreement is between the Company and an Investor, solely, and not between the Company and the Investors collectively
and not between and among the Investors. The Company acknowledges and each Investor confirms that it has independently participated in
the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Investor also acknowledges
that Sidley Austin LLP has not rendered legal advice to such Investor. Each Investor shall
be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement,
and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company
has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the Company and not because
it was required or requested to do so by any Investor.
8.13 Headings.
The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.
8.14 Counterparts.
This Agreement may be executed in two (2) or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall
be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an
original, not a facsimile or pdf (or other electronic reproduction of a) signature.
8.15 Entire
Agreement; Amendments. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto)
constitute the entire agreement between the parties hereto respecting the subject matter hereof and thereof and supersede all prior agreements,
negotiations, understandings, representations and statements respecting the subject matter hereof and thereof, whether written or oral.
No amendment, modification, alteration, waiver or change in any of the terms of this Agreement shall be valid or binding upon the parties
hereto unless made in writing and duly executed by the Company and the Investor Majority. Notwithstanding the foregoing, (i) this
Agreement may not be amended with respect to any Investor without the written consent of such Investor unless such amendment applies
to all Investors in the same fashion and (ii) any amendment to Section 5.5, Section 5.10, Section 6.1,
Section 7.1 or this Section 8.15 shall require the consent of each Investor. The Company, on the one hand, and each
Investor, on the other hand, may by an instrument signed in writing by such parties waive the performance, compliance or satisfaction
by such Investor or the Company, respectively, with any term or provision hereof or any condition hereto to be performed, complied with
or satisfied by such Investor or the Company, respectively. Notwithstanding the foregoing or anything else to the contrary, no amendment,
modification, alteration, change or waiver of this Section 8.15 that is material and adverse to the Placement Agents
shall be valid without the prior written consent of the Placement Agents, which consent may be granted or withheld in the sole discretion
of the Placement Agents. For the avoidance of doubt, an amendment to this Agreement after the date hereof allowing for the sale of additional
Securities (“Additional Securities”) to one or more Persons (whether or not an existing Investor) shall only require
the approval of the Company and the Investor Majority; provided that the price paid for such Additional Securities is at least
15% greater than the Share Price and Pre-Funded Warrant Price, as applicable.
8.16 Survival.
The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the
delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.
8.17 Mutual
Drafting. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the
mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.
8.18 Arm’s
Length Negotiations. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of the Securities
were determined as a result of arm’s-length negotiations.
8.19 Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents as the other
party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.
[Remainder of Page Intentionally Left
Blank.]
valid
IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the day and year first above written.
| | COMPANY: |
| | |
| | GlycoMimetics, Inc. |
| | |
| | By: |
|
| | |
Name: |
| | |
Title: |
IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the day and year first above written.
Beneficial Ownership Limitation:
[·]
EXHIBIT A
INVESTORS
| Investor
Name and Address |
|
Commitment
Amount |
|
|
Initial
Shares |
|
|
|
Share
Price |
|
|
Shares
Underlying Pre-Funded Warrants |
|
|
Pre-Funded
Warrant Price |
|
|
Convertible
Securities Amount |
|
|
Aggregate
Purchase Price |
|
| [Name] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Address] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Address] |
|
[·] |
|
|
[●] |
|
|
$ |
[●] |
|
|
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
| [Email] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Name] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Address] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Address] |
|
[·] |
|
|
[●] |
|
|
$ |
[●] |
|
|
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
| [Email] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Name] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Address] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| [Address] |
|
[·] |
|
|
[●] |
|
|
$ |
[●] |
|
|
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
| [Email] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TOTAL: |
|
[·] |
|
|
[●] |
|
|
$ |
[●] |
|
|
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
$ |
[●] |
|
EXHIBIT B
FORM OF PRE-FUNDED WARRANT
EXHIBIT C
FORM OF REGISTRATION RIGHTS AGREEMENT
EXHIBIT D
Investor
Representation Letter
___________, 20 _
GlycoMimetics Inc.
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
To Whom It May Concern:
The undersigned (the “Holder”)
hereby requests that the federal securities law restrictive legend be removed from the book entries representing _________ of shares
(the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of GlycoMimetics
Inc. (the “Company”). In connection with the legend removal, Holder hereby represents to, and agrees with, you as
follows:
| 1. | The Shares are owned of record and beneficially by Holder. |
| 2. | Holder agrees that, if the Shares are not eligible to be sold pursuant
to Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities
Act”), any offer, sale or transfer of, or other transaction involving, the Shares
will only be made (i) pursuant to the Company’s Registration Statement (the “Registration
Statement”) filed pursuant to the Securities Act, in a transaction contemplated
in the “Plan of Distribution” section of the prospectus included in the
Registration Statement and in accordance with the terms and conditions set forth in the Registration
Rights Agreement, dated [__], 2025, by and among GlycoMimetics Inc. and the investors named
therein (the “RRA”), including, but not limited to, the restrictions upon
sales that may be imposed as set forth in the RRA or (ii) to an exemption from the registration
requirements of the Securities Act other than Rule 144 subject to receipt of a legal
opinion from Gibson, Dunn & Crutcher LLP or other counsel acceptable to the Company
that such offer, sale or transfer is exempt from the registration requirements of the Securities
Act; |
| 3. | Holder agrees that it will (i) not offer and sell, or cause or
permit to be offered or sold, any Shares in violation of federal and state securities laws,
including, without limitation, prospectus delivery requirements of the Securities Act (unless
exempt therefrom) and (ii) promptly stop selling or transferring Shares pursuant to
the Registration Statement upon receipt of written notice pursuant to the RRA from the Company
that the Registration Statement may not be used to effect offers, sales or other transfers
of the Shares; and |
| 4. | Holder (or, in the case of individuals, Holder’s employer) has
in place internal policies and procedures reasonably designed to monitor and ensure that
no offer, sale or transfer of, or other transaction involving, the Shares is made in violation
of the foregoing restrictions, and Holder will monitor all transactions involving the Shares
for the purpose of ensuring that they comply with all federal and state securities laws. |
| 5. | Holder is familiar with the requirements for effecting resales or transfers
of, or other transactions involving, the Shares in compliance with federal and state securities
laws and acknowledges and agrees that the Company and Gibson, Dunn & Crutcher LLP
are relying on Holder’s representations and agreements in this letter. |
| | Very truly yours, |
| | |
| | [HOLDER] |
| | |
| | By: |
|
| | Name: |
| | Title: |
Exhibit 10.4
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS
AGREEMENT (this “Agreement”), dated as of [•], 2025, is entered into by and among GlycoMimetics, Inc.,
a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor”
and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein
and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the Company
and the Investors party thereto, dated as of October 28, 2024 (as amended, restated, supplemented or otherwise modified from time
to time, the “Purchase Agreement”).
WHEREAS:
A. Upon
the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to certain Investors, and such Investors
have agreed to purchase, severally and not jointly, an aggregate of up to $[•] of (x) shares (the “Initial Shares”)
of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and/or (y) pre-funded warrants
(the “Pre-Funded Warrants”) to purchase shares of Common Stock, in each case, pursuant to the Purchase Agreement.
The Initial Shares and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants are collectively referred to herein
as the “Shares.”
B. To
induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S.
Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the
“Securities Act”), and applicable state securities laws.
NOW, THEREFORE, in
consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Investors hereby agree as follows:
For purposes of this Agreement,
the following terms shall have the following meanings:
(a) “Filing
Deadline” means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the
Closing Date and, with respect to any New Registration Statements or other Registration Statement filed hereunder, the 30th calendar
day following the later of (i) date on which the Company is permitted by SEC Guidance to file such New Registration Statement related
to the Registrable Securities and (ii) the date on which the Company becomes aware of the necessity of filing such New Registration
Statement related to the Registrable Securities.
(b) “Person”
means any individual or entity including but not limited to any corporation, limited liability company, association, partnership, organization,
business, individual, governmental or political subdivision thereof or a governmental agency.
(c) “Register,”
“Registered,” and “Registration” refer to a registration effected by preparing and filing one or
more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous
basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission
(the “SEC”).
(d) “Registrable
Securities” means (i) the Shares, (ii) any Shares of Common Stock issued to an Investor on or around the date hereof
pursuant to that certain Agreement and Plan of Merger and Reorganization, dated on or around the date hereof, by and among the Company,
Crescent Biopharma, Inc., Gemini Merger Sub Corp. and Gemini Merger Sub II, LLC, and (iii) any Common Stock issued or issuable
with respect to the foregoing as a result of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event.
Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness
of any, or file another, Registration Statement hereunder with respect thereto) upon the earliest to occur of (A) the date on which
such Investor shall have resold such Registrable Securities covered by the Registration Statement, (B) such Registrable Securities
have been previously sold by such Investor in accordance with Rule 144, (C) such securities become eligible for resale by such
Investor without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in
compliance with the current public information requirement under Rule 144 and (D) five (5) years after the date of this
Agreement.
(e) “Registration
Expenses” means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to
this Agreement, including (i) all registration, qualification, and filing fees, printing expenses, and any other fees and expenses
associated with filings required to be made with the SEC, FINRA or any other regulatory authority, (ii) all fees and expenses in
connection with compliance with or clearing the Registrable Securities for sale under any securities or “Blue Sky” laws,
(iii) all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv) all fees
and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses
of any special audit and cold comfort letters required by or incident to such performance); provided that in no event shall the Company
be responsible for any underwriting, broker or similar fees or commissions of any Investor or, except to the extent provided for in the
Purchase Agreement, any legal fees or other costs of the Investors.
(f) “Registration
Statement” means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act,
that Registers Registrable Securities, including the related preliminary or final prospectus, amendments and supplements to such registration
statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration
statement as may be necessary to comply with applicable securities laws. “Registration Statement” shall also include a New
Registration Statement, as amended when each became effective, including all documents filed as part thereof or incorporated by reference
therein, and including any information contained in a prospectus subsequently filed with the SEC.
(g) “SEC
Guidance” means (i) any publicly-available written or oral guidance of the SEC staff, or any comments, requirements or
requests of the SEC staff (whether or not publicly-available); provided, that any such oral guidance, comments, requirements or requests
are reduced to writing by the SEC (and shared with the Investors upon request if not publicly-available) and (ii) the Securities
Act.
(h) “Selling
Expenses” means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all
similar fees and commissions relating to an Investor’s disposition of its Registrable Securities.
(a) Mandatory
Registration. The Company shall, as promptly as reasonably practicable and in any event no later than the Filing Deadline, prepare
and file with the SEC an initial Registration Statement (the “Initial Registration Statement”) covering the resale
of all Registrable Securities. Before filing the Registration Statement, the Company shall furnish to the Investors a copy of the Registration
Statement. The Investors and their respective counsel shall have at least three (3) Business Days prior to the anticipated filing
date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement to such Registration
Statement and any related prospectus (including any documents incorporated by reference therein), prior to its filing with the SEC. The
Company shall (a) consider in good faith any comments as the Investor or its counsel reasonably proposed by the Investor to such
document prior to being so filed with the SEC, and (b) not file any Registration Statement or related prospectus or any amendment
or supplement thereto containing information regarding the Investor to which Investor reasonably believes contains untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading, unless such information is required (in the opinion of the Company)
to comply with any applicable law or regulation or SEC Guidance. Each Investor shall furnish all information reasonably requested by
the Company with respect to such Investor as shall be reasonably required in connection with any registration referred to in this Agreement.
(b) Effectiveness.
The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment declared effective
by the SEC at the earliest possible date but no later than the earlier of the sixtieth (60th) calendar day following the initial filing
date of the Initial Registration Statement if the SEC notifies the Company that it will “review” the Initial Registration
Statement and (b) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier)
by the SEC that the Initial Registration Statement will not be “reviewed” or will not be subject to further review (the “Effectiveness
Deadline”). The Company shall notify the Investor by e-mail as promptly as practicable, and in any event, within twenty-four
(24) hours, after the Initial Registration Statement is declared effective or is supplemented and shall provide the Investor with copies
of any related prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company
shall use commercially reasonable efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415
promulgated under the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered thereby
at all times until the earlier to occur of the following events: (i) the date on which the Investors shall have resold all the Registrable
Securities covered thereby; (ii) the date on which the Registrable Securities may be resold by the Investors without registration
and without regard to any volume or manner-of-sale limitations by reason of Rule 144, and without the requirement for the Company
to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of
similar effect and (iii) five (5) years after the date of this Agreement (the “Registration Period”). The
Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements
therein, in light of the circumstances in which they were made, not misleading.
(c) Sufficient
Number of Shares Registered. In the event the number of shares available under the Initial Registration Statement at any time is
insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration
Statement or file a new registration statement (together with any prospectuses or prospectus supplements thereunder, a “New
Registration Statement”), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event
not later than the Filing Deadline. The Company shall use its commercially reasonable efforts to have such amendment and/or New
Registration Statement become effective as soon as reasonably practicable following the filing thereof but no later than the earlier
of (a) the seventy-fifth (75th) calendar day following the initial filing date of the New Registration Statement if the SEC notifies
the Company that it will “review” the New Registration Statement and (b) the fifth (5th) Business Day after the date
the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be “reviewed”
or will not be subject to further review. The provisions of Sections 2(a) and 2(b) shall apply to the
New Registration Statement, except as modified hereby.
(d) Allowable
Delays. On no more than two (2) occasions in any twelve (12)-month period for not more than thirty (30) consecutive days or
for a total of not more than sixty (60) days, the Company may delay the effectiveness of the Initial Registration Statement or any other
Registration Statement, or suspend the use of any prospectus included in any Registration Statement, in the event that the Board of Directors
reasonably determines, in good faith and upon advice of legal counsel, that such delay or suspension is necessary to (A) delay the
disclosure of material non-public information concerning the Company, including in connection with the negotiation or consummation of
a material transaction by the Company that is pending, that would require additional disclosure by the Company in the Registration Statement
of material non-public information that the Company has a bona fide business purpose for preserving as confidential and the non-disclosure
of which would be expected, in the reasonable determination of the Board of Directors, upon advice of legal counsel, to cause the Registration
Statement to fail to comply with applicable disclosure requirements, or (B) amend or supplement the affected Registration Statement
or the related prospectus so that such Registration Statement or prospectus shall not include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus
in light of the circumstances under which they were made, not misleading (an “Allowed Delay”); provided, that
the Company shall promptly (a) notify each Investor in writing of the commencement of an Allowed Delay, but shall not (without the
prior written consent of an Investor) disclose to such Investor any material non-public information giving rise to an Allowed Delay,
(b) advise the Investors in writing to cease all sales under the applicable Registration Statement until the end of the Allowed
Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable. Each Investor may deliver
written notice (an “Opt-Out Notice”) to the Company requesting that such Investor not receive notices from the Company
otherwise required by this Section 2; provided, however, that such Investor may later revoke any such
Opt-Out Notice in writing, which shall be effective five (5) Business Days after the receipt thereof. Following receipt of an Opt-Out
Notice from an Investor (unless subsequently revoked), the Company shall not deliver any notices pursuant to this Section 2(d) to
such Investor and such Investor shall no longer be entitled to the rights associated with any such notice.
(e) Rule 415;
Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration
Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act
(provided, however, the Company shall be obligated to use commercially reasonable efforts to advocate with the SEC for
the registration of all of the Registrable Securities) or requires any Investor to be named as an “underwriter,” the Company
shall (i) promptly notify each holder of Registrable Securities thereof and (ii) make commercially reasonable efforts to persuade
the SEC that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering “by or
on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter.” Each Investor
shall have the right to have its legal counsel, at such Investor’s expense, to review and oversee any registration or matters pursuant
to this Section 2(e), including to comment on any written submission made to the SEC with respect thereto. In the event
that, despite the Company’s commercially reasonable efforts and compliance with the terms of this Section 2(e),
the SEC refuses to alter its position, the Company shall (i) remove from such Registration Statement such portion of the Registrable
Securities and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as
the SEC may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC
Restrictions”); provided, however, that the Company shall not name any Investor as an “underwriter”
in such Registration Statement without the prior written consent of such Investor (provided that, in the event an Investor withholds
such consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Investor in any Registration
Statement covering the resale thereof until such time as the SEC no longer requires such Investor to be named as an “underwriter”
in such Registration Statement or such Investor otherwise consents in writing to being so named). Any cut-back imposed on the Investors
pursuant to this Section 2(e) shall be allocated among the Investors on a pro rata basis and shall be applied first
to any of the Registrable Securities of an Investor that the SEC has indicated cannot be included or must be limited in the number of
Registrable Securities that can be included, and thereafter to all other Investors, unless the SEC Restrictions otherwise require or
provides otherwise, or an Investor otherwise agrees.
(f) Each
Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the
Registrable Securities on Form S-3, in which case such registration shall be on another form in accordance with the provisions of
this Section 2(f)). If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder,
the Company shall (i) register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register
the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness
of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities
has been declared effective by the SEC.
| 3. | RELATED COMPANY OBLIGATIONS. |
With respect to the Registration
Statement and whenever any Registrable Securities are to be Registered pursuant to Section 2, including on the Initial
Registration Statement or on any New Registration Statement, the Company shall use its commercially reasonable efforts to effect the
registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company
shall have the following obligations:
(a) Notifications.
The Company will promptly notify the Investors of the time when any subsequent amendment to the Initial Registration Statement or any
New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or
where a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for
any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus or for additional information
regarding the Investor.
(b) Amendments.
The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement,
any New Registration Statement or any related prospectus, as applicable, that, (a) as may be necessary to keep such Registration
Statement effective for the Registration Period and to comply with the provisions of the Securities Act and the Exchange Act with respect
to the distribution of all of the Registrable Securities covered thereby, or (b) in the reasonable opinion of the Investors and
the Company, as may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investors.
(c) Investor
Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any
prospectus, other than documents incorporated by reference, relating to any Investor, the Registrable Securities or the transactions
contemplated hereby unless (A) such Investor and its counsel shall have been advised and afforded the opportunity to review and
comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable
due consideration to any comments thereon received from such Investor or its counsel.
(d) Copies
Available. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its
counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein),
any prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any
New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished
to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company
to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such
Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment)
and such other documents as such Investor may reasonably request in order to facilitate the disposition
of the Registrable Securities owned by such Investor that are covered by such Registration Statement, in each case as soon as
reasonably practicable upon such Investor’s request and in such quantities as such Investor may from time to time reasonably request;
provided, however, that the Company shall not be required to furnish any document to such Investor to the extent such document
is available on EDGAR.
(e) Notification
of Stop Orders; Material Changes. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop
order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as
practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing,
in each case: (i) of the Company’s receipt of notice of any request by the SEC or any other federal or state governmental
authority for amendment of or a supplement to the Registration Statement or any prospectus or for any additional information; (ii) of
the Company’s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order
suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus
supplement, or any New Registration Statement, or of the Company’s receipt of any notification of the suspension of qualification
of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding
for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material
fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements
then made in any Registration Statement or any prospectus in order to state a material fact required by the Securities Act to be stated
therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances
under which they were made) not misleading, or of the necessity to amend any Registration Statement or any prospectus to comply with
the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons
of any of the events set forth in clauses (i) through (iii) of the immediately preceding sentence (each, a “Suspension
Event”), but rather, shall only be required to disclose that the event has occurred; provided that the Company shall not provide
any material non-public information to the Investors in such notice. If at any time the SEC, or any other federal or state governmental
authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use
of any prospectus or prospectus supplement, the Company shall use its commercially reasonable efforts to obtain the withdrawal of such
order at the earliest practicable time. The Company shall furnish to any Investor upon request, without charge, a copy of any correspondence
from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its representatives relating
to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be.
In the event of a Suspension Event set forth in clause (iii) of the second sentence of this Section 3(e), the Company
will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve
the matter such that sales under Registration Statements may resume.
(f) Confirmation
of Effectiveness. If requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver to
such Investor a written confirmation (email being sufficient) from Company’s counsel of whether or not the effectiveness of such
Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether
or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.
(g) Listing.
The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed
on the Nasdaq Global Market and/or any other National Exchange upon which the Registrable Securities are listed.
(h) Compliance.
The Company shall otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under
the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus,
including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor
in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and,
as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and
take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make
available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an
earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement,
which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated
thereunder (for the purpose of this Section 3(h), “Availability Date” means the forty-fifth (45th)
day following the end of the fourth (4th) fiscal quarter that includes the effective date of such Registration Statement,
except that, if such fourth (4th) fiscal quarter is the last quarter of the Company’s fiscal year, “Availability
Date” means the ninetieth (90th) day after the end of such fourth (4th) fiscal quarter).
(i) Blue-Sky.
The Company shall use commercially reasonable efforts to register or qualify or cooperate with any Investor and its counsel in connection
with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of
such jurisdictions reasonably requested by such Investor; provided, however, that the Company shall not be required in connection therewith
or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify
but for this Section 3(i), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise
be so subject but for this Section 3(i), or (iii) file a general consent to service of process in any such jurisdiction.
(j) Rule 144.
With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation
of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants
and agrees to use commercially reasonable efforts to make and keep adequate current public information available, as those terms are
understood and defined in Rule 144, until the date as all of the Initial Shares may be sold without restriction by the holders thereof
pursuant to Rule 144 or any other rule of similar effect (without the requirement for the Company to be in compliance with
any current public information requirements). In addition for so long as any Registrable Securities are outstanding, the Company covenants
and agrees to use commercially reasonable efforts to (i) file with the SEC in a timely manner all reports and other documents required
of the Company under the Exchange Act; (ii) furnish electronically to each Investor upon request, as long as such Investor owns
any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the Exchange
Act, (B) a copy of or electronic access to the Company’s most recent Annual Report on Form 10-K or Quarterly Report on
Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or
regulation of the SEC that permits the selling of any such Registrable Securities without registration, and (iii) provide any legal
opinions.
(k) Cooperation. The
Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates
or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144
free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of
the Registrable Securities may reasonably request in accordance with the provisions of the Purchase Agreement, and the Company may satisfy
its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company’s Direct
Registration System.
(l) Removal
of Restrictive Legends. Without limiting Section 5.5 of the Purchase Agreement, the Company shall use commercially reasonable
efforts to cause the Company’s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as
practicable following effectiveness of the applicable Registration Statement, without any request for removal being required from any
holder of Registrable Securities.
| 4. | OBLIGATIONS OF THE INVESTORS. |
(a) Investor
Information. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as Exhibit A
or such other form of questionnaire or information required by the Company in connection with the registration of the Registrable Securities
within three (3) Business Days of request by the Company and no later than the end of the third (3rd) Business Day following the
date on which such Investor receives draft materials in accordance with Section 2(a).
(b) Suspension
of Sales. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company
of the existence of an Allowed Delay or Suspension Event, the Investor will promptly discontinue disposition of Registrable Securities
pursuant to any Registration Statement covering such Registrable Securities until the Investor’s receipt of a notice from the Company
confirming the resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made.
(c) Investor
Cooperation. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably
requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement
or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its
Registrable Securities from such Registration Statement.
| 5. | EXPENSES OF REGISTRATION. |
All Registration Expenses incurred
in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities
registered on behalf of an Investor shall be borne by such Investor.
(a) To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person,
if any, who controls each Investor, the shareholders, directors, officers, partners, employees, members, managers, agents, representatives
and advisors of each Investor and each Person, if any, who controls any of the foregoing within the meaning of the Securities Act or
the Exchange Act (each, an “Indemnified Person”), against any losses, obligation, claims, damages, liabilities, contingencies,
judgments, fines, penalties, charges and costs (including, without limitation, court costs and costs of preparation), reasonable and
documented attorneys’ fees, amounts paid in settlement or reasonable and documented expenses (collectively, “Indemnified
Damages”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation
or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC,
whether pending or threatened, whether or not an indemnified party is or may be a party thereto (“Claims”), to which
any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof)
arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material
fact contained in any Registration Statement, or (ii) any violation or alleged violation by the Company or any of its Subsidiaries
of the Securities Act, Exchange Act or any other state securities or other “blue sky” laws of any jurisdiction in which Registrable
Securities are offered or any rule or regulation promulgated thereunder applicable to the Company or its agents and relating to
action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing
clauses (i) and (ii) being, collectively, “Violations”). The Company shall reimburse each Indemnified
Person promptly as such Indemnified Damages are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other
reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (A) shall
not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity
with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration
Statement and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the
preparation of any Registration Statement; (B) with respect to any superseded prospectus, shall not inure to the benefit of any
such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the
benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus
was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing
not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not be available
to the extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus
to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation
of the sale of Registrable Securities; and (D) shall not apply to amounts paid in settlement of any Claim if such settlement is
effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such
indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall
survive the transfer of the Registrable Securities by the Investor pursuant to Section 8.
(b) In
connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not
jointly, agrees to indemnify, hold harmless and defend, the Company, each of its directors, and officers who signed the Initial Registration
Statement or signs any New Registration Statement, and each Person, if any, who controls the Company within the meaning of the Securities
Act or the Exchange Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities and expense
(including reasonable attorney fees) resulting from any untrue statement or alleged untrue statement or omission or alleged omission
of any material fact contained in any Registration Statement or (ii) any violation or alleged violation by Investor of its obligations
under this Agreement, in each case to the extent, and only to the extent, that such violation occurs in reliance upon and in conformity
with information about such Investor furnished in writing by such Investor to the Company expressly for use in connection with the preparation
of the Registration Statement, any New Registration Statement. In no event shall the liability of an Investor be greater in amount than
the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this Section 6
and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received
by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification
obligation. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(b),
shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the such
Investor, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities
by an Investor pursuant to Section 8.
(c) Promptly
after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any
action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party
shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the
indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and,
to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the
defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as
the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party
for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense
thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons
and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with
the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying
party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate
due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by
such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection
with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all
information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying
party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations
with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without
its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition
its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of
any judgment or enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation
on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing
such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or
litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance
by or on behalf of, the Indemnified Party or Indemnified Person. Following indemnification as provided for hereunder, the indemnifying
party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations
relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party
within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified
Person or Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced in
its ability to defend such action.
(d) The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment
pursuant to this Section 6 which person is later determined to not be entitled to such payment shall return such payment
(including reimbursement of expenses) to the person making it.
(e) The
indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party
or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to
pursuant to the law.
To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided,
however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation;
and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all
expenses paid by such holder in connection with any claim relating to this Section 7 and the amount of any damages such
holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received
by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.
| 8. | ASSIGNMENT OF REGISTRATION RIGHTS. |
The Company shall not assign
this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of
the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then
outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together
as a single class); provided, however, that in any transaction, whether by merger, reorganization, restructuring, consolidation,
financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities
of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed
to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and
the term “Registrable Securities” shall be deemed to include the securities received by the Investor in connection with such
transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior
written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded
Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants)
shall not be required for such transaction. No Investor may assign its rights under this Agreement, other than to an affiliate of
such Investor or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of the Investor,
without the prior written consent of the Company. The provisions of this Agreement shall be binding upon and inure to the benefit of
the Investor and its successors and permitted assigns.
| 9. | AMENDMENTS AND WAIVERS. |
The provisions of this Agreement,
including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed
by (a) the Company and (b) the holders of a majority of the then outstanding Registrable Securities (determined as if all of
the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded
Warrants) (voting together as a single class), provided that (i) any party may give a waiver as to itself, (ii) any
amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor
relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected
Investor or each Investor, as applicable, and (iii) any amendments to Section 6 or to the definitions of “Filing
Deadline,” “Effectiveness Deadline,” or “Registration Period” shall require the written consent of each
Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates
exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors
may be given by Investors holding a majority of the Registrable Securities (determined as if all of the Pre-Funded Warrants then outstanding
have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) to which such waiver or consent
relates.
(a) Notices.
Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when
delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, provided
no rejection or undeliverable notice is received, (c) three (3) days after having been sent by certified or registered mail,
return-receipt requested and postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight
courier, freight prepaid, specifying next business day delivery, with written verification of receipt:
i. If
to the Company, addressed as follows:
GlycoMimetics, Inc.
9708 Medical Center Drive
Rockville, Maryland 20850
Attention: Christian Dinneen-Long
Email: cdinneen-long@glycomimetics.com
with a copy (which shall not constitute
notice), prior to the Closing:
Sidley Austin, LLP
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Attention: Asher Rubin
Email: arubin@sidley.com
with a copy (which shall not constitute
notice), following the Closing:
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
Attention: Ryan Murr, Branden Berns; Chris Trester
Email: rmurr@gibsondunn.com, bberns@gibsondunn.com; ctrester@gibsondunn.com
ii. If
to any Investor, at its e-mail address or address set forth on Exhibit A to the Purchase Agreement or to such e-mail address,
or address as subsequently modified by written notice given in accordance with this Section 10.
Any Person may change the address to which notices
and communications to it are to be addressed by notification as provided for herein.
(b) No
Waiver. No failure or delay on the part of either party hereto in the exercise of any power, right or privilege under this Agreement
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other
or further exercise thereof or of any other right, power or privilege.
(c) Governing
Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury. The provisions of Section 8.5 of the Purchase Agreement are
incorporated by reference herein mutatis mutandis.
(d) Integration.
This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto) constitute the entire agreement
between the parties hereto respecting the subject matter hereof and thereof and supersedes all prior agreements, negotiations, understandings,
representations and statements respecting the subject matter hereof and thereof, whether written or oral.
(e) Headings.
The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.
(f) Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be
considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original,
not a facsimile or pdf (or other electronic reproduction of a) signature.
(g) Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
(h) Contract
Interpretation. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to
the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.
(i) No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as expressly provided
in this Agreement. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except
as expressly provided in this Agreement.
(j) Severability.
If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding
upon the parties hereto.
(k) Non-Recourse.
Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse
under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or
future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees
thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation
or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed
on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of
the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents
or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or
their creation.
(l) Specific
Performance. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement,
each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other
injunction or equitable relief as may be granted by a court of competent jurisdiction.
(m) Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.
[Signature Page Follows]
IN WITNESS WHEREOF, the parties have caused
this Registration Rights Agreement to be duly executed as of date first written above.
| |
COMPANY: |
| |
|
| |
Glycomimetics,
inc. |
| |
|
| |
By: |
|
| |
Name: |
| |
Title: |
[Signature Page to Registration Rights
Agreement]
IN WITNESS WHEREOF, the parties have caused
this Registration Rights Agreement to be duly executed as of date first written above.
| |
INVESTOR: |
| |
|
| |
[NAME] |
| |
|
| |
By: |
|
| |
Name: |
| |
Title: |
[Signature Page to Registration Rights
Agreement]
Exhibit A
Investor Questionnaire
The undersigned hereby provides the following
information to the Company and represents and warrants that such information is accurate:
QUESTIONNAIRE
| |
(a) | Full Legal Name of Investor |
| |
| |
| |
| |
| |
(b) | Full Legal Name of Registered Holder (if not the same as (a) above)
through which Registrable Securities are held: |
| |
| |
| |
| |
| |
(c) | Full Legal Name of Natural Control Person (which means a natural person
who directly or indirectly alone or with others has power to vote or dispose of the securities covered
by this Questionnaire): |
| |
| |
| |
| |
| 2. |
Address for Notices to Investor: |
| (a) | Are you a broker-dealer? |
Yes
¨ No ¨
| (b) | If “yes” to Section 3(a),
did you receive your Registrable Securities as compensation for investment banking services
to the Company? |
Yes
¨ No ¨
| Note: | If “no” to Section 3(b),
the SEC’s staff has indicated that you should be identified as an underwriter in the
Registration Statement. |
| (c) | Are you an affiliate of a broker-dealer? |
Yes
¨ No ¨
| (d) | If you are an affiliate of a broker-dealer,
do you certify that you purchased the Registrable Securities in the ordinary course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable
Securities? |
Yes
¨ No ¨
| Note: | If “no” to Section 3(d),
the SEC’s staff has indicated that you should be identified as an underwriter in the
Registration Statement. |
| 4. |
Beneficial Ownership of Securities of the Company Owned by the Investor. |
Except as set forth below in this
Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable
pursuant to the Purchase Agreement.
| (a) | Type and Amount of other securities beneficially
owned by the Investor: |
| | | |
| | | |
| | | |
| | | |
| | | |
| 5. |
Relationships with the Company: |
| |
|
| |
Except as set forth below, neither the undersigned
nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the
undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or
affiliates) during the past three years. |
| |
|
| |
State any exceptions here: |
| |
|
| |
|
| |
|
| |
|
The undersigned agrees to
promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify
the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.
By signing below, the undersigned
consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information
in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that
such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and
the related prospectus and any amendments or supplements thereto.
IN WITNESS WHEREOF the undersigned,
by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized
agent.
PLEASE EMAIL A .PDF COPY OF THE COMPLETED
AND EXECUTED QUESTIONNAIRE TO:
Exhibit 10.5
LOCK-UP AGREEMENT
October [·], 2024
GlycoMimetics, Inc., 9708 Medical Center Drive
Rockville, Maryland 20850
Attention: Christian Dinneen-Long
Email: cdinneen-long@glycomimetics.com
Ladies and Gentlemen:
The undersigned signatory of this lock-up agreement (this “Lock-Up
Agreement”) understands that GlycoMimetics, Inc., a Delaware corporation (“Parent”), has entered into
an Agreement and Plan of Merger and Reorganization, dated as of October [•], 2024 (as the same may be amended from time to time,
the “Merger Agreement”) with Gemini Merger Sub Corp., a Delaware corporation
and a wholly owned subsidiary of Parent, Gemini Merger Sub II, LLC, a Delaware limited
liability company and a wholly owned subsidiary of Parent, and Crescent Biopharma, Inc., a Delaware corporation (the “Company”).
Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
| 1. | As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated
thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned
hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned
will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the “Restricted
Period”); provided, that if a registration statement covering the shares of Parent Common Stock and pre-funded warrants
of Parent issued and sold in connection with the Parent Financing (other than any shares or pre-funded warrants of Parent held by affiliates
of Parent) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on
such later date upon which such registration statement is first declared effective: |
| a. | offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or
any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares
of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the
rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent
Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except
as set forth below (collectively, the “Undersigned’s Shares”); |
| b. | enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of the Undersigned’s Shares regardless of whether any such transaction described in clause (a) above or this clause
(b) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise; |
| c. | make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security
convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement);
or |
| d. | publicly disclose the intention to do any of the foregoing. |
| 2. | The restrictions and obligations contemplated by this Lock-Up Agreement shall not apply to: |
| a. | transfers of the Undersigned’s Shares: |
| i. | (A) to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who
is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a “Family Member”),
or to a trust formed for the benefit of the undersigned or any of the undersigned’s Family Members, (B) to the undersigned’s
estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable
contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to
any partnership, corporation or limited liability company which is controlled by or under common control with the undersigned and/or by
any such Family Member(s); |
| ii. | if the undersigned is a corporation, partnership, limited liability company or other entity, (A) to another corporation, partnership,
limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act)
of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with,
or is controlled or managed by, the undersigned, (B) as a distribution or dividend to equity holders, current or former general or
limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the
liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned’s equity holders),
(C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of
an immediate family member of a beneficial owner (as defined in Rule 13d-3 of the Exchange Act) of the Undersigned’s Shares
or (D) transfers or dispositions not involving a change in beneficial ownership; or |
| iii. | if the undersigned is a trust, to any grantors or beneficiaries of the trust; |
provided
that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant
to 1(A), 1(E) or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock-up
agreement in the form of this Lock-Up Agreement with respect to the shares of Parent Common Stock or such other securities that have been
so transferred or distributed;
| b. | the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase
shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise
price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes
(including estimated taxes) due as a result of the exercise of such options; provided that, for the avoidance of doubt, the underlying
shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement; |
| c. | transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future
shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; provided that,
for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer
set forth in this Lock-Up Agreement; |
| d. | the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Parent Common
Stock; provided that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period; |
| e. | transfers by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public or private
offering by Parent, in each case at or following the Effective Time (including for avoidance of doubt, the Parent Financing); |
| f. | pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent’s
capital stock involving a change of control of Parent, provided that in the event that such tender offer, merger, consolidation
or other such transaction is not completed, the Undersigned’s Shares shall remain subject to the restrictions contained in this
Lock-Up Agreement; or |
| g. | pursuant to an order of a court or regulatory agency. |
and provided, further, that, with respect to each
of (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee)
under Section 16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership
of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection
with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under Section 16(a) of
the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common
Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or
announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer
and that the shares remain subject to the lock-up agreement.
| 3. | For purposes of this Lock-Up Agreement, “change of control” shall mean the transfer (whether by tender offer, merger,
consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated
persons, of the Company’s voting securities if, after such transfer, the Company’s stockholders as of immediately prior to
such transfer do not hold a majority of the outstanding voting securities of the Company (or the surviving entity). |
| 4. | Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported
transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be
recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer
agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities
if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend
substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the
undersigned’s ownership of Parent Common Stock: |
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND
MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.
| 5. | The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement.
All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors,
assigns, heirs or personal representatives of the undersigned. |
| 6. | The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all
obligations under this Lock-Up Agreement. The undersigned understands that Parent is proceeding with the transactions contemplated by
the Merger Agreement in reliance upon this Lock-Up Agreement. |
| 7. | Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and
not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy
will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available,
would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance
with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were
otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of
this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having
jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives
any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees
that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party
has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. |
| 8. | In the event that any holder of Parent’s securities that are subject to a substantially similar agreement entered into by such
holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for
value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases
or waivers), the same percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the
percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver
that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions
set forth herein (the “Pro-Rata Release”); provided, however, that such Pro-Rata Release shall not be
applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or
dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number
of shares of Parent Common Stock subject to a substantially similar agreement. In the event of any Pro-Rata Release, Parent shall promptly
(and in any event within two (2) Business Days of such release) inform each relevant holder of Parent Common Stock or warrants of
the terms of such Pro-Rata Release. |
| 9. | Upon the release of any of the Undersigned’s Shares from this Lock-Up Agreement, Parent will reasonably cooperate with the undersigned
to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above
or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement. |
| 10. | This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the
laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties
arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits
to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject
matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees
that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause
(i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives
any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally
waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement
and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the
subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all
of which shall constitute one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise)
by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions
of this Agreement. |
[SIGNATURE PAGE FOLLOWS]
| |
|
|
Very truly yours, |
| |
|
|
|
| |
Print Name of Stockholder: |
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
Signature (for individuals): |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
Signature (for entities): |
| |
|
|
|
|
| |
|
|
By: |
|
| |
|
|
|
Name: |
| |
|
|
|
Title: |
[Signature Page to Lock-Up Agreement]
| Accepted and Agreed |
|
| by GlycoMimetics, Inc. |
|
| |
|
| By: |
|
|
| Name: |
|
| Title: |
|
[Signature Page to Lock-Up Agreement]
Exhibit 99.1
GlycoMimetics
Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
ROCKVILLE, Md.--(BUSINESS WIRE)—
October 29, 2024-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing
glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study
of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with
newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for intensive chemotherapy. This study did not show a
statistically significant improvement in event free survival (EFS) for patients receiving uproleselan in combination with 7+3 chemotherapy
versus chemotherapy alone.
GlycoMimetics is
coordinating with the Alliance for transfer of full trial data for additional analysis, including subgroup analysis to evaluate if there
are efficacy signals in any patient population that may merit further study in future clinical trials. Top-line results from NCI/Alliance
trial are expected to be presented by the NCI at a future medical conference.
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage
biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases.
The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized
chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition
in diverse disease states, including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases
with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region.
Learn more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of, and timing for
analysis and presentation of data from, clinical trials; and potential development and regulatory activities. Actual results may differ
materially from those described in these forward-looking statements. For a further description of the risks associated with these statements,
as well as other risks facing GlycoMimetics, please see the risk factors described in the company’s Annual Report on Form 10-K
filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2024, the company’s Quarterly Reports
on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024, and other filings GlycoMimetics makes with
the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes
no obligation to update or revise these statements, except as may be required by law.
Investor
Contact:
Argot Partners
Leo Vartorella
212-600-1902
Glycomimetics@argotpartners.com
Exhibit 99.2
GlycoMimetics
enters into acquisition agreement with Crescent Biopharma
Following closing, the combined company will advance
Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors
Crescent’s lead program CR-001, a tetravalent
PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected
to have preliminary proof of concept data in 2H26
Crescent pipeline also includes two novel antibody-drug
conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003
Concurrent financing of approximately $200 million
anticipated to fund operations through 2027
Companies to hold a conference call on Tuesday
October 29, at 8:00am EDT
ROCKVILLE, Md.--(BUSINESS WIRE)--October 29, 2024 -- GlycoMimetics,
Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. (“Crescent”),
a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of
the transaction, the Company plans to operate under the name Crescent Biopharma, Inc.
In support of the acquisition, a syndicate
of investors led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a large investment management firm, with participation
from Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital, Perceptive Advisers,
Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP, and Wellington Management,
has committed $200 million to purchase GlycoMimetics common stock and GlycoMimetics pre-funded warrants to purchase its common
stock. The transaction is expected to close in the second quarter of 2025. The financing is expected to close immediately following the
completion of the transaction. The Company’s cash balance at closing is anticipated to fund operations through 2027, including advancement
of the Company’s lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody, through preliminary proof of concept clinical
data in solid tumor patients expected in the second half of 2026.
“Crescent was founded to harness recent breakthroughs in immuno-oncology
and antibody-drug conjugates that pave the way for a next generation of therapies for patients with solid tumors,” said Jonathan
Violin, interim CEO at Crescent and Venture Partner at Fairmount. “Our lead program CR-001 was precision engineered to impart a
cooperative binding pharmacology for VEGF x PD-1 bispecific blockade; this mechanism recently demonstrated superior efficacy to the anti-PD1
antibody pembrolizumab in a third party head-to-head Phase 3 clinical trial. The specific level of cooperativity engineered into CR-001
reflects a delicate mechanistic balance, which is essential to our confidence in this program. This transaction and financing enable a
potentially rapid development path for CR-001, and for the antibody drug conjugate programs CR-002 and CR-003.”
Crescent is the fifth company to launch with assets discovered and
developed by Paragon Therapeutics. CR-001, a tetravalent PD-1 x VEGF bispecific antibody, matches the format and pharmacology of ivonescimab,
which delivered superior efficacy compared to the current market leader pembrolizumab in a large third party Phase 3 trial. In addition
to CR-001, Crescent is developing CR-002 and CR-003, antibody-drug conjugates (ADCs) against undisclosed targets using topoisomerase inhibitor
payloads; ADCs with topoisomerase inhibitor payloads have shown improved efficacy and safety compared to ADCs with alternative payloads.
The Company anticipates that the IND for CR-001 will be filed in 4Q25
or 1Q26, and interim Phase 1 data from patients is expected in 2H26. CR-002, Crescent’s first ADC program, is designed to be best-in-class
and is expected to initiate Phase 1 in 2026; the Company plans to disclose the target for CR-002 as the program approaches the clinic.
The Company intends to determine potential paths forward for its late
stage clinical candidate, Uproleselan, including by supporting continued data analyses of Uproleselan from NCI, its corporate partner
for China, Apollomics, and investigator initiated studies.
“We are confident that our transaction with Crescent represents
a significant opportunity for GlycoMimetics and its stockholders,” said Harout Semerjian, CEO of GlycoMimetics. “This transaction
is the result of a comprehensive strategic review, and with additional funding for Crescent’s portfolio of novel biologics, we believe
the company is well-positioned to carry forward the mission of seeking to improve the lives of patients.”
About the Proposed Transactions
Under the terms of the acquisition agreement, the pre-acquisition GlycoMimetics
stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of
those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company. The percentage of
the company that GlycoMimetics’s stockholders will own as of the closing of the acquisition is subject to adjustment based on the
amount of GlycoMimetics’s net cash at the closing date.
The transaction has received approval by the Board of Directors of
both companies and is expected to close in the second quarter of 2025, subject to certain closing conditions, including, among other things,
approval by the stockholders of each company and the satisfaction of customary closing conditions.
The company will be named Crescent Biopharma, Inc. and be led by Jonathan
Violin, Ph.D., Crescent’s interim Chief Executive Officer, who will be joined on Crescent’s Board of Directors by Peter Harwin,
Managing Member of Fairmount. Wedbush PacGrow is serving as strategic advisor and Gibson, Dunn & Crutcher LLP is serving as legal
counsel to Crescent. Jefferies, TD Cowen, Stifel, and LifeSci Capital are serving as the placement agents to Crescent. Covington is serving
as legal counsel to the placement agents. Lucid Capital Markets is serving as financial advisor and Sidley Austin is serving as legal
counsel to GlycoMimetics.
Conference Call Details
The companies plan to hold a joint conference call on October 29, 2024
at 8:00 AM EDT to discuss the merger details.
To access the call by phone, please go to
this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes
in advance of the scheduled start time.
A live webcast of the call will be available
on the “Investors” tab on the GlycoMimetics website. A webcast replay will be available for 30 days following
the call.
About GlycoMimetics
GlycoMimetics is a late clinical-stage biotechnology company discovering
and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific
approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can
be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states,
including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases with high unmet medical
need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
About Crescent Biopharma
Crescent Biopharma is a biotechnology company dedicated to advancing
novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company’s pipeline
of three programs harnesses proven biology to accelerate the path to market for potentially best in class therapeutics. For more information,
visit www.crescentbiopharma.com
Forward Looking Statements
Certain statements in this press release, other than purely historical
information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for
purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, concerning GlycoMimetics, Crescent,
the proposed pre-closing financing and the proposed acquisition by GlycoMimetics of Crescent (collectively, the “Proposed Transactions”)
and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to GlycoMimetics’s
and Crescent’s management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future including, without
limitation, statements regarding: the Proposed Transactions and the expected effects, perceived benefits or opportunities, including investment
amounts from investors and expected proceeds, and related timing with respect thereto, expectations regarding or plans for discovery,
preclinical studies, clinical trials and research and development programs, in particular with respect to CR-001, and any developments
or results in connection therewith, including the target product profile of CR-001; the anticipated timing of the commencement of and
results from those studies and trials; expectations regarding the use of proceeds, the sufficiency of post-transaction resources to support
the advancement of Crescent’s pipeline through certain milestones and the time period over which Crescent’s post-transaction
capital resources will be sufficient to fund its anticipated operations; the cash balance of the combined entity at closing; expectations
regarding the treatment of solid tumors; and expectations related to GlycoMimetics’s late stage clinical candidate, Uproleselan.
In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including
any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,”
“pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,”
“achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,”
“will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify
forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking
statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance
that future developments affecting GlycoMimetics, Crescent or the Proposed Transactions will be those that have been anticipated. These
forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of GlycoMimetics and Crescent)
or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the closing
or consummation of the Proposed Transactions are not satisfied, including GlycoMimetics’s failure to obtain stockholder approval
for the proposed merger; the risk that the proposed pre-closing financing is not completed in a timely manner or at all; uncertainties
as to the timing of the consummation of the Proposed Transactions and the ability of each of GlycoMimetics and Crescent to consummate
the transactions contemplated by the Proposed Transactions; risks related to GlycoMimetics’s continued listing on Nasdaq until closing
of the Proposed Transactions and the combined company’s ability to remain listed following the Proposed Transactions; risks related
to GlycoMimetics’s and Crescent’s ability to correctly estimate their respective operating expenses and expenses associated
with the Proposed Transactions, as applicable, as well as uncertainties regarding the impact any delay in the closing of any of the Proposed
Transactions would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated
spending and costs that could reduce the combined company’s cash resources; the failure or delay in obtaining required approvals
from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change
or other circumstance or condition that could give rise to the termination of the business combination between GlycoMimetics and Crescent;
the effect of the announcement or pendency of the merger on GlycoMimetics’s or Crescent’s business relationships, operating
results and business generally; costs related to the merger; as a result of adjustments to the exchange ratio, Crescent stockholders and
GlycoMimetics stockholders could own more or less of the combined company than is currently anticipated; the outcome of any legal proceedings
that may be instituted against GlycoMimetics, Crescent or any of their respective directors or officers related to the merger agreement
or the transactions contemplated thereby; the ability of GlycoMimetics and Crescent to protect their respective intellectual property
rights; competitive responses to the Proposed Transactions; unexpected costs, charges or expenses resulting from the Proposed Transactions;
potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Proposed Transactions;
failure to realize certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating
results; the risk that GlycoMimetics stockholders receive more or less of the cash dividend than is currently anticipated; legislative,
regulatory, political and economic developments; and those uncertainties and factors described under the heading “Risk Factors”
and “Business” in GlycoMimetics’s most recent Annual Report on Form 10-K filed with the SEC on March 27, 2024, as well
as discussions of potential risks, uncertainties, and other important factors included in other filings by GlycoMimetics from time to
time, any risk factors related to GlycoMimetics or Crescent made available to you in connection with the Proposed Transactions, as well
as risk factors associated with companies, such as Crescent, that operate in the biopharma industry. Should one or more of these risks
or uncertainties materialize, or should any of GlycoMimetics’s or Crescent’s assumptions prove incorrect, actual results may
vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as
a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results
of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release,
which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither
GlycoMimetics nor Crescent undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements.
This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in GlycoMimetics or
Crescent.
No Offer or Solicitation
This press release and the information contained herein is not intended
to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed
Transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe
for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities
in any jurisdiction in contravention of applicable law. No offer of securities shall be made except in accordance with the requirements
of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators
or certain facts to be ascertained, no public offer will be made directly or indirectly, in or into any jurisdiction where to do so would
constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without
limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities
exchange, of any such jurisdiction.
NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESS RELEASE IS TRUTHFUL OR COMPLETE.
Important Additional Information about the Proposed Transaction
Will be Filed with the SEC
This press release is not a substitute for the proxy statement or for
any other document that GlycoMimetics may file with the SEC in connection with the Proposed Transactions. In connection with the Proposed
Transactions between GlycoMimetics and Crescent, GlycoMimetics intends to file relevant materials with the SEC, including a proxy statement
of GlycoMimetics. GLYCOMIMETICS URGES INVESTORS AND STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY
BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GLYCOMIMETICS, CRESCENT, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.
Investors and stockholders will be able to obtain free copies of the proxy statement and other documents filed by GlycoMimetics with the
SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Stockholders are urged to read the proxy statement
and the other relevant materials when they become available before making any voting or investment decision with respect to the Proposed
Transactions. In addition, investors and stockholders should note that GlycoMimetics communicates with investors and the public using
its website (https://https://ir.glycomimetics.com/investor-relations).
Participants in the Solicitation
GlycoMimetics, Crescent and their respective
directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with
the Proposed Transactions. Information about GlycoMimetics’s directors and executive officers, including a description of their
interests in GlycoMimetics, is included in GlycoMimetics’s most recent Annual Report on Form 10-K, including any information incorporated
therein by reference, as filed with the SEC. Additional information regarding these persons and their interests in the transaction will
be included in the proxy statement relating to the Proposed Transactions when it is filed with the SEC. These documents can be obtained
free of charge from the sources indicated above.
Investor Contact:
Argot
Partners
Leo Vartorella
212-600-1902
Glycomimetics@argotpartners.com
Exhibit 99.3
CONFIDENTIAL October 2024 Crescent Biopharma Confidential Overview
2 Disclaimer CONFIDENTIAL This presentation is strictly confidential and being made to you solely as a prospective investor in the proposed offering (the “Offering”) of common stock, par value $ 0 . 001 per share, or, in lieu thereof, pre - funded warrants (together, the “Securities”) of GlycoMimetics , Inc . (the “we,” “us,” “our” or the “Company”) in connection with the transactions contemplated by the agreement and plan of merger and reorganization to be entered into by the Company and Crescent Biopharma, Inc . , a Delaware corporation, among others (the “Merger Agreement”) . The Securities have not been and will not be registered under the U . S . Securities Act of 1933 (as amended, the “Securities Act”) or any state securities laws or the laws of any foreign jurisdiction . The Securities are being offered only to persons in reliance upon the exemption from securities registration for transactions not involving any public offering afforded by Section 4 (a)( 2 ) of the Securities Act . The Securities have not been approved or disapproved by the United States Securities and Exchange Commission, or any other securities regulating body or agency, nor has any such authority, commission, or body passed on the accuracy or adequacy of this presentation . Any representation to the contrary is a criminal offense . By accepting this presentation, you will be deemed to represent that you are a sophisticated institutional investor, have the capacity to protect your own interests in connection with the Offering, and have sufficient knowledge and experience in investing in investments similar to the Securities to properly evaluate the merits and risks of the investment in the Securities . This presentation is meant only for the intended recipient based on its representations regarding such qualifications . This presentation is for informational purposes only and only a summary of certain information related to the Company . It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision . You may not take away, reproduce, or distribute this presentation, in whole or in part, and you may not disclose any of the contents of this presentation to any other person . Acceptance of this presentation constitutes an agreement to be bound by the terms set forth herein . The information contained herein does not constitute investment, legal, accounting, regulatory, taxation or other advice, and the information does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs . Investors must conduct their own investigation of the investment opportunity and evaluate the risks of acquiring the Securities based solely upon such investor’s independent examination and judgment as to the prospects of the Company as determined from information in the possession of such investor or obtained by such investor from the Company, including the merits and risks involved . Statements in this presentation are made as of the date hereof unless stated otherwise herein, and neither the delivery of this presentation at any time, nor any sale of Securities, shall under any circumstances create an implication that the information contained herein is correct as of any time subsequent to such date . The Company is under no obligation to update or keep current the information contained in this document . No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein, and any reliance you place on them will be at your sole risk . The Company, its affiliates and advisors do not accept any liability whatsoever for any loss howsoever arising, directly or indirectly, from the use of this document or its contents, or otherwise arising in connection with the Offering . Forward - Looking Statements Certain statements contained in this presentation that are not descriptions of historical facts are “forward - looking statements . ” When we use words such as “potentially,” “could,” “will,” “projected,” “possible,” “expect,” “illustrative,” “estimated” or similar expressions that do not relate solely to historical matters, we are making forward - looking statements . Forward - looking statements are not guarantees of future performance and involve risks and uncertainties that may cause our actual results to differ materially from our expectations discussed in the forward - looking statements . This may be a result of various factors, including, but not limited to : our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding : the Offering and the transactions contemplated by the Merger Agreement, and the expected effects, perceived benefits or opportunities and related timing with respect thereto, expectations regarding or plans for discovery, preclinical studies, clinical trials and research and development programs and therapies ; expectations regarding the use of proceeds and the time period over which our capital resources will be sufficient to fund our anticipated operations ; and statements regarding the market and potential opportunities for solid tumor treatments and therapies . All forward - looking statements, expressed or implied, included in this presentation are expressly qualified in their entirety by this cautionary statement . You are cautioned not to place undue reliance on any forward - looking statements . Except as otherwise required by applicable law, we disclaim any duty to update any forward - looking statements, all of which are expressly qualified by this cautionary statement, to reflect events or circumstances after the date of this presentation . Industry and Market Data Market and industry data and forecasts used in this presentation have been obtained from independent industry sources as well as from research reports prepared for other purposes . Although we believe these third - party sources to be reliable, we have not independently verified the data obtained from these sources and we cannot assure you of the accuracy or completeness of the data . Forecasts and other forward - looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward - looking statements in this presentation . Statements as to our market and competitive position data are based on market data currently available to us, as well as management’s internal analyses and assumptions regarding the Company, which involve certain assumptions and estimates . These internal analyses have not been verified by any independent sources and there can be no assurance that the assumptions or estimates are accurate . While we are not aware of any misstatements regarding our industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors . As a result, we cannot guarantee the accuracy or completeness of such information contained in this presentation .
3 Crescent Biopharma aims to advance the next wave of innovation in cancer therapy CONFIDENTIAL Potential Indications Stage MoA Program Clinical IND - enabling Discovery NSCLC, other solid tumors YE25 / 1Q26 PD - 1 x VEGF (same cooperative MoA as ivonescimab) CR - 001 1 Solid tumors Mid - 26 Undisclosed #1 (ADC, TopoI payload) CR - 002 Solid tumors Undisclosed #2 (ADC, TopoI payload) CR - 003 Crescent’s pipeline consists of potentially best - in - class therapies for the treatment of solid tumors . • Crescent is the fifth company launched with assets discovered and in - development in - house by Paragon Therapeutics, a leading biotech incubator founded by Fairmount Funds in 2021. • Prior companies founded with Paragon assets have collectively raised >$2B and generated significant value . Notes: 1 Anticipated expiration for filed provisional patent is 2045+
4 Crescent is advancing three highly impactful oncology programs with best - in - class potential CONFIDENTIAL CR - 001 PD - 1 x VEGF cooperative tetravalent bsAb ; same MoA as ivonescimab CR - 002 & CR - 003 ADCs with topoisomerase inhibitor payloads; potentially best - in - class • Designed to reproduce ivonescimab’s established pharmacology . • Pipeline in a program opportunity across solid tumor indications, with potential to move to frontline use in the $50B+ PD - (L)1 immunotherapy market. • IND expected YE25 / 1Q26 . • Two unique, undisclosed targets with significant potential across solid tumors as single agents. • Each has potential to synergize with CR - 001 in combination studies, further driving clinical efficacy. • Both utilize the best - in - modality cytotoxic payload : topoisomerase inhibitor . • CR - 002 IND expected mid - 26 . Anti - VEGF Anti - PD - 1 scFvs
5 PD - (L)1 - targeted therapies, annualizing $50B+, have transformed oncology – with Keytruda now the best - selling drug in the world CONFIDENTIAL Notes: 1. 5 - year follow up demonstrated mOS of 22.0 vs 10.6 months. NSQ: Non - squamous. NSCLC: Non - small cell lung cancer. mOS : median overall survival. Sources: 2018 Gandhi (NEJM); 2023 Garassino (J Clin Oncol); GlobalData ; FactSet; Pembrolizumab FDA Label PD - (L)1 inhibitors have significantly prolonged survival , shifting 1L treatment to immunotherapy PD - (L)1 - targeted therapies are one of the largest drug classes , with Keytruda (pembrolizumab) the dominant player 21 25 29 9 10 11 4 5 4 4 4 0 10 20 30 40 50 $ 60 B anti - PD - (L)1 global sales 3 2022 2023 2024E $ 38 B $ 45 B $ 51 B +33% Keytruda Opdivo Imfinzi Tecentriq Libtayo Bavencio Jemperli • For example, in 1L NSQ NSCLC, addition of pembrolizumab to chemo significantly improved mOS ( NR vs 11.3 months 1 with a HR of 0.49 ). Keytruda alone is approved in 20+ oncology indications with expected revenue of ~$30B in 2024 . Pembrolizumab + chemotherapy Chemotherapy 0 3 6 9 12 15 18 24 100 90 80 70 60 50 40 30 20 10 0 Hazard ratio for death, 0.49 (P<0.001) Patients who survived (%) Months
6 Ivonescimab, a cooperative PD - 1 x VEGF bispecific, doubled progression - free survival vs. Keytruda in a P3 NSCLC trial CONFIDENTIAL Notes: HR: hazard ratio. PFS: progression - free survival. AE: adverse event. NSQ: Non - squamous SQ: Squamous. Akeso has licensed ivonescimab to Summit in North America, South America, Europe, Africa, Middle East, and Japan. Akeso maintains rights in Asia (ex - Japan / Middle East) and in Oceania. Sources: 2024 Zhou (WCLC Presentation on HARMONi - 2); Summit Therapeutics; 2018 Paz - Area (NEJM); 2019 Mok (Lancet); 2022 De Castr o Jr (J Clin Oncol); Avastin Label • Broader efficacy : Ivonescimab demonstrates benefit in patients where anti - PD - (L)1 efficacy has historically been modest (e.g., squamous, PD - (L)1 low ). • Promising safety : Ivonescimab had lower AEs than expected versus anti - VEGF monotherapy. This suggests a differentiated profile driven by cooperativity - driven tissue targeting. Ivonescimab is the first drug to demonstrate superiority in PFS over pembrolizumab in a randomized Phase 3 Ivonescimab’s novel MoA raises the bar on efficacy and safety Squamous Non - squamous PD - L1 high ( TPS ≥50% ) PD - L1 low ( TPS 1 - 49% ) 0.48 0.54 0.46 0.54 HR 1 2 Time (months) Progression - free survival (%) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 10 20 30 40 50 60 70 80 90 100 Ivonescimab Pembrolizumab 9 - mo: 40% 9 - mo: 56% Median follow - up: 8.67 mos Pembrolizumab Ivonescimab 5.82 11.14 mPFS , mos 0.51 PFS HR 38.5 50.0 ORR, % Dual blockade of PD - 1 and VEGF through a cooperative bispecific antibody has led to unprecedented clinical results , demonstrating superiority to pembrolizumab… and a $15B+ market cap for ivo’s ex - China sponsor, Summit Therapeutics .
7 CONFIDENTIAL CR - 001 Cooperative, tetravalent PD - 1 x VEGF bispecific antibody
8 Ivonescimab’s novel, cooperative MoA hypothesized to drive enhanced anti - tumor activity while maintaining tolerability CONFIDENTIAL Notes: AE: adverse event. TME: Tumor microenvironment Sources: 2023 Zhong (SITC Poster); Summit Therapeutics Ivo’s cooperative binding blocks PD - 1 / PD - L1 interactions and inhibits VEGF VEGF binding increases PD - 1 affinity by ~18x PD - 1 binding increases VEGF affinity by ~4x A B VEGF dimer PD - 1 PD - L1 Ivonescimab VEGF drives tumor angiogenesis and PD - L1 expression suppresses T cells T cell Tumor cell Dual blockade of PD - 1 and VEGF through a novel tetravalent bispecific format with cooperative binding effects has led to unprecedented clinical results in third party trials . x Cooperativity : VEGF binding to i vonescimab increases affinity to PD - 1 and vice versa , enhancing both T - cell activation and VEGF - signaling blockade . This helps explain the cross - trial outperformance of ivonescimab vs. an anti - PD - L1 + anti - VEGF combination. x Tumor targeting : PD - 1 arm concentrates VEGF inhibition in the TME, potentially sparing healthy tissue and reducing AEs.
9 CR - 001 is a highly potent PD - 1 x VEGF bsAb designed to recapitulate ivonescimab’s cooperative pharmacology CONFIDENTIAL Designed to match ivonescimab PK • Native FcRn binding to match distribution and elimination of ivonescimab Effector - null human IgG Fc • Equivalent to ivonescimab • ADCC carries additional AE risk Highly potent & stable scFvs • Designed to be the best possible anti - PD - 1 epitope / binding domain • Anti - PD - 1s have historically outperformed anti - PD - L1s in meta - analyses of solid tumor studies • Contains proprietary engineering to enable functional and stable scFvs Same design as ivonescimab • Pairs anti - VEGF IgG & anti - PD - 1 scFvs • Avoids risk of alternative, clinically unprecedented constructs (e.g., VEGF trap, anti - PD - L1 IgG, ADCC) Potential for reduced AEs • Cooperative binding increases anti - VEGF activity in TME , reducing AE risks in healthy tissue • Identical VEGF potency to preserve safety
10 CR - 001 replicates ivonescimab’s cooperative effect, with greater binding to and inhibition of PD - 1 signaling in presence of VEGF CONFIDENTIAL Notes: Ivonescimab generated internally based on published sequence. PD - 1 / PD - L1 signaling inhibition measured in RLU (relative light units), a measure of luminescence that increases with greater inhibition. PD - 1 binding measured in MFI (mean fluorescence intensity), a measure of fluorescence that in creases with binding and is measured via FACS. Sources: Internal data CR - 001 lead, like ivonescimab, is more potent in an NFAT reporter assay in the presence of VEGF … … and also increases PD - 1 binding on PD - 1+ Jurkat cells in the presence of VEGF . CR - 001 lead demonstrates same cooperative effect as ivonescimab across multiple assays.
11 Replicating ivonescimab’s tetravalent format and cooperativity, with stable scFvs, requires complex protein engineering CONFIDENTIAL Ivonescimab’s unique structure and geometry – and resulting cooperative function – is challenging to replicate ; alternative constructs risk not reproducing ivonescimab’s superior efficacy and safety in clinical practice. Standard mAbs can be improved with established protein engineering approaches … … but ensuring cooperative effect, stability, and developability of tetravalent PD - (L)1 x VEGF bispecific antibody is more difficult CDRs improved via diversification and/or affinity maturation to maximize potency Fc engineering tunes ADCC, CDC, half - life , etc. IgG format bound to VEGF dimer required to daisy chain ; different potency may alter chaining kinetics and VEGF trap geometry does not work scFv format can require significant engineering to ensure stability Fc silencing helps reduce risk of AEs CR - 001 has novel composition of matter IP related to proprietary, stabilized scFvs Leading anti - PD - 1s are unstable and aggregate in scFv format, potentially hampering developability
12 CR - 001 has potential to transform SoC across a multitude of oncology indications, with numerous first - in - class opportunities CONFIDENTIAL Notes: EGFRm = mutant epidermal growth factor receptor. Sources: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli Label; Loqtorzi Label; Zynyz Label; Avastin Label; Cyramza Label; Lenvima Label; Votrient Label Anti - VEGF approvals Anti - PD - (L)1 approvals Anti - VEGF and anti - PD(L) - 1 approvals Ongoing / announced global study from Summit or BioNTech GASTROINTESTINAL Colorectal (all comers) Colorectal ( MSI - H / dMMR ) Gastric / Gastroesophageal junction (GEJ) Primary peritoneal BRAIN Glioblastoma HEMATOLOGICAL Classical Hodgki n lymphoma Primary mediastinal large B - cell l ymphoma (PMBCL) LIVER & BILIARY Biliary tract Hepatocellular carcinoma (HCC) SOFT TISSUE Alveolar soft part sarcoma Soft tissue sarcoma TISSUE - AGNOSTIC High microsatellite instability (MSI - H) / deficient DNA mismatch repair ( dMMR ) High tumor mutational burden (TMB - H) SKIN Basal c ell carcinoma Cutaneous squamous cell carcinoma Melanoma Merkel cell carcinoma KIDNEY Renal cell carcinoma (RCC) HEAD & NECK Head & neck squamous cell carcinoma (HNSCC) Nasopharyngeal Thyroid CHEST/THORACIC Esophageal EGFRm non - small cell lung cancer (NSCLC) Non - squamous NSCLC Squamous NSCLC Small cell lung cancer (SCLC) Pleural mesothelioma REPRODUCTIVE Cervical Endometrial Fallopian tube Ovarian (epithelial) Triple negative breast cancer (TNBC) Urothelial
13 Development programs across key late - stage competitors include numerous P3s with PFS & OS readouts, paving the way for CR - 001 CONFIDENTIAL *Summit has announced P3 in 1L PD - L1+ NSCLC, monotherapy vs. pembro , but has not released trial details. Akeso has announced P3 in 1L pancreatic ductal adenocarcinoma (PDAC), combined with chemo, but has not released trial details. Notes: List of trials is not exhaustive. All confirmed trials have b een initiated prior to 2025. NSCLC = non - small cell lung cancer; TNBC = triple negative breast cancer; SCLC = small cell lung cancer; HNSCC = head & neck squamous cell carcinoma. PFS and OS rea douts estimated based on PEP (primary endpoints) and completion dates listed on ClinicalTrials.gov. Sources: ClinicalTrials.gov; Company websites; Company presenta tio ns 2025 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 PFS complete; OS expected in 2025 OS expected in 2025 Active and contemplated global & Chinese / Australian Phase 3s – across tumor types, lines of therapy, and combinations – will help guide clinical development for CR - 001 . Phase Combo Population Indication 3 Chemo 2L EGFRm+ mNSCLC 3 Chemo 1L squamous 3 None 1L PD - L1+* Additional global Phase 3s planned 3 None 1L PD - L1+ mNSCLC 3 Chemo 1L squamous 3 anti - CD47 1L PD - L1+ r/m HNSCC 3 Chemo 1L Biliary tract 3 Chemo 1L* PDAC Multiple global / Chinese Phase 2/3s and Phase 3s planned ; lead indications include SCLC, TNBC, and NSCLC Ivonescimab Global studies Ivonescimab China / Australia studies BNT327 Global studies vs. PD - (L)1 comparator PEP: PFS PEP: OS PEP: PFS & OS Est. P1 interim data for CR - 001
14 Parallel clinical development paths offer potential for both first - in - class and lower risk opportunities for CR - 001 CONFIDENTIAL Focus on potential first - in - class opportunities and with potentially rapid path to market (i.e., efficient development strategy, anticipated likelihood of PFS and OS success ) • Numerous indications with clinically meaningful anti - PD - (L)1 +/ - VEGF efficacy and potential to combine with chemo / orthogonal MoAs . Plan to rapidly follow ivonescimab in indications where clinical validation vs. anti - PD - (L)1 is highly differentiating • High conviction that CR - 001 can replicate ivonescimab’s efficacy given similar construct and equivalent MoA . NSCLC TNBC TBD Based on ongoing Phase 3 trials POTENTIAL INDICATIONS CR - 001 1 2
15 CR - 001 Phase 1 data offer potential for early de - risking – a rarity for a solid tumor oncology program CONFIDENTIAL ILLUSTRATIVE Phase 3s (validated indications) Phase 2/3s (first - in - class opportunities) Phase 1 (solid tumor all - comers) CR - 001 IND • Key derisking preliminary data: x PK x Safety x Efficacy (e.g., ORR) YE25 / 1Q26 PoC Interim 2H26 • Higher confidence to fund and accelerate CR - 001 into P3s after P1 interim data, given replication of ivonescimab’s cooperative pharmacology High conviction in CR - 001’s clinical profile can be reached in ~9 - 12 months , offering potential for significant early value inflection . Phase 1 interim proof - of - concept data are a potentially significant value - generating event for CR - 001. • Preliminary data from early Phase 1 cohorts provides substantial validation of program because CR - 001 structural design and preclinical data are similar to ivonescimab . • Early Phase 1 data, as single agent and in combination with SoC, rapidly enables late - stage development in multiple solid tumor types, unlocking broad first - in - class and fast - follower opportunities . • CR - 001 is markedly differentiated from novel constructs, which may require significantly more patients’ worth of safety and efficacy data in tumor - specific expansion cohorts and/or Phase 2s to establish conviction before initiating Phase 3s.
16 CR - 001 preclinical data reproduces ivonescimab’s breakthrough pharmacology and is rapidly advancing to generate significant value CONFIDENTIAL Unprecedented third - party data validates PD - 1 x VEGF cooperativity Transformative MoA for $50B+ market CR - 001’s proprietary engineering is designed to replicate ivonescimab Built by the proven Paragon team CR - 001 is a highly potent PD - 1 x VEGF bsAb reproducing cooperative binding qualities critical to ivonescimab Paragon has a demonstrated track record discovering and developing best - in - class molecules Ivonescimab significantly improved PFS versus pembrolizumab in Phase 3 in 1L NSCLC – the first therapy to do so head - to - head Poised to transform NSCLC standard of care , with broad application across $50B+ anti - PD - (L)1 market
17 CONFIDENTIAL CR - 002 & CR - 003 Topoisomerase inhibitor ADCs against validated targets
18 ADCs with topoisomerase inhibitor payloads have demonstrated best - in - modality efficacy and safety Notes: NSCLC = non - small cell lung cancer; GEJ = gastroesophageal junction; A = approved; R = in registration. PN rates are weig hted averages, by number of patients, across indications / trials and include PN, PSN, PMN, and PSMN when separately measured; full list of trials and references availabl e o n request. Disitamab vedotin is approved in China and in Phase 3 development globally. Sources: Enhertu Label; 2024 Smit (Lancet Onc ); Kadcyla Label; 2019 Peters (Clin Cancer Res); 2017 Thuss - Patience (Lancet Onc ); 2024 Oaknin (ESMO Pres); 2024 Ahn (JCO); 2018 King (Invest New Drugs) CROSS - TRIAL COMPARISONS TopoI payload - based ADCs have demonstrated superior ORR vs. microtubule inhibitor - based ADCs in cross - trial comparisons… … and have shown much lower rates of peripheral neuropathy , a critical AE that can drive dose reductions & discontinuations CR - 002 and CR - 003 utilize the best - in - ADC payload in their potentially best - in - class profiles . 0 20 40 60 80 100 ORR (%) 83% 44% 54% 20% 41% 21% 49% 0% 26% 0% Topoisomerase inhibitor payload Microtubule inhibitor payload Only difference in HER2 ADCs is payload – both use trastuzumab 0 20 40 60 PN (all grades, %) 13% 2% 0% 0% 0% 41% 40% 27% 16% 48% Indication Target Breast HER2 ( Enhertu vs. Kadcyla ) NSCLC Gastric / GEJ Ovarian TROP2 ( Dato - DXd vs. PF - 06664178 ) NSCLC Phase Molecule Target A Enhertu HER2 TopoI payload R Dato - DXd TROP2 R Patritumab - DXd HER3 3 Ifinatamab - DXd B7 - H3 2 Raludotatug - DXd CDH6 A Adcetris CD30 MT payload A Padcev Nectin - 4 A Tivdak TF A Kadcyla HER2 3 Disitamab vedotin HER2 CONFIDENTIAL
19 CONFIDENTIAL Corporate
20 CONFIDENTIAL Evan Thompson COO Neta Batscha SVP, Strategy & Operations Mike Meehl SVP, Biologics Research Hussam Shaheen Head of Research Jason Oh SVP, Biology Shawn Russell SVP, CMC Jonathan Violin Interim CEO Damon Banks Head of Legal Keri Lantz Head of Finance Peter Harwin Board of Directors Chris Doughty CBO Leadership with deep experience building leading biotechnology companies Partnership with Paragon Therapeutics provides proven expertise in antibody engineering and development
21 Financing expected to fund Crescent programs through key anticipated value - generating catalysts CONFIDENTIAL 2H: Initial clinical data CR - 001 (cooperative PD - 1 x VEGF bsAb ) Mid - year: IND 2H: DC CR - 002 (undisclosed, ADC #1 with TopoI payload) 1H: DC CR - 003 (undisclosed, ADC #2 with TopoI payload) Multiple P3 trials ongoing or planned (e.g., SCLC, TNBC, NSCLC) , with numerous PFS & OS readouts expected in 2026 and beyond 1H: BNT327 P2/3 EGFRm NSQ mNSCLC interim (China) 1H: Ivo P3 1L SQ mNSCLC interim (China) 2H: BNT327 P2/3 1L ES - SCLC interim (China) 2H: Ivo P3 HARMONi - 2 1L mNSCLC OS data (China) 2H: Ivo P3 HARMONi EGFRm NSQ mNSCLC interim (global) 2H: Ivo P3 HARMONi - A EGFRm NSQ mNSCLC completion (China) Key external events 2026 2025 Notes: mNSCLC = metastatic non - small cell lung cancer; TNBC = triple negative breast cancer; SCLC = small cell lung cancer; ES = extensive st age. NSQ = non - squamous; SQ = squamous; EGFRm = mutant EGFR. Sources: ClinicalTrials.gov; Company websites YE25 / 1Q26: IND
22 Estimated capitalization following close of transactions CONFIDENTIAL Estimated total shares of common stock of the combined company post - closing 2,081,292,577 Shares on an as - converted basis 64,532,953 • Shares of common stock outstanding GlycoMimetics • Shares of common stock outstanding 105,137,814 Crescent Biopharma • Series A shares 298,298,000 Pre - closing financing 1,339,680,730 • Shares of common stock • Pre - funded warrants 273,643,080 Expecte d ownership of the combined company 3.1% 96.9%
CONFIDENTIAL Thank you
Exhibit 99.4
CORPORATE PARTICIPANTS
Harout Semerjian
President & Chief Executive Officer, GlycoMimetics, Inc.
Jonathan Violin, PhD
Chief Executive Officer, CRESCENT Biopharma, Inc.
MANAGEMENT DISCUSSION SECTION
Operator: Good morning, ladies and gentlemen. Thank you for
standing by. Welcome to the GlycoMimetics-CRESCENT Biopharma Transaction Conference Call. I would also like to remind you that this call
is being recorded for replay.
I will now turn the conference over to Christian Dineen-Long.
Christian Dineen-Long
Thank you and good morning. Before we begin, I'd like to remind you
that during this call, we may make forward-looking statements. These statements include the expectations of both GlycoMimetic’s
and Crescent’s management teams regarding the future. Statements including but not limited to those referring to the timing of the
transaction’s close, the expected investment amount related to the transaction, the use of proceeds, the cash balance of the combined
entities at closing - including the expected cash runway, the sufficiency of post-transaction resources to advance Crescent’s pipeline
through key milestones, and expectations for programs CR-001, CR-002, and CR-003, including their target product profiles and the timing
of clinical trials, are subject to certain risks and uncertainties.
Our actual results may differ materially from expectations. For a discussion
of risks and uncertainties, please review the descriptions included under the heading “Risk Factors” and “Business”
in GlycoMimetics’s most recent Annual Report on Form 10-K filed with the SEC, as well as other SEC filings made by GlycoMimetics
from time to time. These filings are available through the website maintained by the SEC at www.sec.gov and also available on GLYCOMIMETICS's
website.
All forward-looking statements are made as of today's date. Except
to the extent required by law, we do not undertake any obligation to update any forward-looking statements. We also caution you against
placing undue reliance on any forward-looking statements.
I will now turn the conference over to Harout Semerjian, President
& Chief Executive Officer of GlycoMimetics.
Harout Semerjian
President & Chief Executive Officer, GlycoMimetics,
Inc
Thank you Christian. Joining me on today's call is Jonathan Violin,
the Chief Executive Officer of CRESCENT Biopharma, who is expected to become the interim Chief Executive Officer of the company following
the closing of the transaction. I will review the details of our proposed acquisition agreement with CRESCENT BIOPHARMA and the pre-closing
private placement by leading biotech investors to support the Crescent programs. Jonathan will then provide an overview of CRESCENT, its
strategy, and pipeline.
As you saw in our press release this morning, GlycoMimetics and Crescent,
a private company, have entered into an acquisition agreement for GlycoMimetics to acquire Crescent in an all-stock transaction. Upon
completion of the acquisition, the combined company plans to operate under the name Crescent Biopharma, Inc.
The companies’ combined cash position includes a $200 million
pre-closing private placement in Crescent, consisting of common stock and common stock equivalents offered to a syndicate of investors
led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a large investment management firm,
with participation from Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital,
Perceptive Advisers, Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP,
and Wellington Management. With this capital, we are confident Crescent is well-equipped to advance through key value-driving
milestones to support it’s pipeline development strategy.
After the closing of the proposed agreements, the company's cash balance
is expected to provide runway through 2027. Under the terms of the agreement, the pre-merger GLYCOMIMETICS shareholders are expected to
own approximately 3.1% of the combined company and the pre-acquisition CRESCENT stockholders, inclusive of those participating in the
CRESCENT pre-closing financing, are expected to own approximately 96.9% of the combined company.
The percentage of the combined company that GLYCOMIMETICS shareholders
will own as of the close of the acquisition is subject to adjustments based on the amount of GLYCOMIMETICS's net cash at the closing date.
We would like to thank the GLYCOMIMETICS and CRESCENT board members
for their commitment and support as they have approved the transaction, which is, of course, subject to stockholder approval and customary
closing conditions. We expect the merger transaction to close in the second quarter of 2025.
We at GLYCOMIMETICS have been impressed with the leadership at CRESCENT
and have confidence in their ability to deliver on their strategy going forward. Our decision to pursue this agreement with CRESCENT follows
an extensive review of strategic alternatives by our board and management team and we are confident this represents the best path forward
for the Company and its shareholders. We believe the Company is well positioned to carry forward the mission of improving the lives of
patients.
Now, I'd like to pass it over to Jonathan Violin, CEO of CRESCENT BIOPHARMA.
Over to you, Jonathan.
Jonathan Violin
Chief Executive Officer, CRESCENT BIOPHARMA, Inc.
Thank you, Harout, and good morning, everyone. First off, I want to
thank the GLYCOMIMETICS management team and board for their confidence in our team and our company's strategy.
Before we jump in, I'd like to point out that our listeners can access
additional information on CRESCENT in our corporate presentation, which has been uploaded to the CRESCENT website at www.CRESCENTbiopharma.com.
We're thrilled today to have the opportunity to tell you about CRESCENT
BIOPHARMA and our plans to advance a pipeline of novel, precision-engineered biologics that we believe could meaningfully advance the
standard of care for patients with solid tumors.
CRESCENT's pipeline consists of 3 programs which originated at Paragon
Therapeutics. Paragon has a biologics engineering team with deep experience in discovering and developing novel, complex biologics, including
bispecifics and antibody-drug conjugates. This is the same team that discovered the molecules that launched Apogee, Spyre, Oruka, and
Jade over the last few years.
Each of our 3 programs were designed to optimize efficacy and safety
by leveraging proven science to de-risk each program and provide the conviction we believe is necessary to aggressively accelerate development.
Our lead program, CR-001, is a tetravalent PD-1 x VEGF bispecific antibody
that was carefully designed to recapitulate the unique cooperative binding that led to the breakthrough performance delivered by ivonescimab.
As you know, ivonescimab recently beat the market leading anti-PD-1 antibody, pembrolizumab, in a head-to-head Phase 3 trial in non-small
cell lung cancer (NSCLC). This was the first time pembrolizumab had been beaten in a Phase 3 head to head trial, and ivonescimab did so
by delivering nearly a halving of progression free survival coupled with a compelling safety profile. The remarkable result derives from
the novel, differentiated MOA of ivonescimab– it’s a tetravalent bispecific antibody that imparts cooperative binding of VEGF
and PD-1 bispecific blockade, meaning it’s most active in the presence of both VEGF and PD-1. This enables the molecule to deliver
benefits to patients that are more than the sum of its parts, and to do so safely. This novel format enables VEGF to create “daisy
chains” of drug molecule, linking them together and increasing the potency for PD-1 blockade. This unique design also may enable
localization of drug to the tumor microenvironment, which may help reduce systemic toxicity.
This is a true breakthrough. Immuno-oncology is a tricky space, as
the oncology field has come to learn over the last decade. Enhancing the remarkable immune effects of the PD-1 class is not easy, and
if you do find a way to enhance the effects, doing so safely can be challenging. This is why the field’s efforts to improve upon
PD-1 has been littered with failures. Adding the profound effects of VEGF inhibition to the equation further highlights the importance
of threading the safety needle with molecule design.
We intentionally designed our molecule to replicate the pharmacology
and pharmacokinetics of ivonescimab – to be the best version of this structural format - in order to avoid disrupting the balance
of activities that have shown such striking promise in clinical trials. We considered many other changes to this structure as we were
designing CR-001, even small ones that could lead to some potential improvement, but each time our team concluded the new design
may actually increase the risks to efficacy, safety, or both, and no matter what, it would make it hard for us – and our
investors - to assign a similarly compelling probability of success to CR-001.
Like ivonescimab, CR-001 comprises the bevacizumab sequence to block
VEGF and enable daisy-chaining, whereby VEGF dimers bridge CR-001 molecules to create a molecular chain of active drug. And it is enabling
the specific level of Ivonescimab daisy chaining, no less, no more. In addition, like ivonescimab the bevacizumab domain is Fc
silenced to reduce risk of AEs, and is attached to stable scFv domains targeting PD-1. In our case, we have used proprietary engineering
of an scFv domain that targets the same epitope as pembrolizumab. Of all the approaches to blocking the PD-1 axis, if you can find a
way to hit the epitope of the current market leader – to leverage all the clinical trials teaching us how blocking this epitope
translates to outcomes - then we believe you should. And we’ve done so with targeted engineering to create highly stable scFv domains,
an important factor in manufacturing this class of drug. So to summarize: CR-001 is a purpose built molecule, designed to recapitulate
precisely the pharmacology of ivonescimab, and to enhance stability and manufacturability – we’re very excited about this
new molecule, and we have filed provisional patents to cover composition of matter.
The CR-001 program is currently undergoing IND-enabling work, and is
on track for an IND filing in 4Q25 or 1Q26. We anticipate we’ll have our first clinical data in the second half of 2026 –
which will include interim Phase 1 data in patients with solid tumors. Because we’ve designed 001 precisely to recapitulate ivonescimab
pharmacology, the initial clinical data offers a substantial opportunity to de-risk our development plans, something unique to our construct.
We aim to show that 001 behaves well, with the expected exposure and pharmacokinetics, along with preliminary PD and tumor response data,
so we can gain confidence that data from just a few dozen patients can connect the dots back to the data produced from the hundreds of
patients treated with ivonescimab. This is an unusual position to be in – if we’d designed some different pharmacology, or
structural features, compared to ivonescimab, we’d be viewed as a “novel” program in immuno-oncology, and we would need
hundreds of patients worth of data to generate confidence in both the efficacy and the safety to accelerate development.
Instead, given our design, we believe our early data can generate the
confidence to rapidly advance to late stage development, where we can pursue two parallel paths that we'll describe at a high level today.
Firstly, we can focus on first in class opportunities where we believe
there is a high probability of success on hitting both PFS and OS, and which offer an efficient development path the Crescent team can
execute. The VEGF and PD1/PD-L1 class is approved in dozens of indications, so there’s a rich landscape to mine, and we’ve
identified several potential opportunities to prioritize that we are very enthusiastic about. We look forward to disclosing more detail
in the future .
Secondly: there are about to be numerous large ph III studies,
launched by Summit and BioNTech, largely in 1st line of a variety of major tumor types like NSCLC. We plan to be fully
enabled with the appropriate drug combinations to leverage data produced by those trials to support our clinical development
strategy. Again, given our design and the functional similarities of CR-001 to Ivonescimab, we feel we will be uniquely positioned
to leverage those datasets with confidence – something we couldn’t do if we had a molecule that behaved differently, and
thus wouldn’t provide that connection back to what safely worked.
We know the ivonescimab data has catalyzed massive interest in advancing
next generation checkpoint inhibitor therapy – the PD1/PDL1 class is currently a $50B market and growing, so when something beats
the leader of such a large and important drug class, we expect competition. We anticipate this will be similar to what we have seen recently
in the obesity field - and we believe we have the advantage of strategic design. CR-001 was crafted specifically to thread the same immunotherapy
needle as ivonescimab, putting us in a strong competitive position. With today’s transaction and the support of the leading biotech
investors who have funded us, we are well positioned to deliver on our mission of building a world-class solid tumor oncology company.
Before I end, I should also note that we believe firmly in the power
of optionality, and the value of a rich pipeline. That’s why we’re so pleased to have CR-002 as a second program, advancing
quickly to clinic just a few quarters behind 001. We’re not disclosing details yet, but CR-002 targets a highly compelling pathway
with a topoisomerase inhibitor payload. Topoisomerase inhibitor payloads have produced profound results across a variety of targets and
tumor types, with increased efficacy and less of the debilitating peripheral neuropathy associated with auristatins; we’ve seen
this for HER2 antibodies in breast, NSCLC, and gastric cancers, and also for TROP2 antibodies in breast and NSCLC - just to name a few.
We hope to see the same benefits for CR-002 - with the chance to be first in class. The Paragon team has crafted CR-002 specifically for
this purpose – the mAb is designed to overcome limitations that will hinder robust ADC efficacy for some of the other existing antibodies
for this target. We’re not saying more about CR-002 solely for competitive reasons but are excited to unveil this program in due
course.
We also have a third program in our pipeline – another ADC to
a different target, again with a topoisomerase inhibitor payload. We’ll be excited to share more about that program when the time
is right.
Together we believe the 3 programs in our pipeline represent an exciting
opportunity –, offering best in class efficacy while balancing safety, with the potential for combinations to drive even further
efficacy for patients living with deadly solid tumors. We’re thrilled to have the opportunity to move these programs forward.
We’re grateful for the level of support we saw in this
fundraising from a group of leading biotech investors and healthcare-focused mutual funds. The robust [over-subscribed] private
investment of [$XXX] we announced today funds the advancement of all 3 of our pipeline programs, and will fund CR-001 through
initial dose escalation data in solid tumor patients which we anticipate will be delivered in the second half of 2026. Our funding
provides the company cash runway through 2027.
We are excited by the opportunity that comes with building a biotechnology
company focused on developing new therapies for patients with solid tumors. We are driven by the potential our pipeline offers to patients
and we are eager to help innovate within the treatment landscape for oncology. Our team is working diligently to deliver on the goal of
bringing best-in-class therapies to patients with solid tumors.
With that, I'll conclude my remarks
and hand the call back to the operator. Thanks for joining the call today.
Operator: Ladies and gentlemen, this concludes our conference
for [ph] today (12:57). All parties may now disconnect.
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Nov 2024 to Nov 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Nov 2023 to Nov 2024
